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Abstract 
 
Colorectal cancer (CRC), which includes cancer of the large bowel and rectum 
is the third most common cancer in men and the second in women and there is 
a poorer survival rate in less developed regions of the world such as West 
Africa mainly due to the ‘out of reach’ costs of chemotherapy. 
Evidence suggests that aspirin, a non-steroidal anti-inflammatory drug (NSAID) 
has the potential to decrease incidence of, or mortality from a number of 
cancers including CRC through several mechanisms of action. However, this 
evidence is dampened by aspirin’s gastrointestinal (GI) toxicity, which have 
been found to be mostly age-dependent. The search for potential aspirin-related 
compounds with the same or better cytotoxic effects against cancer cells 
accompanied by a safer toxicity profile has been ongoing over the years and led 
to us to synthesise a number of novel aspirin analogues. One of the 
mechanisms of action suggested for the anticancer property of aspirin is the 
COX-dependent pathway. In this thesis SW480 cell line, a CRC cell line that is 
COX-2 negative and mismatch repair (MMR) proficient was used to study the 
possible COX-independent mechanism of action for aspirin, its analogues and 
diflunisal at 0.5 mM. Diflunisal was included in this study because it is also a 
salicylate with reports of having cytotoxic effects. OE33 and FLO1 oesophageal 
cancer cells were also employed in the epidermal growth factor receptor 
(EGFR) and synergy experiments to show effects were not just specific to 
SW480 cells alone. These aspirin analogues were synthesised, identified using 
nuclear magnetic resonance (NMR) and infra-red (IR) spectroscopy, and tested 
for purity using thin layer chromatography (TLC) and melting point. The findings 
of this study suggest that these compounds breakdown into salicylates and 
perturb epidermal growth factor (EGF) internalization with PN517 
(fumaryldiaspirin) and PN590 (ortho-thioaspirin) also driving EGF co-localization 
with early-endosome antigen-1 (EEA1). The perturbation of the internalization 
of EGF by aspirin and PN517 was also observed by a time-lapse assay using 
live confocal imaging. These compounds also had specific effects on different 
tyrosine phosphorylation sites of the EGFR, with none but PN590 inhibiting 
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phosphorylation at Y1068, and all but PN502 (ortho-aspirin), PN548 (meta-
aspirin) and PN549 (para-aspirin) inhibiting phosphorylation at Y1045 and 
Y1173. Given that the EGF internalization assay involved the cells being treated 
with compounds for 2 h, cells were also treated for this same time period and 
probed with pEGFR 1045, which resulted in the compounds having no 
significant effect on phosphorylation at that site which is responsible for the 
ubiquitination of the EGFR. Most of these compounds were apoptotic with some 
showing a combination of apoptosis and necrosis. Aspirin and its isomers drove 
apoptotic cell death in SW480 cells via the BCL2-BAX pathway while the 
thioaspirins appear to follow the p21 pathway by decreasing the expression of 
the protein. In addition, it was shown that PN502 (aspirin), PN517 and PN590 
had synergistic effects when used in combination with oxaliplatin at ED50, ED75 
and ED90 in SW480 CRC cells. The cytotoxicity of these compounds individually 
or in combination was determined using MTT assay followed by the use of the 
CompuSyn and CalcuSyn software to calculate combination index (CI), which 
indicated whether a drug combination was synergistic, antagonistic or additive. 
PN517 and PN524 were synergistic when used in combination with cisplatin in 
OE33 oesophageal cancer cells. Effect of these compounds on the EGFR 
indicates a delay or disruption of the signalling pathway involved in the 
proliferation of cancer cells, thus, translating into protection against tumour 
formation or progression while the synergistic effects of these compounds when 
used in combination with platinum compounds can provide patients with less 
toxic chemotherapeutic regimen especially in patients with CRC tumours that 
harbour mutant TP53 gene and normally resistant to oxaliplatin.  
It is therefore proposed that the perturbation of EGF internalization is a novel 
mechanism of action for aspirin and its analogues in cancer therapy.  
These positive findings shed light on the understanding of the possible 
mechanism of action for aspirins and gives hope for a more affordable, less 
toxic therapy for the prevention, treatment and management of cancer. 
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Chapter 1. Introduction 
1.1 Cancer 
Cancer arises as a consequence of the accumulation of genomic changes, 
which include genetic mutations, disruption in the functionality of these genes 
and deregulation of signalling pathways. These genetic mutations result in an 
increase in functionality of oncogenes and a decrease or loss in the functionality 
of tumour suppressor genes (Hanahan and Weinberg, 2000). These genetic 
changes result in alterations in cell physiology termed as the hallmarks of 
cancer (Colotta et al., 2009, Hanahan and Weinberg, 2000, Hanahan and 
Weinberg, 2011). 
1.2 The Hallmarks of Cancer 
The genomic changes were initially thought to be as a result of six alterations in 
cell physiology termed as the six hallmarks of cancer. They include sustaining 
proliferative signalling, evading growth suppressors, activating invasion and 
metastasis, enabling replicative immortality, inducing angiogenesis and 
resisting apoptosis (Hanahan and Weinberg, 2000). Later on, cancer-related 
inflammation has been included as the seventh hallmark of cancer (Colotta et 
al., 2009) (Figure 1.1).  
 
 27 
 
 
Figure 1.1 The seven hallmarks of Cancer.  
Cancers acquire these capabilities during development in order to progress and invade 
other neighbouring tissues. These capabilities also contribute to poor prognosis 
[Adapted from (Colotta et al., 2009, Hanahan and Weinberg, 2000, Hanahan and 
Weinberg, 2011)]. 
 
1.2.1 ‘Sustaining Growth Signalling’  
Mitogenic growth signals are required for cell to change from a rest phase to a 
proliferative phase by transmembrane receptors (Bhowmick and Moses, 2005). 
Normal growth signals are mimicked by oncogenes (Liotta and Kohn, 2001). 
This enables tumour cells to generate their own signalling programme. For 
example, cancer cells do not rely on normal cells for the production of growth 
factors such as platelet-derived growth factor (PDGF) and tumour growth factor 
α (TGFα), but rather produce these growth factors independently. In addition, 
cancer cells may also send signals to normal cells, which in turn supply the 
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cancer cells with various growth factors (Cheng et al., 2008). Cell surface 
receptors responsible for this signalling also undergo deregulation resulting in 
overexpression. For example, the epidermal growth factor receptor (EGFR) 
when overexpressed becomes hyper-responsive to background levels of growth 
factor (Sebastian et al., 2006, Yarden and Ullrich, 1988) or ligand-independent 
signalling (Di Fiore et al., 1987). Similarly, somatic mutations in the DNA of 
cancer cells result in an increase in signalling through the Raf to mitogen-
activated protein-kinase (MAPK) pathway (Davies and Samuels, 2010) and the 
phosphoinositide 3-kinase (PI 3-K) signalling pathway (Jiang and Liu, 2009).  
Cancer cells can also choose to express extracellular receptors that produce 
proliferative signals, which could lead to resistance to apoptosis and entry into 
the active cell cycle. An example is the effects of integrin on growth factors 
(Giancotti and Ruoslahti, 1999). 
In some contexts however, oncoproteins such as Ras and Raf, producing high 
levels of signalling can stimulate apoptosis or entry into the rest phase of the 
cell cycle (Collado and Serrano, 2010, Lowe et al., 2004) 
1.2.2 ‘Evading Growth Suppressors’ 
Antiproliferative signals are responsible for maintaining tissue homeostasis. 
Antigrowth signals from tumour suppressor genes block cell proliferation either 
by forcing the cell cycle into rest (G0) phase or by causing apoptosis (Hanahan 
and Weinberg, 2000, Hanahan and Weinberg, 2011). Examples of tumour 
suppressors include RB (retinoblastoma-associated) and TP53. The RB gene, 
as part of a wider network acts as a ‘gatekeeper’ to cells for entry or 
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progression into the cell cycle (Burkhart and Sage, 2008) and its inactivation 
can lead to cellular proliferation. TP53 regulates cell growth or division by 
halting cell cycle progression or activating apoptosis when stress signals, as a 
result of damage to the genome, are received (Hanahan and Weinberg, 2011). 
Another mechanism in which cancer cells operate to evade growth suppressors 
is by corrupting the TGF-β pathway (Ikushima and Miyazono, 2010), where 
TGF-β regulates the G1 phase of the cell cycle by suppressing c-myc gene and 
also causes synthesis of p21 and p15 proteins, which inhibits G1 cyclin CDK 
leading to cell apoptosis (Datto et al., 1997). 
1.2.3 ‘Resisting Cell Death’ 
Resisting apoptosis, also known as programmed cell death, is a contributing 
factor in cancer development (Adams and Cory, 1998, Adams and Cory, 2007, 
Lowe et al., 2004) and thus, a hallmark of cancer. Apoptosis is a step-by-step 
process that takes place within 2 h. It involves disruption of the cellular 
membrane; break down of the cytoplasmic and nuclear organelles, degradation 
of the chromosomes, and fragmentation of the nucleus. Finally, the shrivelled 
cell is engulfed by nearby cells by a process known as phagocytosis (Wyllie et 
al., 1980). The mitochondria release cytochrome C, a catalyst for apoptosis 
when proapoptotic signals are received (Green and Reed, 1998). Apoptosis can 
either be caspase-dependent or caspase-independent, where the former 
involves the triggering of caspase by the release of apoptosis inducing factors 
(AIF) (van Gurp et al., 2003) and the latter entails translocation of AIF into the 
nucleus, which induces chromatin condensation (Cregan et al., 2004). 
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Proapoptotic proteins include BCL-2 associated X protein (BAX), BCL-2 
homologous antagonist killer (BAK), BH3 interacting-domain death agonist 
(BID) and BCL-2-like protein 11 (BIM) while the antiapoptotic proteins include 
B-cell lymphoma 2 (BCL-2), B-cell lymphoma-extra large (BCL-XL) and BCL-2-
like protein 2 (BCL-W), all of which are of the BCL-2 family (Gross et al., 1999). 
Upon DNA damage, p53 tumour suppressor upregulates BAX, which results in 
the release cytochrome C by the mitochondria (Hanahan and Weinberg, 2000). 
Autophagy, another form of cell death, is a degradation system that enables the 
delivery of cytoplasmic materials of aged cells during starvation conditions to 
lysosomes and is important in maintaining cell homeostasis (Jiang et al., 2015, 
Seglen et al., 1996). Insufficiency of survival signals leads to the 
downregulation of the PI 3-K signalling pathway, which results in the stimulation 
of autophagy and/or apoptosis (Levine and Kroemer, 2008). 
1.2.4 ‘Enabling Replicative Immortality’ 
Telomeres, which are composed of several thousand repeats of a short 6-base-
pair sequence element, protect the ends of chromosomes and are mainly 
responsible for proliferation in cells (Blasco, 2005). The loss of a number of 
telomeric DNA base-pair from the ends of every chromosome occurs after every 
cell cycle. Progressive reduction in number of the telomeres results in their 
inability to protect the ends of chromosomal DNA, triggering cell senescence 
and eventually death. In other words, end-to-end chromosomal fusion occurs 
due to the chromosome being unprotected, which eventually leads to cell death 
(Counter et al., 1992). Telomerase, an enzyme that adds telomeres to the ends 
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of chromosomes permits indefinite replication and is almost absent in 
nonimmortalized cells but expressed in high levels in immortalized/cancer cells 
(Hanahan and Weinberg, 2011). This means that cells are resistant to 
apoptosis and replicate continuously. 
1.2.5 ‘Inducing Angiogenesis’ 
Angiogenesis, the growth of new blood vessels is carefully regulated. It begins 
with the birth of new endothelial cells and their assembly into tubes 
(vasculogenesis) (Risau and Flamme, 1995) and then the sprouting of new 
vessels from existing ones (angiogenesis) (Hanahan and Weinberg, 2000, 
Ramjiawan et al., 2017). This happens to be switched on and off in processes 
such as wound healing and female reproductive cycling. However, in tumour 
progression, the switch remains turned on causing continuous sprouting of 
blood vessels that feed cancer cells (Hanahan and Folkman, 1996). An inducer 
of angiogenesis is the vascular endothelial growth factor-A (VEGF-A), which 
can be upregulated by hypoxia and signalling by oncogenes (Ferrara, 2009). 
Thrombospondin-1, fragments of plasmin and type 18 collagen function as 
inhibitors to angiogenesis (Ribatti, 2009) and has been shown to suppress 
tumour growth (Kazerounian et al., 2008). 
1.2.6 ‘Activating Invasion and Metastasis’ 
Metastasis, the distant travel or spread of tumour cells, is the cause of about 
90% of mortality from cancer (Sporn, 1996). The shape and ability of cells to 
attach to other cells is altered in cancer cells due the loss of E-cadherin, a cell-
to-cell adhesion molecule. The loss of E-cadherin enables cancer cells to move 
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away from assembled epithelial cell sheets and move freely thereby losing its 
state of quiescence (Berx and van Roy, 2009, Canel et al., 2013).  N-cadherin, 
an adhesion molecule expressed in migrating neurons is upregulated in 
invasive cancer cells (Cavallaro and Christofori, 2004, Qian et al., 2014). 
1.2.7 ‘Cancer-related Inflammation’ 
As far back as the 17th century, the relationship between cancer and 
inflammation was hypothesised by Rudolf Virchow (Balkwill and Mantovani, 
2001). This hypothesis has since then been reiterated by other scientists 
(Colotta et al., 2009, Hanahan and Weinberg, 2011) and can easily be proven 
due to the development of better markers for histochemical staining that can 
accurately identify distinct cell types of the immune system (Pages et al., 2010). 
Inflammation, a simple but powerful defence mechanism programmed to halt 
tissue damage and stimulate repair (Munn, 2017), leads to the progression of 
the other six hallmarks of cancer by activating growth factors, which sustain 
proliferative signalling, survival factors that resist cell death, factors that induce 
angiogenesis, stimulating genetic mutation (Grivennikov et al., 2010, Hanahan 
and Weinberg, 2011) due to increased levels of nuclear factor-κB (NF-κB), 
reactive oxygen and nitrogen species (RONS), cytokines, prostaglandins and 
microRNAs (Schetter et al., 2010). 
 
Ten hallmarks of cancer with corresponding therapeutic targets were 
subsequently described in 2011 (Hanahan and Weinberg, 2011) (Figure 1.2). 
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Figure 1.2 Therapeutic Targeting of the Hallmarks of Cancer.  
These drugs are used in combination therapies for the treatment of cancers (Hanahan 
and Weinberg, 2011). EGFR inhibitors such as cetuximab act by inhibiting the cell 
growth regulatory pathway (Kohne and Lenz, 2009). 
 
The additional hallmarks are: 
 
1.2.8 ‘Genome Instability and Mutation’ 
Mutations found in certain genes of cancer cells lead to their dominance in 
population (Hanahan and Weinberg, 2011). For example, inactivation of tumour 
suppressor genes due to TP53 mutations (Goh et al., 2015, Lane, 1992), 
inactivation of MMR genes due to mutations (Negrini et al., 2010), chromosome 
instability (CIN) and microsatellite instability (MIN) (Artandi and DePinho, 2010). 
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1.2.9 ‘Deregulating Cellular Energies’ 
In normal cells, under anaerobic conditions, glycolysis is the main process for 
energy metabolism with a small amount of pyruvate delivered to the 
mitochondria (Hanahan and Weinberg, 2011). However, cancer cells are able to 
redirect their energy metabolism even under aerobic conditions to glycolysis. 
This process known as ‘aerobic condition’ is accompanied by low adenosine 
triphosphate (ATP) production and often compensated for by an increase in 
uptake and utilization of glucose (DeBerardinis et al., 2008), even though the 
preference for glycolysis is quite puzzling (Hanahan and Weinberg, 2011). Two 
different cell populations can be found in some cancer cells with different 
pathways for energy metabolism. One of the populations are glucose-
dependent cells that produce lactate (Warburg-effect) while the other uses the 
lactate produced by neighbouring cells as their source of energy (Kennedy and 
Dewhirst, 2010). This indicates that normoxia or hypoxia is not a permanent 
condition for survival in cancer cells but this fluctuates depending on the 
condition the cells find themselves (Hardee et al., 2009). 
1.2.10 ‘Avoiding Immune Destruction’ 
Hanahan and Weinberg (2011) suggested this hallmark with some 
considerations that it was not a firmly established contributing factor. However, 
the emergence of immunotherapy in the treatment of cancer reiterates failure of 
the immune system to detect and destroy cancer cells as one of the hallmarks 
of cancer (Lynch and Murphy, 2016, Morse et al., 2013, Xiang et al., 2013). For 
example, there is better prognosis in colon and ovarian tumour patients with 
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high levels of killer lymphocytes as compared to those that lack such cells as 
part of their immune system (Pages et al., 2010). It has also been found that 
cancer cells are able to secrete immunosuppressive factors that disable T 
lymphocytes/killer cells (Lynch and Murphy, 2016) and thus the emergence of 
checkpoint inhibitors such as ipilimumab, tremelimumab and pembrolizumab 
(Section 1.4.6.5) used in the treatment of some cancers (Gangadhar and 
Salama, 2015, Gong et al., 2017, Wherry, 2011).   
 
1.3 Colorectal cancer 
Colorectal cancer (CRC), which includes cancer of the large bowel and rectum, 
is the third most common cancer in men with over 750,000 cases and the 
second in women (GLOBOCAN 2012) with about 600,000 cases worldwide 
(Garcia-Albeniz and Chan, 2011). While this is becoming a global phenomenon, 
over 50% of these cases are found in more developed regions of the world, the 
estimated incidence rates being higher in Australia/New Zealand and the lowest 
in West Africa. However, there is a poorer survival rate in the less developed 
regions of the world such as West Africa. In the UK, over 40,000 people were 
diagnosed with this disease in 2014 alone with almost 16,000 deaths that same 
year, which translates to roughly over forty deaths per day (CRUK). 
Unfortunately, incidence rates of CRC in the UK have increased by 6% over the 
last ten years. The median survival duration of patients with metastatic CRC is 
about six months if untreated (Van Cutsem and Geboes, 2007). 
 36 
 
Over 90% of colorectal cancers are adenocarcinomas and about 1% of these 
are lymphomas (CRUK). 
CRC arises as a consequence of the accumulation of variable and specific 
changes to the genome, which includes mutations to genes such as KRAS 
oncogene resulting in deregulation of the EGFR signalling pathway or the up-
regulation of β-catenin resulting in deregulation of the Wnt signalling pathway. 
These genomic changes alter normal cell function (Figure 1.3). 
 
 
Figure 1.3 CRC tumourigenesis.  
Progression of CRC to metastasis from normal cells is as a result of the accumulation 
of abnormalities in the signalling pathways. Most CRC harbour APC mutations (Rowan 
et al., 2000), which usually occur in the early stages of carcinogenesis leading to the 
deregulation of the Wnt signalling pathway. Some tumours harbour TP53 mutations 
that lead to loss of activity while others bear mutations of the KRAS oncogene, which 
leads to deregulation of the EGFR signalling pathway. ECM (extracellular matrix), EMT 
(epithelial-mesenchymal transition). [Adapted from (Bustin and Murphy, 2013)].  
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1.3.1 Types of Colorectal cancer (CRC) 
Based on clinical and pathological data, CRC can be divided into three main 
types (Tomlinson et al., 1998); namely: 
1.3.1.1 Adenocarcinomas 
An adenocarcinoma can be described as a lesion in the colon or rectum 
containing clear abnormality in tissue growth (epithelial neoplasia) (Quirke et al., 
2011). Adenocarcinomas develop from the adenoma and are the most common 
type of CRC. They are found mostly in the left hand side of the large intestine.  
1.3.1.2  Replication errors (RER) Colorectal cancer 
Replication errors (RER) CRC has tumours with widespread RERs. They make 
up about 90% of CRC in patients with hereditary non-polyposis colorectal 
cancer (HNPCC) syndrome (Papadopoulos et al., 1994, Peltomaki, 1995). They 
are mostly found on the right hand side of the bowel (Aaltonen et al., 1993). 
1.3.1.3 Ulcerative colitis-associated Colorectal cancer (UCACRC) 
Ulcerative colitis-associated (UCA) CRC are found mostly on the left hand side 
of the bowel and usually develop from a distant dysplasia, which can be found 
in the rectum or sigmoid colon (Connell et al., 1994). Mutations at APC and 
KRAS loci occur less frequently in UCACRC when compared with the other 
types of CRC (Tomlinson et al., 1998). 
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1.3.2 Pathways involved in the development of CRC 
Cancer is as a result of the accumulation of gene mutations that eventually lead 
to uncontrolled cell proliferation (Garraway and Lander, 2013). Sources of 
which include hereditary [(H) germline mutations], environmental factors [(E) 
such as exposure to UV, cigarette smoke] or due to Replicative mutations (R) 
(Tomasetti et al., 2017). Approximately three mutations occur whenever a 
normal human stem cell divides (Tomasetti et al., 2013) and the number of 
these normal cell divisions determines cancer risk in most mouse model organs 
(Zhu et al., 2016).  
Genetic instability drives cell mutations, which result in the development of 
different cancers (Loeb, 1991). Genetic alterations in tumours can be divided 
into four main categories; namely; (i) Subtle sequence changes comprising of a 
few base pair substitutions, deletions or insertion of nucleotides, (ii) Alterations 
in chromosome number, which involves losses or gains of whole chromosomes, 
(iii) Chromosome translocations that results in fusions between two different 
genes, and (iv) Gene amplifications that results in the formation of ‘amplicons’, 
which contain 0.5-10 mega bases of DNA (Lengauer et al., 1998). Hereditary 
CRC syndromes are as a result of germline mutations while sporadic CRC is by 
alteration of DNA structure [mutation] or DNA function [epigenetics] (Obuch and 
Ahnen, 2016). 
1.3.2.1 Chromosome Instability (CIN)  
Chromosomal instability (CIN) is more common than microsatellite instability 
(MIN) and occurs in about 70% of human cancers (Obuch and Ahnen, 2016). 
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This involves gains and losses of whole chromosomes known as chromosome 
missegregation and has an important role in tumourigenesis (Lengauer et al., 
1998). CIN is driven by activation of mutations in oncogenes such as KRAS and 
tumour suppressor genes such as APC or P53 (Obuch and Ahnen, 2016), 
which results in aneuploidy, the presence of an abnormal number of 
chromosomes in a cell and a cause for tumorigenesis (Boveri, 2008, Thompson 
and Compton, 2008) (Figure 1.3). Individuals with medical conditions 
characterised by aneuploidy such as Down syndrome and Turner syndrome 
have been found to show high incidence of cancer (Sullivan et al., 2007). 
However, in CIN, aneuploidy found in the tumour cell population is 
heterogeneous and has the capability of selective evolution resulting in 
metastasis (Bakhoum and Compton, 2012). 
Studies have shown that CIN is responsible for tumorigenesis (Schvartzman et 
al., 2010). For instance, chromosome misseggregation was induced in mice by 
perturbing microtubule attachments to chromosomes. This led to the formation 
of lymphomas and lung tumours (Weaver et al., 2007). However, disruption or 
inactivation of the P53/P21 pathway was required for aneuploidy karyotypes to 
survive because chromosome misseggregation in cells with a functional 
P53/P21 system will lead to cell cycle arrest. CRC cell lines SW480, HRT-18, 
HT-29, DLD-1 have been found to possess mutation status at P53 gene (Din et 
al., 2004), which suggests that chromosomal misseggregation in CRC is mainly 
via the CIN pathway. 
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1.3.2.2  Microsatellite Instability (MIN) 
Microsatellite instability (MIN) pathway results in about 5% of CRCs with the 
chromosome number not affected (diploid). It is caused by germline mutations 
in one of the DNA MMR genes, which are responsible for recognising and 
repairing errors that occur during DNA replication and also repair of DNA 
damage (Iyer et al., 2006). Mutations in MMR genes eventually leads to Lynch 
syndrome CRCs (Obuch and Ahnen, 2016). Mutations found in regulatory 
regions of the MMR genes MSH2, MSH6, MLH1 and PMS2, which leads to MIN 
are one of the hallmarks (1.2.8) for the development of CRC in humans (Fishel 
and Kolodner, 1995, Herman et al., 1998, Kane et al., 1997, Modrich and Lahue, 
1996). About 90% of mutations in Lynch Syndrome are caused by MLH1 and 
MSH2 mutations, with 7-10% by MSH6 mutations, less than 5% by PMS2 
(Tutlewska et al., 2013) and about 3% by EPCAM gene mutation (Kuiper et al., 
2011). The EPCAM gene is responsible for intercellular adhesion and 
intracellular signalling, migration and proliferation with its deletion leading to 
MSH2 silencing (Tutlewska et al., 2013). MIN occurs in most patients with 
HNPCC (Aaltonen et al., 1993) and is as a result of defects in the MMR genes, 
mutS homologue (hMSH2) and mutL homologue (hMLH1) (Strand et al., 1993) 
(Figure 1.4). There are six mutL and mutS homologues all of which when 
deactivated as a result of mutation will lead to the development of cancer 
through the MIN pathway (Peltomaki and de la Chapelle, 1997).  
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1.3.2.3 CpG island Methylator Phenotype (CIMP) 
CpG island methylator phenotype (CIMP) is also known as the serrated 
pathway, which results in CRCs that are DNA MMR deficient (MSI) or DNA 
MMR proficient (MSS), and make up about 25% of CRCs. The CIMP phenotype 
can be grouped into CIMP-high and CIMP-low with the BRAF oncogene 
mutation often found in CIMP-high CRC characterised by increased cell 
proliferation, progression of carcinogenesis (Ogino et al., 2009). Unlike CIN and 
MIN pathways, CIMP does not involve the activation of KRAS mutations (Janne 
and Mayer, 2000). However, in some contexts, KRAS mutations are found in 
CIMP CRCs and referred to as CIMP-low (Colussi et al., 2013). 
CRCs that are formed via MIN and CIMP pathways may be more difficult to 
diagnose than those that are formed via CIN pathway because they are 
commonly found in the proximal region of the colon are not detected easily by 
endoscopy and may develop quickly into cancer (Patel and Ahnen, 2014). 
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Figure 1.4 Different steps in the pathways to genetic instability and relationship 
between ploidy and CIN in terms of tumour initiation and growth. 
Different number of mutational ‘hits’ are required by each pathway to result in instability 
of either the microenvironment or the chromosome. In a heterozygote with one 
defective MMR allele, the MIN pathway commences only when there is inactivation of 
the normal allele inherited from the unaffected parent (step 2). For the CIN pathway, 
however, only one mutational ‘hit’ is required to produce the CIN phenotype. An 
example of a gene that follows the CIN pathway is hBUB1, a component of the mitotic 
spindle checkpoint (MSC), which is responsible for controlling mitotic checkpoints and 
chromosome segregation. Loss-of-function mutations of the BUB1 gene results in 
aneuploidy (Cahill et al., 1998). Aneuploidy leads to additional chromosome 
missegregation and DNA damage. p53/p21 tumour suppressor pathway is triggered as 
a result of aneuploidy to limit further proliferation of aneuploidy cells. However, if the 
p53/p21 gene is mutated, this function becomes null and void [Adapted from (Bakhoum 
and Compton, 2012, Lengauer et al., 1998)]. 
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1.4 Treatment of CRC 
Prognosis for patients with metastatic CRC (mCRC) is still poor (Lynch and 
Murphy, 2016). In CRC, when detected early (while still localized), surgical 
removal may be curative. However, the early detection happens in only 39% of 
cases (Kohne and Lenz, 2009) and chemotherapy is often the only option. 
 
Up until 1996, 5-fluorouracil (5-FU)-based therapy was the only one used in 
mCRC. Irinotecan, a topoisomerase inhibitor, was then approved that year and 
the platinum compound, oxaliplatin in 2004. A combination of 5-FU with 
irinotecan is termed FOLFIRI while the combinations of 5-FU and leucovorin 
plus oxaliplatin is termed FOLFOX (Kohne and Lenz, 2009). To further improve 
chemotherapy regimens, monoclonal antibodies; bevacizumab, cetuximab and 
panitumumab were then introduced as combinations with FOLFIRI and 
FOLFOX (Goldberg et al., 2007, Kohne and Lenz, 2009) (Figure 1.5). 
 
The new trend in CRC therapy however is the emergence of immunotherapy, 
which is as a result of decades of research and the understanding of the 
relationship between the immune system and cancer. This has led to the 
development of therapies approved by the FDA such as a cancer vaccine in 
2010 known as sipuleucel-T and immunomodulatory antibodies, iplimumab in 
2011, nivolumab and pembrolizumab (Callahan et al., 2013, DeFrancesco, 
2010, Lynch and Murphy, 2016). Whole-cancer-cell immunotherapies also have 
a promising future in the treatment of CRC with OncoVAX® in its confirmatory 
Phase IIIb clinical trials (Melero et al., 2014). Various success stories about the 
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use of immunotherapy in the treatment of cancer have been published. Such 
treatments include T-cell transfer therapy involving tumour-infiltrating 
lymphocytes (TIL) consisting of CD8+ T-cells obtained from a patient with 
mCRC which was able to recognise cancer cells harbouring mutant KRAS 
G12D gene (Tran et al., 2016). Many human cancers harbour mutations in the 
KRAS oncogene with reports of KRAS G12D expressed in about 13% of CRCs 
(Vaughn et al., 2011). A patient receiving TILs consisting of about 75% CD8+ T-
cells reactive to KRAS G12D, showed regression of all seven metastatic lung 
lesions in the patient after 40 days of therapy with only one of the lesions 
progressing after 9 months (Tran et al., 2016).  
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Figure 1.5 Intensive and less intensive treatment lines for metastatic CRC. 
*Cetuximab maybe be administered alone for patients intolerant to irinotecan 
(Goldberg et al., 2007). 
 
 
 
 46 
 
1.4.1 Cetuximab 
Cetuximab is marketed as Erbitux® and is an inhibitor of the EGFR. It targets 
the EGF-mediated cell growth regulatory pathway (Kohne and Lenz, 2009). 
Cetuximab is administered in combination with irinotecan or alone for patients 
intolerant to irinotecan (Goldberg et al., 2007) (Figure 1.5). 
1.4.2 Panitumumab 
Panitumumab is marketed as Vectibix® and also an EGFR inhibitor that targets 
the EGF pathway (Kohne and Lenz, 2009). 
1.4.3 Bevacizumab 
Bevacizumab, marketed as Avastin® targets the VEGF-mediated angiogenesis 
pathway by interfering with VEGF-A binding to the receptor, thus blocking 
VEGF-mediated intracellular signalling for angiogenesis and tumour growth 
(Hicklin and Ellis, 2005). This is used in combination with FOLFIRI or FOLFOX 
(Figure 1.5). 
1.4.4 5-Fluorouracil (5-FU) 
5-Fluorouracil (5-FU) is converted to fluorodeoxyuridine monophosphate by 
thymidine phophorylase enzyme. In the presence of reduced folate, 
fluorodeoxyuridine reacts with thymidylate synthase to form a complex that 
interferes with DNA synthesis and subsequently causing apoptosis in the 
tumour cells. Leucovorin (folinic acid) is often added to 5-FU because of its 
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ability to enhance binding between fluorodeoxyuridine monophosphate and 
thymidylate synthase (1992, Kohne and Lenz, 2009).  
1.4.5 Oxaliplatin  
Oxaliplatin is a third-generation diaminocyclohexane platinum compound, which 
is effective in cisplatin-resistant tumours (Ramanathan et al., 2003). Similar to 
other platinum derivatives (Table 1.1), oxaliplatin mediates its action via 
formation of platinum-DNA adducts with N(7) guanines of DNA to form 
monoadducts (Levi et al., 2000) and subsequently diadducts, which are capable 
of blocking DNA replication (Knox et al., 1986). This results in oxaliplatin 
inducing primary and secondary DNA lesions leading to cell-cycle arrest, 
autophagy and apoptosis in human cancer cells (Liu et al., 2015, Raymond et 
al., 1998). Oxaliplatin in combination with 5-FU and Leucovorin (Figure 1.5) 
resulted in an improvement in disease-free survival of patients from CRC and a 
23% relative reduction in the risk of recurrence (Andre et al., 2004). 
Peripheral neuropathy is the main safety concern associated with oxaliplatin. 
Frequent, transient, distal paresthesias are induced by oxaliplatin shortly after 
administration (Andre et al., 2004). Lean body mass (LBM) have been found to 
be a significant predictor in toxicity and neuropathy in patients undergoing 
FOLFOX therapy such that patients with low LBM are susceptible to oxaliplatin 
toxicity, which has led to a cut off dose point of 3.09 mg oxaliplatin/kg LBM. It is 
therefore essential to use conventional body surface area dosing in order to 
reduce such serious side effects (Ali et al., 2016). 
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Drug and Structure Mechanism 
of action 
Major Side 
Effects 
Mechanisms 
of 
Resistance 
 
DNA 
crosslinker 
nephrotoxicity; 
neurotoxicity; 
ototoxicity 
 
decreased 
uptake; 
increased 
efflux; 
increased 
DNA repair 
capacity; 
enhanced 
replication 
bypass; 
failure of 
death 
pathways  
 
DNA 
crosslinker 
hepatotoxicity; 
neurotoxicity; 
pulmonary toxicity 
 
DNA 
crosslinker 
myelosuppression 
Table 1.1 Structure and Properties of Platinum-based antineoplastics. 
[Adapted from (Cheung-Ong et al., 2013, Weiss and Christian, 1993)]. 
 
1.4.6 Immunotherapy 
Immunotherapy has the ability to cause the immune system to attack and 
destroy cancer cells by recognising specific antigens that are found on tumour 
cells.  
Carcinoembryonic antigen (CEA) is the most widely studied tumour associated 
antigen (TAA) in CRC and has been on-going since the 1960s (Gold and 
Freedman, 1965). CEA is a plasma membrane-associated glycoprotein 
expressed by adult tissues and overexpressed by adenocarcinomas of the 
colon, breast lungs, which can be found in the serum (Hammarstrom, 1999). 
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Another TAA targeted in immunotherapy is MUC1 (mucin), a transmembrane 
glycoprotein, found on the surface of secretory epithelial cells which protects 
the body from bacterial invasion by binding to pathogens (Hollingsworth and 
Swanson, 2004). The overexpression of MUC1 in CRC regulates β-catenin and 
Ras tumour promoting signalling pathways leading to poor prognosis (Singh 
and Hollingsworth, 2006). An adenoviral gene delivery platform encoding CEA 
antigen, Ad5 has been shown to cause cell mediated immunity in over 60% of 
patients with advanced stage CRC (Morse et al., 2013). 
1.4.6.1 Cancer vaccines 
Cancer vaccines stimulate the immune system in to recognising tumour-specific 
antigens harboured by cancer cells as foreign bodies. This facilitates the attack 
of cancer cells by the immune system (Lynch and Murphy, 2016). Cancer 
vaccines can be categorised into autologous tumour cell vaccines, dendritic cell 
vaccines, DNA vaccines and viral vector-based vaccines (Xiang et al., 2013). 
1.4.6.2 Cytokine therapy 
Studies on the use of cytokine therapy in CRC is quite limited (Lynch and 
Murphy, 2016). PEGylated recombinant IL-10 (AM0010) in a phase I study 
resulted in a sustained systemic Th 1 immune stimulation with a CRC patient 
having the cancer under control for over 40 weeks (Lynch and Murphy, 2016). 
1.4.6.3 Toll-like receptors (TLR) agonists 
Toll-like receptors (TLR) agonists act by targeting the innate immune system 
(Wittig et al., 2015) with TLR-9 out of the ten human TLRs (TLR-1 to TLR-10) 
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exhibiting protective role against malignant transformation in colorectal mucosa 
(Eiro et al., 2012). Examples of TLR agonists in early clinical trials include CpG-
oligodeoxynucleotides (CpG-ODN) and MGN1703, a synthetic DNA-based 
immunomodulator with a dumbbell-like structure, which are being designed as 
maintenance therapy in mCRC patients after standard first-line therapy (Lynch 
and Murphy, 2016). 
1.4.6.4 Adoptive cell transfer (ACT) 
Adoptive cell transfer (ACT) involves the harvesting of autologous T-cells from 
TILs, activating and expanding them in number ex vivo after which they are 
then re-introduced into the patient host. This method of introducing large 
numbers of T-cells has been beneficial in tumour regression (Rosenberg et al., 
2011). This method of therapy is particularly attractive because it targets driver 
mutations, which are tumour-specific and may likely be harboured by all the 
tumour cells (McGranahan et al., 2015). However, limitations in this therapy 
include lack of immune memory, protracted time and cost of T-cells production 
and risk of severe side effects (Xiang et al., 2013).  
1.4.6.5 Checkpoint inhibition 
Checkpoint inhibitors are monoclonal antibodies that deregulate the Major 
Histocompatibility Complexes T-cell Receptor signalling pathways by targeting 
co-inhibitory molecules that are responsible for the suppression of the immune 
system via stimulating T-cell dysfunction or apoptosis (Schreiber et al., 2011). 
These co-inhibitory molecules include CTLA-4, PD-1, PD-L1/2, lymphocyte-
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activation gene-3, T-cell immunoglobulin, T-cell immunoglobulin mucin-3 (Lynch 
and Murphy, 2016).  
1.4.6.5.1 CTLA-4 (Cytotoxic T-lymphocyte associated protein-4) inhibitors: 
CTLA-4 is a receptor found on the surface of CD4 and CD8 T cell membranes 
responsible for inhibiting the activation of the immune system. Examples of 
CTLA-4 inhibitors include ipilimumab and tremelimumab used for melanoma 
(Lynch and Murphy, 2016). These inhibitors however have not been successful 
in CRC therapy (Chung et al., 2010). 
1.4.6.5.2 PD-1 (Programmed death-1) inhibitors: 
PD-1 receptor induces exhaustion in effector T-cells (Wherry, 2011). PD-1 
inhibitors such as pembrolizumab block the interaction between PD-1 receptor 
and its ligands, PD-L1 and PD-L2 in order to enable T-cell activation and 
subsequent antitumor immune response (Gangadhar and Salama, 2015). About 
50% of CRCs express PD-L1 (Dong et al., 2002). Pembrolizumab has been 
shown to be effective in patients with MSI (DNA MMR deficient) and also in a 
patient with MSS (DNA MMR proficient) CRC (Gong et al., 2017, Kieler et al., 
2016). 
1.4.7 Aspirin 
Aspirin, a non-steroidal anti-inflammatory drug (NSAID) is an old drug 
commonly used for pain, inflammatory conditions and fever therapy (Langley et 
al., 2011). Its active metabolite is known to be salicylic acid, which was used 
over two centuries ago by a Greek physician as extracts of the willow bark to 
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treat fever (Gensini and Conti, 2009). The elimination of salicylates depends on 
two major pathways: formation of salicyluric acid and salicyl phenolic 
glucoronide. As these pathways are readily saturated, salicylates behave 
differently from most other drugs in that they show pseudo-zero order kinetics, 
meaning their half-life in the serum is directly proportional to its concentration 
(Paulus et al., 1971). 
1.4.7.1 Pharmacology of Aspirin 
Several modes of action for aspirin as an antiproliferative and 
chemopreventative agent have been suggested. They include:  
i. The accepted pathway by which aspirin acts as an anti-inflammatory 
agent: irreversible cyclooxygenase inactivation through non-enzymatic 
acetylation of a single serine residue, which ultimately leads to the 
inhibition of prostaglandin biosynthesis (Patrignani et al., 2017, Patrono 
et al., 2008, Schror, 2011, Warner et al., 1999). 
ii. The inhibition of NF-κB activity (Gurpinar et al., 2013, Kopp and Ghosh, 
1994). 
iii. Inhibition of the JNK pathway (Schwenger et al., 1997). 
iv. Activation of AMP kinase (AMPK) (Hawley et al., 2012). 
v. Aspirin has been found to cause apoptosis through the Wnt-β-catenin 
pathway (Deng et al., 2009), which provides a link between the Wnt-β-
catenin pathway and apoptosis. 
vi. Normalising EGFR expression (Li et al., 2015). 
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vii. Increase in the expression of hMLH1, hPMS2, hMSH2 and hMLH1, 
which are DNA MMR proteins (Goel et al., 2003). 
viii. Inhibition of VEGF, which leads to the suppression of angiogenesis 
(Borthwick et al., 2006, Ouyang et al., 2008).  
 
The general pharmacology of aspirin and other NSAIDs is known to be the 
inhibition of COX-1 and COX-2 (cyclooxygenase) (Figure 1.6) to prevent the 
generation of prostanoids from arachidonic acid. These prostanoids, which are 
biologically active lipid mediators, play significant roles in many physiologic 
pathways and include prostaglandin PGD2, PGE2, PGF2α, prostacyclin and 
thromboxane (TX)A2  (Bruno et al., 2012). Prostanoids have an effect in various 
health conditions such as inflammation, pain, asthma, platelet function, renal 
function, cardiovascular homeostasis and cancer (Smyth et al., 2009). 
It has been shown that repeated doses of aspirin at a low dose (75-100 mg/day) 
causes maximal inhibition of platelet COX-1 activity after several days without 
greatly affecting cells elsewhere in the body. This effect lasts to about 24 hours 
(Bruno et al., 2012). Aspirin is primarily absorbed in the stomach when taken 
orally and goes through the GI tract and hepatic first-pass metabolism (Hatori et 
al., 1984). Aspirin undergoes hydrolysis by non-specific esterases and inhibits 
COX by acetylation before it is absorbed into the system and thus the reason 
for reduced systemic levels of aspirin and high levels of salicylic acid which is 
not as potent (Bruno et al., 2012). 
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1.4.7.2 Chemoprevention with Aspirin 
 Chemopreventitive and chemotherapeutic effects of aspirin in cancer have 
been widely studied (Elwood et al., 2009) and it has been found to reduce the 
risk of CRC. 
Despite a population-based cohort study that concluded non-aspirin NSAIDs to 
have a greater effect than aspirin in reducing the risk of CRC (Garcia Rodriguez 
et al., 2001), over the years a number of randomised controlled studies have 
been carried out which have suggested a protected effect or reduced risk 
against colorectal adenoma/cancer with the regular use of aspirin (Benamouzig 
et al., 2012, Bosetti et al., 2012, Burn et al., 2011a, Burn et al., 2011b, Chan et 
al., 2012, Johnson et al., 2010, Sandler et al., 2003), which also led to the 
recommendation of low dose aspirin for the prevention of CRC by the United 
States preventative services task force (Chan and Ladabaum, 2016). 
An analysis of individual patient data from three large UK trials based on daily 
aspirin versus non-aspirin with approximately four years duration of treatment 
was the first proof in man that indeed aspirin reduced mortality from several 
cancers (Rothwell et al., 2011). Aspirin has a dose-dependent effect on CRC 
risk with probably the highest risk reduction in patients taking a lower dose with 
a reduction of CRC after five years of continuous use (Din et al., 2010). 
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Figure 1.6 COX-dependent and COX-independent mechanisms of antitumoural effects of aspirin.  
Mechanisms of action include: (i) inhibition of the Wnt/β-catenin pathway, which targets gene expression 
involved in tumorigenesis when β-catenin interacts with T-cell factor (Tcf) in the nucleus; (ii) inhibition of the 
binding of c-Raf to Ras resulting in the inhibition of extracellular signal-regulated protein kinase (ERK) pathway, 
which is involved in various downstream signals that cause proliferation, cell differentiation and cell survival; (iii) 
inhibition of I-kappa kinase (IκK), thereby preventing the activation by NF-κB  and its ability to regulate gene 
expressions that cause antiapoptosis in cancer cells; (iv) inhibition of COX-2 derived PGE2 formation and 
recovery of apoptosis [Adapted from (Bruno et al., 2012, Schror, 2011) ].  
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1.4.7.3 Risks associated with aspirin therapy 
There is increasing evidence of the benefits of aspirin in the prevention of CRC 
and it is a standard treatment used in the prevention of cardiovascular events. 
However, it still presents with some health risks such as gastrointestinal (GI) 
toxicity, in particular GI bleeding and peptic ulcer, which have been found to be 
mostly age-dependent (Li et al., 2017, Patrono et al., 2005) and rarely fatal 
(Roderick et al., 1993). 
Data from randomised, controlled, trials have shown there to be about a two-
fold increase in the risk of GI complications (Roderick et al., 1993) regardless of 
the aspirin being in enteric-coated or buffered formulation (Garcia Rodriguez et 
al., 2001). However, administration of proton-pump inhibitors in combination 
with aspirin greatly reduced GI effects (Garcia Rodriguez et al., 2016). 
There are contradicting facts in regards to the effect of dose and duration of 
aspirin usage on risk of GI bleeding (Huang et al., 2010). Some data suggest 
that the GI mucosa adapts to the side effect of aspirin when used for a long 
duration of time and an increased risk of GI bleeding when used for a shorter 
duration (Griffin et al., 1991, Langman et al., 1994). But other studies show that 
this increased risk in GI bleeding is cumulative overtime (Nelson et al., 1994). 
However, these contradictions may be due to heterogeneous conditions of the 
individual studies (Huang et al., 2010). 
The symptoms of GI complications are made worse in the presence of H. pylori 
infection even though it does not initiate or predispose to NSAID gastropathy 
(Goggin et al., 1993). It is thus recommended for patients to undergo H. pylori 
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screening before commencing on aspirin therapy to reduce the possibility of GI 
side effects. 
1.5 Aims and Objectives 
In this study it is intended to synthesize novel aspirin analogues, identify and 
study their chemical and pharmacological properties/effects as anti-cancer 
agent in SW480 CRC cell line. The research questions include: 
i. Are these aspirin analogues stable at room temperature when in 
solution? 
ii. Do these compounds breakdown into salicylates? 
iii. What is the best organic solvent to dissolve these compounds with the 
least effect on cell viability? 
iv. How cytotoxic are these compounds against SW480 CRC cells, OE33 
and FLO1 oesophageal cell lines in vitro?  
v. Do these compounds cause cell death through apoptosis, necrosis or a 
mixture of both? 
vi. Do these aspirin analogues affect the pharmacology of the EGFR and its 
signalling pathway? If so, what is the possible mechanism of action? 
vii. Do these compounds synergise with platinum compounds in SW480 
CRC and OE33 oesophageal cell lines in vitro? 
viii. Are these aspirin analogues toxic in silico? 
 
These investigations will be carried out using different laboratory tools and 
techniques, which include; Cell tissue culture, MTT assays, TLC (thin layer 
chromatography), IR (infra-red) and NMR (nuclear magnetic resonance) 
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spectroscopy, salicylate assay developed using fluorescent quantification of 
salicylic acid, flow cytometry, western blots using SDS-PAGE gels and 
immunocytochemistry using confocal microscopy. The 
CompuSyn®/CalcuSyn® software will also be adopted for the synergy 
experiments and DEREK software for possible toxicities of these 
compounds based on pre-existing stored data. 
The main aim of this chapter is to find out whether these aspirins can be 
used as a more affordable adjunct or in combination with other anti-cancer 
agents in the prevention, maintenance and possible cure for colorectal and  
oesophageal cancer.
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Chapter 2. Materials & Methods 
2.1 Materials 
2.1.1 Lab instruments 
Equipment used is listed in Table 2.1 
 
Instrument Company 
Amersham Biosciences Storm 860 3-
Scan Mode Phospho Lab imager 
Amersham Biosciences Ltd. 
Amersham place, Little Chalfont 
Buckinghamshire 
HP7 9NA, UK 
AmScope Pre-cleaned Microscope 
slides 
AmScope  
BD Accuri™ C6 flow cytometer Becton Dickinson (BD) 
The Danby Building 
Edmund Halley Road 
Oxford Science Park, Oxford  
OX4 4DQ, UK 
Beckman Z1 Coulter® Single 
threshold particle counter 
Beckman Coulter (UK) Ltd.  
Oakley Court  
Kingsmead Business Park  
London Road, High Wycombe  
HP11 1JU, UK  
Bio-Rad Power Pac 200/2.0  
Electrophoresis Power Supply 
164-5050, Bio-Rad laboratories Ltd. 
Bio-Rad House, Maxted Road 
Hemel Hempsted, Hertfordshire  
HP2 7DX, UK  
CLARIOstar® monochromator 
microplate reader 
BMG LABTECH  
5 Alton House Office Park 
Gatehouse Way 
Aylesbury 
HP19 8XU, UK 
Glass base dish (Glass) IWAKI brand 
Asahi Glass Co., Ltd. 
Japan 
Microplate Reader Thermo Multiskan 
Ascent 96 & 384 
MTX Lab Systems, LLC 
1114 Palma Sola Blvd. 
Bradenton 
FL 34209, USA 
Mono-Mixer Desaga, Sarstedt-Gruppe 
Sarstedt AG & Co. 
Sarstedtstraße 1 
51588 Nümbrecht 
Germany 
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Instrument 
 
Company 
Non-vented tissue culture flasks Sarstedt Ltd. 
68 Boston Road 
Leicester 
LE4 1AW, UK 
Olympus Microscope CK2-TR Olympus 
KeyMed House 
Stock Road, Southend-on-Sea 
SS2 5QH, UK 
Panasonic Direct Heat CO2 incubator Panasonic Healthcare Co. Ltd.  
1-1-1 Sakata, Oizumi-Machi Ora-Gun, 
Gunma 370-0596 Japan 
Square cover glass (22X22mm) AmScope 
Storm System Optical Scanner Amersham Biosciences UK Limited 
Amersham Place Little Chalfont 
Buckinghamshire 
HP7 9NA, UK 
Stuart® SMP 10 Melting Point 
Apparatus 
Bibby Scientific Ltd. 
Beacon Road 
Stone, Staffordshire 
ST15 0SA, UK 
Vented tissue culture flasks 
 
 
Sarstedt Ltd. 
68 Boston Road 
Leicester 
LE4 1AW, UK 
VWR Digital Heat Block VWR  
Hunter Boulevard, Magna Park 
Lutterworth, Leicestershire  
LE17 4XN, UK 
Zeiss LSM 880 Confocal Microscope  
 
Carl Zeiss Ltd.  
509 Coldhams Lane, Cambridge 
Cambridgeshire  
CB1 3JS, UK 
Table 2.1 List of instruments and equipment used in this study. 
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2.1.2  Media and Reagents/Chemicals 
All media and reagents/chemicals used were standard grade or higher and 
purchased from Sigma-Aldrich unless otherwise stated. Details are provided 
in Table 2.2. 
 
 
Name 
 
Product code 
 
Company 
40% Acrylamide Solution 
(Acrylamide: Bis-
Acrylamide, 29:1), 
Electrophoresis Grade 
BP1408-1 Fisher Scientific 
Bishop Meadow Road 
Loughborough 
LE11 5RG, UK 
Acetaminophen 1706 TOCRIS Bioscience 
The Watkins Building 
Atlantic Road 
Avonmouth, Bristol 
BS11 9QD, UK  
Acetic acid, 99.5% pure 124040025 ACROS ORGANICS 
Fisher Scientific Ltd. 
Bishop Meadow Road 
Loughborough 
LE11 5RG, UK 
Acetone 40308 Sigma® Sigma-Aldrich 
Company Ltd., The 
Old Brickyard, New 
Road Gillingham 
Dorset  
SP8 4XT, UK 
Acetylsalicylic acid (Aspirin) A5376 Sigma® Sigma-Aldrich 
Company Ltd. 
 
Annexin-V-FLUOS Staining 
kit 
11 858 777 001 
1 988 549 
Roche Diagnostics 
Ltd. 
Applied Science 
Charles Avenue 
Burgess Hill 
West Sussex 
RH15 9RY, UK 
Ammonium Persulphate 
(APS) 
A-3678 Sigma® Sigma-Aldrich 
Company Ltd. 
Bovine Serum Albumin 
(BSA) 
BP9702-100 Fisher Scientific 
Bromophenol blue B-5525 Sigma® Sigma-Aldrich 
Co. 
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Name 
 
Product code 
 
Company 
Carboplatin S1215 Stratech Scientific Ltd. 
Unit 7, Business 
Centre, Oaks Drive 
Newmarket 
CB8 7SY, UK 
CellTiter 96® Aqueous One 
Solution Cell Proliferation 
Assay kit 
G3580 Promega Corporation 
Delta House 
Southhampton Sience 
Park, Southhampton 
SO16 7NS, UK 
Cisplatin S1166 Stratech Scientific Ltd. 
Diclofenac sodium salt 4454 TOCRIS Bioscience 
The Watkins Building 
Atlantic Road 
Avonmouth, Bristol 
BS11 9QD, UK 
Diflunisal D3281 Sigma-Aldrich® 
Sigma-Aldrich Inc. 
Dimethyl sulfoxide (DMSO) D5879 Honeywell Sigma-
Aldrich Company Ltd 
Dulbecco’s Modified Eagle 
Medium (DMEM)  
11965-092 gibco® life 
technologies™ 
ThermoFisher 
Scientific 
Epidermal Growth Factor, 
Biotinylated, complexed to 
Alexa Fluor® 555 
Streptavidin (Alexa Fluor® 
555 EGF complex) 
E35350 Molecular Probes 
Eugene, Oregon, 
USA 
Ethyl acetate, 99.8% pure 270989 Sigma-Aldrich® 
Sigma-Aldrich Inc. 
Foetal Bovine Serum (FBS) FB-1001/500 Labtech International 
Ltd. 
2 Birch House 
Brambleside  
Bellbrook Ind. Est. 
Uckfield, East Sussex 
TN22 1QQ, UK 
Glycerol G5516 Sigma-Aldrich® 
Sigma-Aldrich Inc.  
Glycine powder J64365 Alfa Aesar, Shore 
Road, Port of 
Heysham Industrial 
Park, Lancashire  
LA3 2XY, UK 
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Name 
 
Product code 
 
Company 
Hexane, ≥95% pure 439177 Sigma-Aldrich® 
Sigma-Aldrich Inc. 
Hydrogen peroxide H-1009 Sigma® Sigma-Aldrich 
Co. 
Indomethacin 1708 TOCRIS Bioscience 
Leibovitz’s L-15 Medium 11415-049 gibco® life 
technologies™ 
ThermoFisher 
Scientific 
Methanol 34860-1L-R Sigma® Sigma-Aldrich 
Company Ltd 
N,N,N’,N’-
Tetramethylethylenediamine 
(TEMED) 
T9281 Sigma-Aldrich® 
Sigma-Aldrich Inc. 
Naproxen 2655 TOCRIS Bioscience 
Oxaliplatin S1224 Stratech Scientific Ltd. 
Penicillin streptomycin 
(10,000U/ml) 
15140122 ThermoFisher 
Scientific, Scientific 
Phosphate Buffered Saline 
(PBS) pH 7.4 (1X) 
10010-015 gibco® life 
technologies™ 
ThermoFisher 
Scientific 
3 Fountain Drive 
Inchinnan business 
Park, Paisley 
PA4 9RF 
Protease Inhibitor Cocktail 
(100X) 
5871S Cell Signalling 
Technology, Inc.  
New England Biolabs 
75-77 Knowl Piece 
Protein Plus Protein™ Dual 
Color Standards 
161-0374 Bio-Rad Laboratories 
Ltd., Bio-Rad House, 
Maxted Road, Hemel 
Hempstead, 
Hertfordshire HP2 
7DX, UK 
RPMI Medium 11875-093 gibco® life 
technologies™ 
ThermoFisher 
Scientific 
Salicylic acid 105910 Sigma-Aldrich®, 
Sigma-Aldrich Co. 
Sodium chloride 301237S BDH GPR™, VWR 
International Ltd. 
Poole  
BH15 1TD, UK 
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Name 
 
Product code 
 
Company 
 
Sodium dodecyl sulphate 
(SDS) 
  
Sigma® Sigma-Aldrich 
Co. 
Staurosporine S1421 Selleckchem.com 
Stratech Scientific Ltd. 
Unit 7 Acorn Business 
Centre 
Oaks Drive 
Newmarket, Suffolk 
CB8 7SY, UK 
Thermo ScientificTM 
PierceTM ECL 2 western 
Blotting Substrate 
80196 Thermo Scientific 
Hunter Boulevard 
Magna Park 
Lutterworth 
Leichestershire 
LE17 4XN, UK 
Thiazolyl Blue Tetrazolium 
Bromide 
M2128 Sigma® Sigma-Aldrich 
Company Ltd 
Tris-(hydroxymethyl) 
aminomethane 
443866G VWR BDH 
PROLABO®  
Unit 15, The Birches 
Willard Way 
Imberhorne Industrial 
Estate 
East Grinstead 
West Sussex 
RH19 1XZ, UK 
Trypsin solution T4674 Sigma-Aldrich® 
Sigma-Aldrich Inc. 
Trypsin-EDTA 1X 
[0.25%(w/v)-0.53mM EDTA] 
solution 
T3924 Sigma-Aldrich® 
Sigma-Aldrich Inc. 
Tween®-20 P1379 Sigma-Aldrich® 
Sigma-Aldrich Inc. 
Vectashield® Mounting 
Medium with DAPI 
 Vector Laboratories 
Inc. 
3 Accent Park 
Bakewell Road 
Orton Southgate 
Peterborough 
PE2 6XS, UK 
Vybrant® Apoptosis Assay 
Kit #4, YO-PRO®-
1/Propidium Iodide 
V13243 Life Technologies 
Corporation 
Table 2.2 List of Reagents, Drugs, Culture media and other chemicals used in 
this study. 
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2.1.3  Buffers and solutions 
According to each experimental protocol, different buffers and solutions were 
required to be made up. A list of buffers used in this study is provided in Table 
2.3. 
 
Buffers Ingredients 
Antibody dilution buffer #1 5%(w/v) non-fat dry milk (NFM), 
0.1%(v/v) Tween-20 in Tris Buffered 
Saline (TBS) 
Antibody dilution buffer #2 5%(w/v) BSA, 0.1%(v/v) Tween-20 in 
TBS 
Blocking buffer #1 5%(w/v) NFM, 0.1%(v/v) Tween-20 in 
TBS 
Blocking buffer #2 5%(w/v) BSA, 0.1%(v/v) Tween-20 in 
TBS 
Blocking buffer #3 3%(w/v) BSA, 0.2%(v/v) Tween-20 in 
Phosphate Buffered Saline (PBS) 
Freezing solution FBS+10%(v/v) DMSO 
Running buffer Tris base 3g, Glycine 14.4g, 10%SDS 
10ml, Water to 1L 
Transfer buffer Tris base 3g, Glycine 14.4g, 
Methanol 200ml, Water to 1L 
Laemmli Sample buffer (2X) Tris 0.125M pH 6.8, 4% SDS, 20% 
Glycerol, 10% β-mercaptoethanol, 
0.004% bromophenol blue 
Phosphate Buffered Saline (PBS) 1 tablet of PBS dissolved in 200ml of 
deionised water 
Tris Buffered Saline (TBS) 10X 24g Tris base, 88g NaCl, dissolved in 
900ml Water; Solution was pH 
adjusted to 7.6 with 12M HCl and 
Water to 1L 
Tris Buffered Saline with Tween-20 
(TBST) 1X 
100ml TBS (10X), 900ml dWater, 1ml 
Tween-20 
Fixing Solution 50%(v/v)Acetone, 50%(v/v)Methanol 
Acid stripping buffer 0.2% BSA in L-15 medium (0.1g BSA 
in 50ml of L-15 medium); Solution 
was pH adjusted to 3.5 with HCl 
Table 2.3 List of buffers used in this study. 
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2.1.4  Primary antibodies 
Primary antibodies were used to detect the levels of antigen or protein of 
interest. Find below the primary antibodies used in this study.  
 
Antibody Isotype Working dilution 
EGF Receptor (D38B1) XP® Rabbit 
mAb 
#4267 
Cell Signalling Technology Inc. 
Schuttersveld 2 
2316 ZA Leiden 
The Netherlands 
Rabbit IgG 1:1000 
EGFR (phospho Y1068) Ab 
#ab5644 
Abcam, 330 Cambridge Science 
Park Cambridge  
CB4 0FL, UK 
Rabbit IgG 1:1000 
EGFR (phospho Y1172) Ab 
#ab135560 Abcam 
Rabbit IgG 1:1000 
EGFR (phospho Y1045) Ab 
#2237S  
Cell Signalling Technology Inc. 
 
Rabbit IgG 1:1000 
EGFR (phospho Y992) Ab 
#9922 
Cell Signalling Technology Inc.  
  
Rabbit IgG 1:1000 
EGFR (phospho Y1101) Ab 
#ab76195  
Abcam 
Mouse IgG 1:1000 
Anti--Tubulin antibody 
#ab15568 
Abcam 
Rabbit IgG 1:2000 
GAPDH (FL-335) antibody 
#sc-25778 
Santa Cruz Biotechnology Inc. 
Bergheimer Str. 89-2 69115 
Heidelberg Germany 
Rabbit IgG 1:1000 
Anti-p21 antibody [EPR3993] 
#ab109199 
Abcam 
Rabbit IgG 1:1000 
Anti-Bcl-2 antibody [E17] 
#ab32124 
Abcam 
Rabbit IgG 1:1000 
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Table 2.4 List of Primary antibodies used in this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antibody Isotype Working dilution 
BAX (N-20) antibody 
#sc-493 
Santa Cruz Biotechnology Inc. 
Mouse IgG 
 
1:200 
Stat3 (79D7) Rabbit mAb 
#4904  
Cell Signalling Technology Inc. 
 
Rabbit IgG 1:2000 
Phospho-Stat3 (Tyr705) Antibody 
#9131  
Cell Signalling Technology Inc. 
Rabbit IgG 1:1000 
Anti-EEA1 antibody [1G11]- Early 
Endosome Marker 
#ab70521 
Abcam 
Mouse IgG 1:1000 
Anti--Catenin antibody 
#ab6302 
Abcam 
Rabbit IgG 1:2000 
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2.1.5  Secondary antibodies 
Secondary antibodies bind to primary antibodies and are normally linked to a 
fluorophore or horseradish peroxidase (HRP) to enable detection when 
excited by laser or enhanced chemiluminescence (ECL) substrate. 
The secondary antibodies used in this study are shown in the table below. 
 
Isotype Species Working dilution 
Anti-Rabbit IgG-Phycoerythrin (PE) 
#ab72465 
Abcam  
330 Cambridge Science Park, Cambridge 
CB4 0FL, UK 
Goat 1:1000 
Anti-Rabbit IgG-Horseradish Peroxidase 
(HRP) 
#ab16284 
Abcam 
Donkey 1:2000 
Anti-Mouse IgG+IgM+IgA-Allophycocyanin 
(APC) 
#ab130775 
Abcam 
Goat 1:1000 
Anti-Mouse IgG-Fluorescein isothiocyanate 
(FITC) 
#ab6728 
Abcam 
Rabbit 1:1000 
Anti-Rabbit IgG (FITC) 
#ab6717 
 
Goat 1:200 
Anti-Rabbit IgG (HRP) 
#7074S 
Cell Signalling Technology Inc. 
Schuttersveld 2 
2316 ZA Leiden 
The Netherlands 
Goat 1:2000 
Table 2.5 List of Secondary antibodies used in this study. 
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2.1.6 Cell lines 
SW480 CRC cells were originally purchased from European Collection of 
Authenticated Cell Cultures (ECACC). 
Characteristics and morphology of these cell lines are presented in Table 2.6. 
The CRC cell line, SW480 is from a colorectal adenocarcinoma and is 
adherent to the floor of the tissue culture flask (Leibovitz et al., 1976). This cell 
line was cultured in L-15 medium supplemented with 10% (v/v) of FBS and 
1% (v/v) penicillin-streptomycin. The cells were cultured in non-vented flasks 
and incubated at 37°C in the presence of 5% CO2. 
The oesophageal cell line, OE33 and FLO-1 were generously provided by Mr 
Tim Underwood, Cancer Sciences Division, University of Southhampton and 
was cultured in RPMI-1640 medium supplemented with 10% (v/v) FBS and 
1% (v/v) penicillin-streptomycin. This cell line originates from an oesophageal 
adenocarcinoma and also grows adherent to floor of the tissue culture flask. 
These cells were grown in vented tissue culture flasks and incubated at 37°C 
with an atmosphere of 5% CO2. U251 MG cells were kindly provided by Prof. 
W. Wang. FLO1 and U251 MG cell lines were originally derived from an 
oesophageal adenocarcinoma and a malignant glioblastoma tumour 
respectively. All these cell lines were cultured in DMEM medium 
supplemented with 10% (v/v) FBS and 1% (v/v) 10,000 U/ml penicillin-10 
mg/ml streptomycin (Table 2.6). Vented tissue culture flasks were used and  
incubated at 37°C in the presence of 5% CO2.
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Cell line SW480 
(ATCC®CCL-
228™) 
OE33 FLO1 U251 MG 
Organism Homo sapiens  Homo sapiens Homo sapiens Homo sapiens 
Tissue Colon Oesophagus Oesophagus Brain 
Cell line origin Metastatic site of 
colorectal 
adenocarcinoma of 
a 50 year old male 
Caucasian 
Adenocarcinoma of the 
lower oesophagus of a 
73 year old female 
patient  
Primary distal 
oesophageal 
adenocarcinoma in a 
68 year old male 
Caucasian 
Derived from a 
malignant 
glioblastoma tumour 
Disease Duke’s type B Barrett’s metaplasia Adenocarcinoma  Human glioblastoma 
astrocytoma 
Culture 
properties 
Adherent Adherent Adherent Adherent 
Morphology Epithelial Epithelial Epithelial Pleumorphic/ 
astrocytoid 
Culture media L-15, 10%(v/v) FBS, 
1%(v/v) 10,000 U/ml 
penicillin-10 mg/ml 
streptomycin 
RPMI-1640, 10%(v/v) 
FBS, 1%(v/v) 10,000 
U/ml penicillin-10 
mg/ml streptomycin 
DMEM, 10%(v/v) 
FBS, 1%(v/v) 10,000 
U/ml penicillin-10 
mg/ml streptomycin 
DMEM, 10%(v/v) 
FBS, 1%(v/v) 10,000 
U/ml penicillin-10 
mg/ml streptomycin 
Table 2.6 Characteristics of cancer cell lines used in this study.  
(Adapted from ATCC (American Type Culture Collection); ECACC (European Collection of Authenticated Cell Cultures) General Cell Collection, 
Public Health England, (Leibovitz et al., 1976).
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2.2 Methods 
2.2.1  Tissue Culture 
The procedures and experiments requiring mammalian cells were all carried out 
aseptically in a laminar tissue culture hood using sterile materials and reagents. 
Cell morphology and confluency were observed using an inverted phase 
contrast microscope (OLYMPUS CK2-TR, Japan). 
The cancer cell lines were regularly split in the appropriate medium 
supplemented with 10% FBS and 1% antibiotic solution (10,000 U/ml penicillin-
10 mg/ml streptomycin) warmed to room temperature to maintain growth and 
confluency of cells for experiments. 
Prior to splitting the cells, they were always washed gently with PBS before 
being detached from the floor of the culture flask using 0.25% (w/v) Trypsin-
0.53 mM EDTA. After the cells had completely detached, medium was added to 
inactivate trypsin. The cells were then seeded in a splitting ratio of 1:6 into 
either T75 (75 cm2) or T175 (175 cm2) tissue culture flasks with fresh medium 
and incubated at 37°C. OE33, FLO1 and U251 cell lines were seeded in vented 
flasks while SW480 CRC cell line was seeded in non-vented flask. This was 
done twice a week. 
2.2.1.1 Cell Counting 
Cells were counted using the Coulter counter (Beckman Z1 Coulter® Single 
threshold particle counter). Twenty μl of the detached cell solution was pipetted 
out into 10ml of isotonic solution (ISOTON® II Diluent, 20 L, Item No: 8546719, 
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Beckman Coulter) and then inserted into the Coulter counter for cell counting. 
Five hundred μl of the diluted cell suspension were counted, representing the 
number of cells per μl of the original material. 
2.2.1.2 Cryopreservation of cells 
Cells were grown to about 80-90% confluency, harvested using 0.25% (w/v) 
trypsin-EDTA before cryopreservation and then centrifuged at 250 x g for 10 
min. The supernatant was aspirated and the cells then washed in PBS and 
centrifuged again. The supernatant PBS was aspirated and cells suspended 
gently in 2 ml of freeze medium [90% (v/v) FBS and 10% (v/v) DMSO]. One ml 
aliquots of cell suspension were pipetted out into cryovials, labelled 
appropriately and cooled slowly to -80°C over 48 h. The frozen cells were then 
transferred to liquid nitrogen (-180°C) for long-term storage. 
2.2.1.3 Resuscitation of frozen cell lines and Sub culturing  
Frozen cells were removed from liquid nitrogen and thawed quickly by dipping 
in a 37°C water bath. The cells were then quickly transferred drop-wise into a 
T25 flask containing 10 ml of warm medium, which had been left in the 
incubator to warm up and to equilibrate the flask with CO2 where appropriate. 
This was then incubated at 37°C overnight to allow cells to recover and get 
attached to the flask. The media was then aspirated and replaced with fresh 
media. Cells were washed with PBS in order to remove any traces of DMSO. 
Cells were then allowed to grow to confluency and sub-cultured accordingly. 
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2.2.2 Preparation of compounds as stock solutions 
Aspirin and analogues were always freshly prepared in acetone (Section 
2.2.5.1.1) at a concentration of 50 mM and then either diluted with PBS (pH7.4) 
or HEPES (pH8) to adjust the pH. These solutions were then further diluted in 
appropriate media supplemented with 10% (v/v) FBS and 1% (v/v) 10,000 U/ml 
penicillin-10 mg/ml streptomycin to either 1 mM or 0.5 mM final concentrations 
for studies. This resulted in 20 mM or 10 mM respectively as the final 
concentration of HEPES, which is known as a suitable buffer for biological 
studies (Good et al., 1966) and within the recommended 10 mM to 25 mM 
concentration for  tissue culture (Eagle, 1971). 
2.2.3  Synthesis of aspirin analogues 
2.2.3.1  PN591 (meta-thioaspirin) 
The procedure was started by dissolving 0.616 g of 3-mercaptobenzoic acid in 
5.6 ml (0.10 mole) of ice cold sodium hydroxide solution. To this solution was 
added 5 g of ice and 0.5 g acetic anhydride whilst stirring for 15 min. The 
resulting mixture was then acidified with HCl drop wise. The precipitate was 
then filtered and washed with water. The powder was left to dry. Mpt is ideally 
152°C - 153°C (Bordwell and Boutan, 1956). This powder is known as PN591. 
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2.2.3.2 PN592 (para-thioaspirin)  
Synthesis of this compound was carried out in accordance to the method 
described by Bordwell and Boutan, 1956. 5 g of ice accompanied by 0.5 g 
acetic anhydride were added to an ice-cold solution of 4-mercaptobenzoic acid 
in sodium hydroxide. This mixture was stirred for 15 min and then acidified with 
hydrochloric acid. The precipitate was filtered off and washed with water. The 
powder was then left to dry. Mpt was found to be 189°C - 190°C. The product is  
known as PN592. 
 
 
Figure 2.1 Chemical reaction for the synthesis of isomers of thioaspirin. 
Synthesis of meta-thioaspirin (PN591) from 3-mercaptobenzoic acid (A) Synthesis of 
para-thioaspirin (PN592) from 4-mercaptobenzoic acid (B). 
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2.2.4 Chemistry of aspirin analogues 
2.2.4.1 Melting point analysis 
The mpts of the compounds were determined using the Stuart SMP 10 
melting point apparatus. Methodology was in line with the Stuart SMP 10 
instructions manual. Samples were placed in a glass capillary tube by tapping 
gently and then placed in the aluminium block inside the sample chamber. The 
block is then heated and the sample observed through the magnifying lens until 
it melted. The melting point temperature was then read on the LED display and 
recorded. Values represent mean of n=3. 
2.2.4.2  Thin Layer Chromatography (TLC) 
TLC is one of the most widely used separation techniques. This is because it is 
quite easy and fast to use, can be applied to a wide range of samples, highly 
sensitive, and relatively cheap (Touchstone, 1992). The main aim is to 
demonstrate purity (or very high concentration of the compound of interest) by 
elution as a single spot in more than one solvent if possible. This is a good, 
practical indicator of relatively high purity. 
It works by allowing an analyte to move up a layer of stationary phase under the 
influence of a mobile phase, which also moves through the stationary phase by 
capillary action (Watson, 2005). 
The test samples made up of aspirin and its analogues dissolved in diethylether 
(or other suitable volatile solvent) and placed as spots about 2cm from the 
bottom of the silica-60 plate (12804281, ALUGRAM UV254). The suitable 
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eluent used in this case was 65:30:5 (v/v) mixtures of hexane (≥95%, 439177, 
Sigma Aldrich), ethylacetate (99.8%, 270989, Sigma Aldrich) and acetic acid 
(99.5%, pure, 124040025, ACROS ORGANICS). The plates were then spotted 
with the compounds in solution (diethylether) and allowed to dry. These plates 
were then placed in the chamber. After elution, ultraviolet light was used to 
detect the travelled compounds (seen as spots). The Rf value was calculated by 
dividing the distance travelled by the compound from the origin (point of 
compound application) by the distance travelled by the solvent from the origin. 
 
 Rf =     Distance moved by spot 
         Distance migrated by solvent 
 
TLC was used to test the purity of aspirin analogues synthesized and also to 
observe any possible breakdown of compounds. 
2.2.4.3  Infrared (IR) Spectroscopy 
IR spectroscopy is a technique used to check the fingerprint that is unique to 
the compound being examined (Williams and Fleming, 2008). This is then 
compared with a standard stored in a database to determine the purity of that 
compound. The bonds between the molecules in the sample of interest absorb 
electromagnetic radiation ranging between 400 cm-1 and 4000 cm-1, causing 
them to stretch or bend. These bonds are then determined by the radiation 
wavelength absorbed (Watson, 2005). 
The powdered compound was transferred to the diamond stage of a Genesis II 
ATR FTIR (Attenuated Total Reflection Fourier Transform IR) instrument, which 
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enables analysis without the need for further sample preparations (Perkin Elmer 
Life and Analytical Sciences, 2005) and the spectrum obtained using the 
WinFIRST software, which controls the FTIR spectrometer. 
The spectrum was then analysed for each sample and the key functional group 
wavenumbers were catalogued. 
(See appendix for the individual spectra of compounds).  
2.2.4.4  Nuclear Magnetic Resonance (NMR) Spectroscopy 
13C NMR was used to confirm the structures of the aspirin analogues before 
use by interpretation using aspirin as a standard and point of reference 
(http://sdbs.db.aist.go.jp/sdbs/cgi-bin/cre_index.cgi). David Townrow using a 
JEOL ECZ-YH 400 MHz NMR spectroscopy machine carried this out. 
(See appendix for the individual spectra of aspirin analogues). 
2.2.5 Cytotoxicity, Toxicity and Breakdown of aspirin analogues  
2.2.5.1  MTS assay for Cell Viability 
Viability of cells after being treated with different aspirin analogues was 
measured using the CellTiter 96 AQueous One solution Cell Proliferation Assay 
kit in accordance to Spruce et al., 2004. Prior to this, the cell viability of SW480 
cells was determined using different solvents as a dissolution medium. The 
principle behind this is the formation of formazan, which is yellow in colour 
(Marker) due to the reduction of tetrazolium compounds by NADPH or NADH 
produced in metabolically active cells (Figure 2.2). 
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Figure 2.2 Illustrated explanation of the principle behind MTS activity. 
 
A standard curve was plotted to show the relationship between concentration 
and absorbance at 490 nm (Figure 4.3). 
The experiments were performed in duplicates and the viable cells were 
calculated as a percentage relative to the negative control cells. The equation 
used. 
 
%Cell viability = Absorbance 490 nm(treated cells-blank)  X 100 
                           Absorbance 490 nm(control cells-blank) 
 
2.2.5.1.1 MTS Assay to determine most suitable dissolution Solvent 
To determine the most appropriate solvent, SW480 cells were seeded in growth 
media at a density of 10,000 cells/well in 96 well plates and incubated overnight. 
The cells were treated with acetone, DMSO or tetrahydrofuran (THF) in serial 
dilutions and incubated for 48 h. A negative control containing only cell culture 
media was also included. 10 μl of CellTiter 96 AQueous (1 ml MTS solution:50 μl 
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coupling agent) was added to each well  and readings were taken using a 
Multiskan microplate reader at 490 nm absorbance for 0-4 h (Spruce et al., 
2004). 
SW480 cells were seeded in growth media at a density of  1 X 104  cells/well in 
96 well plates and incubated overnight. Aspirin and aspirin analogues (3 mM - 
0.1 mM) were prepared in stock solutions of 100 mM with either acetone or 
DMSO and diluted with PBS and Penicillin-Streptomycin solution. The cells 
were further incubated for 48 h. Ten µl of CellTiter 96 AQueous one solution 
reagent was then pipetted into each well to determine the cell viability in control 
and cell treated populations. Using a plate reader, absorbance of the 
colorimetric solution was read at 490 nm at 0 h and after 6 h. A negative and 
vehicle control was also included containing cells treated with medium only and 
medium treated with acetone respectively. 
2.2.5.2 MTT assay 
Cell viability was also measured by 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-
2H-tetrazolium bromide (MTT) reduction assay (Mosmann, 1983) with 
modifications (Carmichael et al., 1987). SW480 cells were seeded at a density 
of 1 X 104 or 5 X 103 cells per well in a 96-well plate and incubated overnight at 
37°C. After 24 h of seeding, the culture medium was then replaced with medium 
containing the drugs at required concentrations and further incubated for 48 h. 
A control that had cells with no treatment was also included in these 
experiments. The medium was then aspirated from each well and cells washed 
once with fresh medium to completely remove drugs and replaced with 300 μl of 
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MTT reagent (0.5 mg/ml). Cells were incubated at 37°C for 3 h at which time 
the medium was aspirated and replaced with 200 μl dimethyl sulfoxide (DMSO). 
The plates were incubated at 37°C for a further 30 min at which time the 
conversion of MTT into formazan crystals by living cells was measured by 
recording changes in the absorbance at 540 nm in a microplate reader 
(Microplate Reader Thermo Multiskan Ascent 96 & 384). Plates were protected 
from light throughout the procedure. Dosage of drugs ranged from 0 to 3 mM. A 
standard curve for formazan was constructed to examine the relation between 
formazan concentration and absorbance. GraphPad Prism was used to plot 
dose-response curves and to determine IC50 values. All assays were performed 
in duplicate (n=3) and the viable cells were expressed as a percentage relative 
to the negative control. The equation used can be found below. 
 
%Cell viability = Absorbance 540nm(treated cells-blank)  X 100 
                           Absorbance 540nm(control cells-blank) 
 
2.2.6 Salicylic acid Analysis 
This analysis was used to measure the amount of salicylic acid as the 
breakdown product of the aspirin analogues of interest (Section 3.4.4.1). It is 
based on the fluorescence enhancement of the As(III)-salicylic acid system 
(Karim et al., 2006). In other words, fluorescence excitation and emission 
spectra of salicylic acid (λex =315 nm, λem =408 nm) were measured due to the 
formation of a As(III)-salicylic acid complex in the presence of sodium dodecyl 
sulphate (SDS). 
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2.2.6.1 Dilution curve for Salicylic acid 
A dilution curve for salicylic acid and aspirin boiled with sodium hydroxide 
(NaOH) for 1 h in order to hydrolyse aspirin into salicylic acid was made to 
make sure the assay was specific to salicylates (Figure 3.11). Different 
concentrations of salicylic acid were prepared in serial dilutions starting from 10 
mM.  
10 μl of 1 mM SDS, 1 μl of 0.1 mM As2O3, 10 μl of 100 mM HEPES buffer (pH7) 
were pipetted into wells of a white flat bottom 96-well assay plate. To this was 
added 50 μl of the prepared salicylic acid compounds. The volume of each well 
was made up to 100 μl with distilled water, which made the final concentration 
of salicylic acid to be 5 mM. The plate was incubated for 10 min and placed into 
the CLARIOStar® fluorescence monochrome microplate reader. The 
fluorescence intensity of the solution in each well was then measured at 408 nm 
with excitation at 315 nm against a reagent blank without salicylic acid. 
The dilution curves of salicylic acid, aspirin boiled with NaOH for 1 h and aspirin 
alone were compared and can be seen in section 3.4.4.1. 
2.2.6.2 Rate of metabolism of Aspirin analogues on SW480 cells using 
salicylic acid analysis 
24-Well tissue culture plates (Sarstedt Ltd.) were prepared with each well 
containing 5X104 SW480 cells and left to incubate for 24 h at 37°C, 5% CO2. 
The cells were then treated with different aspirin analogues at 1mM 
concentration for 48 h. 
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The amount of salicylic acid was measured in duplicates for each well 
containing cells treated with the compounds. 
2.2.7 DEREK Analysis 
The recommended system for the prediction of toxicity in compounds of known 
chemical structure is the Derek Nexus software (Dobo et al., 2012, Sutter et al., 
2013) as it generates clear and scientifically robust predictions. Toxicity of 
compounds can be predicted without the need of animal studies. Thus, the 
Nexus Suite 2.1 Derek Nexus (Version 5.0.1) was used to predict the toxicity 
profile of each compound using its basic chemical structure. 
One of the shortcomings of this software however is that it can only work with 
chemical compounds already stored in its data bank. This led to it not 
recognising the chemical structure of some aspirin analogues and thus not 
providing an accurate prediction. 
2.2.8 SDS-PAGE for separation of proteins and Western blot for detection 
2.2.8.1 Preparation of SDS gels 
Gels were prepared in accordance to the recipe given in Tables 2.7 and 2.8 
below. The various volumes of ingredients needed for separation gel were 
made up and 3.5ml of that poured into already set up glass plates (150 X 100 X 
0.75 mm, Bio Rad mini gel). To the gel was then added 200 μl of isopropanol so 
as to ensure a horizontal upper surface and to get rid of bubbles. The gel was 
then allowed to set. 
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The gel was then rinsed with water and the excess water dabbed off using 
strips of filter paper, after which the stacking gel was prepared and pipetted into 
the glass set up, on top of the separating gel. The gel comb was then 
immediately inserted in order to form the gel wells. This was then allowed to set, 
gel comb removed and the wells were ready of loading of protein samples. 
Table 2.7 and 2.8 shows the recipes for stacking and separating gels. 
Ingredients Volume (ml) 
40% acrylamide (29:1) 1.0 
0.5 M Tris base buffer (pH 6.8) 2.5 
10% SDS 0.1 
Water 6.0 
TEMED 0.05 
APS* 0.05 
Table 2.7 Recipe for preparation of stacking gel. 
*Always made fresh by dissolving 0.02 g APS per 0.2 ml of water. 
 
 
Ingredients Volumes for different % of 
acrylamide 
 6% 8% 10% 
40% acrylamide (29:1) 1.5 2.0 2.5 
1.5 M Tris base buffer (pH 8.8) 2.5 2.5 2.5 
10% SDS 0.1 0.1 0.1 
Water 6.0 5.5 5.0 
TEMED 0.05 0.05 0.05 
APS* 0.05 0.05 0.05 
Table 2.8 Recipe for preparation of separating gel. 
*Always made fresh by dissolving 0.02 g APS per 0.2 ml of water. 
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2.2.8.2 Western blot for detection of proteins 
Treated samples were prepared in accordance with the western blotting 
protocol on the Cell Signalling Technology website. 
The SDS-PAGE loaded with the sample protein of interest was then run using 
electrophoresis for 1.5 h at 150 V in ‘running buffer’. After this, the protein was 
then transferred on to Polyvinylidene difluoride (PVDF) transfer membrane at 
100V for 2 h in the presence of ‘transfer buffer’. The blots were blocked in 
blocking buffer for 1h at room temperature (RT) with gentle rocking. The 
membrane was then probed with the appropriate primary antibodies overnight 
on a rocker at 4°C. The probed membrane was then washed in TBST three 
times for 5 min each and re-probed with a corresponding HRP-linked secondary 
antibody diluted in blocking buffer for 1 h on a rocker at room temperature. The 
HRP bound protein-labelled antibody was visualised using ECL (GE Healthcare 
Amersham™ ECL™ Prime Western Blotting Detection Reagent, RPN2232) for 
5 min and exposed to CL-XPosure™ Film. 
 
2.2.8.2.1 Effect of aspirin and its analogues on EGFR expression  
The effect of aspirin and its analogues on the EGF receptor expression over 
time was observed using western blotting. 
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About 5X104 SW480 CRC cells per well were plated in a 6-well tissue culture 
plate and treated with aspirin, thioaspirin and their isomers at 0.5 mM for 24 h, 
and subsequently for 0 h, 1 h, 3 h, 6 h and overnight. 
200 μl of Laemmli protein buffer containing 0.01% of protease inhibitor cocktail 
(100X) was added to the cells before being scraped off and transferred into 1.5 
ml microcentrifuge tubes. The cells were then treated at 100°C for 20 min and 
centrifuged (20,000 rpm) for 5 min. The samples were analysed by 
electrophoresis in 10% polyacrylamide gels in the presence of 0.1% SDS at 150 
V for 1.2 h. After protein transfer on to PVDF transfer membrane at 100V for 2 h, 
the blots were blocked in blocking buffer #1 (Table 2.3) for 1 h at room 
temperature (RT). The blots were then probed with primary antibodies EGFR 
(D38B1, Cell Signalling Technology) rabbit mAb at 1:1000 and GAPDH (sc-
25778, Santa Cruz Biotechnology) rabbit polyclonal IgG at 1:1000 overnight on 
a rocker at 4°C. The blots were then washed in TBST three times for 5 min 
each and probed with anti-rabbit IgG (7074S, Cell Signalling Technology) HRP-
linked secondary antibody diluted in blocking buffer #1 for 1 h on a rocker at 
room temperature. The HRP bound protein-labelled antibody was visualised 
using ECL (GE Healthcare Amersham™ ECL™ Prime Western Blotting 
Detection Reagent, RPN2232) for 5 min and exposed to CL-XPosure™ Film.  
2.2.8.2.2 Effect of aspirin and its analogues on EGFR tyrosine 
phosphorylation sites 
The effects on the EGFR phosphorylation sites by aspirin analogues were 
examined using western blot analysis. 
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About 5 X104 SW480 cells per well were plated on a 6-well tissue culture plate, 
serum-starved for 2 h. The cells were then treated with aspirin and its 
analogues for 24 h at 0.5 mM. The cells were subsequently also treated at 
various doses to determine a dose response on the phosphorylation sites. 
To abolish effects on the phosphorylation sites due to pH change, another set 
of SW480 cells were treated with compounds that have been pH adjusted with 
HEPES. 
Briefly, cells were washed with cold (4°C) PBS and suspended in 2X Laemmli 
sample buffer containing 10% β-mercaptoethanol (Laemmli, 1970) and 0.01% 
of protease inhibitor cocktail (100X) (5871S, Cell Signalling Technology). The 
cells were then scraped off and transferred into 1.5 ml microcentrifuge tubes 
and treated at 100°C for 20 min and centrifuged (14,000 rpm) for 5 min. The 
samples were analysed by electrophoresis in 6% and 10% polyacrylamide gels 
in the presence of 0.1% SDS at 150 V for 1.2 h. After protein transfer on to 
PVDF transfer membrane at 100 V for 2 h, the blots were blocked in blocking 
buffer #2 (Table 2.3) on a rocker for 1 h at RT. The blots were then subjected to 
immunoblot analysis by probing with either rabbit pEGFR Y1068 (ab5644, 
Abcam) Ab at 1:1000 dilution, rabbit pEGFR Y1045 (2237S, Cell signalling 
technology) Ab at 1:0000, rabbit pEGFR Y1172 (ab135560, Abcam) Ab at 
1:2000, rabbit pEGFR Y992 (9922, Cell Signalling Technology) Ab or mouse 
pEGFR Y1101 (ab7195, Abcam) Ab as primary antibodies overnight on a 
rocker at 4°C. Either GAPDH (sc-25778, Santa Cruz Biotechnology) Ab or beta-
tubulin (ab15568, Abcam) Ab were used as loading controls. The blots were 
then washed in TBST three times for 5 min each and probed with the 
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corresponding secondary antibody (anti-rabbit or anti-mouse) conjugated with 
HRP all diluted in blocking buffer #2 (Table 2.3) for 3 h on a rocker at room 
temperature. The HRP bound protein-labelled antibody was visualised using 
ECL 2 Western blotting substrate kit (80196, Thermo Scientific) and film. 
2.2.8.2.3 Effects of aspirin analogues on pro-apoptotic and anti-apoptotic 
proteins 
About 5 X104 SW480 CRC cells per well were plated in a 6-well tissue culture 
plate and treated with aspirin and some of its analogues at 0.5 mM for 24 h. 
150 μl of Laemmli protein buffer was added to the cells before being scraped off 
and transferred into 1.5 ml microcentrifuge tubes. The cells were then treated at 
100°C for 20 min and centrifuged (14,000 rpm) for 5 min. The samples were 
analysed by electrophoresis in 10% polyacrylamide gels in the presence of 
0.1% SDS at 120V for 1 h. After protein transfer on to PVDF transfer membrane 
at 100V for 2 h, the membrane was blocked in blocking buffer #1 (Table 2.3) for 
1 h at RT. The blots were then probed with primary antibodies p21 (ab109199, 
Abcam) rabbit mAb at 1:1000, BCL-2 (ab32124, Abcam) rabbit mAb at 1:1000 
and BAX (sc-493, Santa Cruz Biotechnology) mouse mAb at 1:200. Anti-beta 
Tubulin Ab (ab15568, Abcam) at 1:2000 was used as loading control overnight 
on a rocker at 4°C. The blots were then washed in TBST three times for 5 min 
each and probed with the corresponding HRP-linked secondary antibody diluted 
in blocking buffer #1 (Table 2.3) for 1 h on a rocker at RT. The HRP bound 
protein-labelled antibody was visualised using ECL (GE Healthcare 
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Amersham™ ECL™ Prime Western Blotting Detection Reagent, RPN2232) for 
5 min and exposed to CL-XPosure™ Film. 
2.2.9 Flow cytometry  
Flow cytometry was used to sort out a population of cells (Figure 2.3) into 
apoptotic cells that are stained with Annexin V due to interaction with 
phosphatidylserine protein exposed by the flipped cell membrane (Vermes et al., 
1995) and necrotic cells that are stained by propidium iodide (PI) due to its 
ability to interact with DNA of cells under stress or dead (Chou et al., 1987). 2 X 
105 of SW480 cells per well were plated out in a 6-well tissue culture plate and 
left in the incubator for 24 h after which they were treated with either aspirin 
analogues, staurosporine as a control for apoptosis (Jacobson et al., 1993) or 
hydrogen peroxide (H2O2) as a control for necrosis (Teramoto et al., 1999). The 
cells were dissociated from the wells using trypsin, 0.25% (w/v) after 16h and 
40 h and centrifuged at 200 X g for 5 min to separate cell pellets from the 
supernatant media. 0.25% (w/v) trypsin lacking EDTA was used in order to 
minimize damage to the cell membrane. The cell pellets were then washed in 
PBS and centrifuged again. The cells were then resuspended in binding buffer 
containing the dyes FITC-Annexin V and PI. After 15 min of incubation at room 
temperature, each sample was then analysed using the BD Accuri™ C6 flow 
cytometer installed with the BD Accuri™ C6 software (Version 1.0.264.21). 
Cells were treated with 0.5 mM, 0.3 mM and 0.1 mM concentrations of aspirin 
and its analogues with staurosprine (Maciel et al., 2014) at 500 nM and H2O2 at 
5 mM. 10,000 cells were acquired for each experimental condition. 
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Figure 2.3 Gating of cells undergoing apoptosis and necrosis using flow 
cytometry. 
The cytogram is divided into four different quadrants in which cell populations are 
grouped according to the fluorescence dye it is stained with. Cell populations that do 
not take up any of the dyes are the live healthy cells and are grouped in the lower-left 
quadrant (Q1-LL) as shown by the BD Accuri™ C6 software. Cells that take up the 
Annexin V dye are those undergoing early apoptosis and are grouped in the lower-right 
quadrant (Q1-LR). Cell populations that take up both dyes are undergoing late 
apoptosis, necrosis or considered dead and fall in the upper-right quadrant (Q1-UR). 
Populations that only take up the PI dye are considered either dead cells or debri and 
fall in the upper-left quadrant (Q1-UL) (Wlodkowic et al., 2011). 
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2.2.10  YO-PRO®-1 and PI 
YO-PRO®-1 is a green florescent dye that selectively passes through the 
membrane of apoptotic cells whereas dyes like the red florescent PI cannot 
(Idziorek et al., 1995). Thus, a combination of these two dyes provides a 
sensitive assay for apoptosis. 
SW480 CRC cells were plated on glass cover slips in 6-well-pates to obtain 
70% confluency after 24 h. These cells were then treated with staurosporine 
and H2O2 as controls for apoptosis and necrosis respectively for 16 and 40 h 
after which were washed with cold PBS once and then treated with 1 μl each of 
YO-PRO®-1 and PI stock solution in 1 ml of PBS per well on ice for 30 min. 
This step was then followed by two washes with cold PBS, left on ice in PBS for 
a further 30 min and then coverslips placed onto a drop of VectaShield® 
mounting medium. Microscopy was done using a Zeiss LSM 880 confocal 
microscope, equipped with 405 and 561 nm excitation lasers using 40X/1.30 oil 
immersion DIC M27 objective. The Zeiss: ZEN2 (blue edition) software was 
used to process images.  Cells were treated with 0.5 mM concentrations of 
aspirin and its analogues with the exception of PN590 at 0.3mM. Cells were 
treated with staurosprine at 500 nM and H2O2 at 5 mM as control for apoptosis 
and necrosis respectively. 
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2.2.11 Epidermal Growth Factor Binding 
The effect of aspirin analogues on EGF binding was assayed using 
immunocytochemistry/confocal microscopy and quantified using ImageJ. 
SW480 cells were cultured on glass coverslips to approximately 70% 
confluency in 6-well tissue culture plates and serum-starved for 48 h. 
Monolayers were cooled to 4°C, and incubated for 1 h in the presence of 100 
ng/ml AlexaFluor 555 EGF on ice. For experiments testing compounds, serum-
starved cells were pre-incubated at 37°C for 30 min in the absence or presence 
of compounds at 0.5 mM, then 15 min at 4°C, prior to addition of equivalent 
volume of cold serum-free culture medium containing 200ng/ml AlexaFluor 555 
EGF for 1 h to allow EGF binding, which resulted in a final concentration of 
100ng/ml EGF. Cells were then washed with cold PBS 3 times and fixed for 5 
min with acetone/methanol (1:1) on ice, and the coverslips then placed onto a 
drop of VectaShield® mounting medium. Microscopy was done using a Zeiss 
LSM 880 confocal microscope, equipped with 405 and 561 nm excitation lasers 
using 40X/1.30 oil immersion DIC M27 objective. ImageJ (1.48v) was used to 
quantify bound EGF by analysing fifty cells per compound in the red channel. 
2.2.12 Epidermal Growth Factor Internalization 
The effect of aspirin and its analogues on EGF internalisation was studied using 
immunocytochemistry/confocal microscopy. 
SW480 cells were cultured on glass coverslips to approximately 70% 
confluency in 6-well tissue culture plates and serum-starved for 48 h. 
Monolayers were cooled to 4°C, and incubated for 1 h in the presence of 100 
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ng/ml AlexaFluor 555 EGF on ice (In subsequent experiments this 
concentration was reduced to 20 ng/ml in order to target the EGFR recycling 
pathway). For experiments testing compounds, serum-starved cells were pre-
incubated at 37°C for 30 min in the absence or presence of compounds, then 
15 min at 4°C, prior to addition of equivalent volume of cold serum-free culture 
medium containing 200 ng/ml AlexaFluor 555 EGF for 1 h to allow EGF binding. 
Cells were warmed to 37°C for 30 min to stimulate EGF internalization, washed 
with cold PBS 3 times and fixed for 5 min with acetone/methanol (1:1) on ice, 
and the coverslips then placed onto a drop of VectaShield® mounting medium. 
Microscopy was done using a Zeiss LSM 880 confocal microscope, equipped 
with 405 and 561 nm excitation lasers using 40X/1.30 oil immersion DIC M27 
objective. The Zeiss: ZEN2 (blue edition) software was used to process images. 
For preliminary experiments, cells were incubated with 0.5 mM aspirin and its 
analogues. 
2.2.13 EGF internalization using Live Confocal Imaging 
SW480 CRC cells were plated in 3 ml DMEM medium (Thermofisher, 11965-
092) supplemented with 10% FBS and 1% antibiotic solution (10,000 U/ml 
penicillin-10 mg/ml streptomycin) on a confocal dish (IWAKI® glass base dish) 
to achieve approximately 70% confluency the next day. DMEM medium was 
used in this assay because phenol-red free medium was needed for clear 
viewing under the microscope and DMEM was the only medium we had that 
had a phenol-red free version. The cells were then serum starved for 24 h 
because starving for 48 h in the confocal dish reduced cell viability. Monolayers 
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were cooled to 4°C, and incubated for 1 h in the presence of 200 ng/ml 
AlexaFluor 555 EGF on ice. For experiments testing compounds, serum-
starved cells were pre-incubated at 37°C for 30 min in the presence of 
compounds, then for 15 min on ice, prior to addition of equivalent volume of 
cold serum-free culture medium containing 400 ng/ml AlexaFluor 555 EGF to 
give a final volume of 200 ng/ml for 1 h to allow EGF binding. Cells were then 
washed with cold PBS once and medium replaced with 3 ml Phenol-red-free 
DMEM (D1145, Sigma®) to enable clear viewing of cells under the confocal 
microscope. Microscopy was done using a Zeiss LSM 880 confocal microscope, 
equipped with 405 and 561 nm excitation lasers using EC Plan-Neofluar 
20X/0.50 DIC M27 objective using the incubation chamber at 37°C, 5% CO2. 
Time series was 120 cycles at 0.5 min intervals. For preliminary experiments, 
cells were either incubated with 0.5 mM PN502 or PN517. 
2.2.14 Quantification of EGF internalization  
Quantification of EGF internalization was attempted using flow cytometry as 
described by Li et al., 2008. 6 X 105 SW480 cells per well were plated in a 6-
well plate and incubated overnight. The cells were then serum-starved in pre-
warmed L-15 medium for 48 h. Receptor internalization was set in motion by 
treating the cells with L-15 medium containing 100 ng/ml EGF or without at 
37°C for 0 and 30 min. This was halted by shifting the cells to ice for 10 min and 
then washed twice in cold PBS for 10 min each at 4°C with gentle shaking. The 
cells were then washed with freshly prepared ice-cold acid stripping buffer 
thrice for 5 min each to remove non-internalized ligand after which they were 
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washed with ice-cold PBS with gentle shaking for 5 min. The next step was to 
incubate the cells in pre-chilled FACS buffer containing 3 μg/ml of Anti-EGFR 
antibody at 4°C for 1 h and washed again three times with cold PBS for 5 min 
each. Cells were then incubated in pre-chilled FACS buffer containing 
secondary antibody conjugated to FITC for 1 h on ice. After washing with PBS, 
the cells were then trypsinised with 300 μl trypsin per well, centrifuged at 1,100 
g for 3 min and washed again with ice-cold FACS buffer. 1% PI in FACS buffer 
was added per tube for 15 min at room temperature prior to flow cytometry to 
distinguish live cells from the dead ones. 20,000 cells were acquired for each 
experiment. 
Another method was attempted by plating 6 X 105 CRC cells and starving for 48 
h after which the cells were incubated with and without an aspirin analogue at 
37°C for 30 min and then at 4°C for 15 min. The cells were then treated with an 
equivalent volume of 200 ng/ml AlexaFluor® 555 EGF resulting in a final 
concentration of 100 ng/ml AlexaFluor® 555 EGF on ice for 1 h. Cells were 
trypsinized with trypsin, neutralized with cell medium and centrifuged at 200 X g 
for 10 min. FACS buffer was added to wash cells and centrifuged once more. 
Cells were then analysed in FACS buffer using flow cytometry. 20,000 cells 
were acquired for each experiment. 
2.2.15 EGF co-localisation with EEA1 
SW480 cells were cultured on glass coverslips (AmScope) to approximately 
70% confluency in 6-well tissue culture plates and serum-starved for 48 h. For 
experiment testing compounds, serum-starved cells were pre-incubated at 37°C 
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for 30 min in the absence or presence of compounds, then for 15 min at 4°C, 
prior to addition of equivalent volume of cold serum-free culture medium 
containing 200 ng/ml AlexaFluor® 555 EGF, resulting in a final concentration of 
100 ng/ml AlexaFluor® 555 EGF on ice for 1 h to allow EGF binding (In later 
experiments, this concentration was reduced to 20 ng/ml). Cells were then 
warmed to 37°C for 30 min to stimulate EGF internalization, washed with cold 
PBS 3 times and fixed for 5 min with acetone/methanol on ice. The cells were 
washed in cold PBS again followed by being blocked in blocking buffer #3 
(Table 2.3) for 2 h in the dark at room temperature. Anti-EEA1 antibody [1G11] 
Early Endosome Marker (ab70521, Abcam) as primary antibody was added to 
cells at 1:1000 and kept at 4°C overnight with gentle rocking. The cells were 
then washed with cold blocking buffer thrice after which Goat Anti-Mouse IgG 
H&L-FITC (ab6785, Abcam) as secondary antibody was added for 2 h at room 
temperature, washed with cold blocking buffer 3 times and finally with cold PBS 
before cover-slips were placed onto a drop of VectaShield® mounting medium. 
Microscopy was performed using a Zeiss LSM 880 confocal microscope, 
equipped with 405 and 561 nm excitation lasers using 40X/1.30 oil immersion 
DIC M27 objective. For preliminary experiments, cells were incubated with 0.5 
mM of aspirin and its analogues.  
2.2.16 Synergy experiments 
SW480 cells were plated in a 96-well plate at a density of 500 cells/well/100μl of 
medium and allowed to set overnight at 37°C. The cells were the treated the 
next day with serial dilutions of cisplatin, oxaliplatin, carboplatin and aspirin with 
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its analogues either for 12 days with drug being replenished at day 6 
(McPherson et al., 2014) or for 72 h (Chan et al., 2014, Luo et al., 2010, 
Toscano et al., 2007, Yan et al., 2010, Zhou et al., 2010). Cell viability was 
measured by MTT assay to determine the IC50 for each drug. 
Combination drug treatments were then performed as above by pairing cisplatin, 
oxaliplatin or carboplatin with each of the other drugs in a constant ratio design 
based on the IC50. Once these ratios were set, a mixture of the two drugs was 
made at 2-fold and then serially diluted to 1-fold, 0.5-fold, 0.125-fold and 
0.0625-fold. All assays were performed in duplicates (n=3). CompuSyn Inc. 
software (Paramus, NJ., 2005) was used to calculate the Combination Index 
(CI) and Dose Reduction Index (DRI). This produces multiple drug dose-effect 
calculations using the Median Effect methods described by Chou and Tatalay 
(Chou and Talalay, 1984). The CI is the quantitative measure of the degree of 
drug interaction in terms of additive effect (CI = 1), synergism (CI < 1), or 
antagonism (CI > 1) while the DRI is the measure of favourable dose reduction 
when two drugs are used in combination. 
Graphpad Prism 7 software (Version 7.0a, April 2016) was used to calculate the 
IC50 of individual compounds and their respective combinations. This software 
was also used for statistical analysis. 
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2.2.17 Statistical Analysis 
Statistical analyses were carried out using GraphPad Prism 7 software 
(GraphPad software Inc., San Diego, CA, USA). The test used to determine 
statistical significance was ordinary one-way ANOVA. Differences between 
control were considered as statistically not significant at p>0.05, and significant 
at p<0.05, p<0.01, p<0.001 or p<0.0001.
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Chapter 3. Chemistry of Aspirin analogues 
3.1 Introduction 
Evidence suggests that the NSAID, aspirin, has the potential to decrease 
incidence of, or mortality from, a number of cancers through several 
mechanisms of action (Benamouzig et al., 2012, Goel et al., 2003, Hawley et al., 
2012, Li et al., 2015, Patrono et al., 2008, Schror, 2011). However, despite 
these evidences, long-term use of aspirin has a potential to cause GI toxicity, in 
particular GI bleeding and peptic ulcer, which have been found to be mostly 
age-dependent (Laine, 2002, Patrono et al., 2005). The search for potential 
aspirin-related compounds with the same or better cytotoxic effects against 
cancer cells accompanied by a safer toxicity profile has been on going over the 
years, which include, mesalazine (5-aminosalicylic acid) in HCT-116 CRC cells 
(Gasche et al., 2005), MDC-43 (4-[(diethoxyphosphoryloxy)methyl]phenyl 2-
acetoxybenzoate) in colon, liver, pancreas and breast cancer cells (Zhao et al., 
2009), NX-4016 (2-(acetoxy)benzoic acid 3-[(nitrooxy)methyl]phenyl ester) in 
ovarian cancer (Selvendiran et al., 2008), PN517 (fumaroyldiapirin) and  PN514 
(benzosalin) in SW480 CRC cell line (Claudius et al., 2014, Deb et al., 2011). 
The meta- and para- isomers of aspirin were found to exhibit the same 
biological profiles from the ortho- isomers accompanied with safer profiles in 
regards to GI toxicity (Kodela et al., 2013). Thus, this chapter includes study in 
the synthesis, identification and stability profile of meta- and para- isomers of 
aspirin and thioaspirin in order to find out if they chemically behave similarly to 
the ortho- form. 
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3.2 Aims and Objectives 
The reason for the work done in this chapter is to confirm that the compounds 
synthesised match with the structures of aspirin analogues of interest and that 
the compounds are of acceptable purity and fit for purpose. The stability of 
these aspirin analogues and rate of breakdown into salicylates was also 
assessed. 
3.3 Methodology 
The methodology has been discussed extensively in chapter two (2.2.5 and 
2.2.7) of this thesis. 
3.4 Results 
The results in this chapter comprise of the synthesis of aspirin analogues, the 
identification and confirmation of their chemical structures, determination of 
their purity and percentage breakdown into salicylate. 
3.4.1 Synthesis of aspirin analogues 
PN591 (meta-thioaspirin) and PN592 (para-thioaspirin) were synthesised from 
3-mercaptobenzoic acid and 4-mercaptobenzoic acid respectively. The rest of 
the aspirin analogues were synthesised by Dr. Chris Perry (School of Pharmacy, 
University of Wolverhampton). 
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3.4.2 Identification/Confirmation of aspirin analogues structures 
NMR and IR spectroscopy were used in combination to confirm the structures 
and approximate purity of the aspirin analogues synthesised. TLC was used as 
an additional technique in order to demonstrate that the compounds used in the 
cell studies were eluting as a single spot, before use. 
3.4.2.1 NMR 
Nuclear Magnetic Resonance (NMR) was first invented in 1946 and its spectra 
have been in use within the field of organic chemistry since 1960 (Williams and 
Fleming, 2008). This method can easily be used to determine chemical 
structures of compounds without the need of an expert. 
13C NMR was carried out on each of the following compounds (Full sized 
Spectra of compounds can be found in appendix 8.1). 
3.4.2.1.1 PN502 (ortho-acetoxybenzoic acid/o-acetylsalicylic acid/aspirin) 
Aspirin is a very common substance and a standard spectrum is available on 
the Spectral Database for Organic Compounds Spectral Data Base System 
(SDBS) from the Japanese National Institute of Advanced Industrial Science 
and Technology (AIST) (http://sdbs.db.aist.go.jp/sdbs/cgi-bin/cre_index.cgi) for 
comparison (Figure 3.1). NMR data from in-house PN502 (Figure 3.2) can be 
favourably compared with data from Figure 3.1. 
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Figure 3.1 NMR Spectrum for o-acetoxybenzoic acid (o-aspirin).  
13C NMR spectrum for aspirin (A). Chemical structure and assigned C atom 
numbering in relation to C peaks on spectrum for interpretation (B) Table for C 
number assignment and corresponding ppm (C). Molecular Formula: C9H8O4, 
Molecular Weight: 180.2 g/mol. (http://sdbs.db.aist.go.jp/sdbs/cgi-bin/cre_index.cgi). 
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Figure 3.2 13C NMR PN502.  
13C NMR spectrum for PN502 [Appendix figure 8.1] (A). Chemical structure and 
assigned C atom numbering in relation to C peaks on spectrum for interpretation 
(B) Table for C number assignment and corresponding ppm (C). Molecular Formula: 
C9H8O4, Molecular Weight: 180.2 g/mol. 
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This compound has nine carbon (C) nuclei and in comparison with the aspirin 
spectrum found in the database, shows peak assignments and chemical shifts 
that are remarkably similar between the two spectra.  
On the PN502 13C NMR spectra, a triplet of peaks are seen at 77 ppm, which is 
classically due to the carbon nucleus in CDCl3 coupling with deuterium, arising 
from the deuterochloroform used as the solvent for compound dissolution. This 
will be excluded from peaks considered in the analysis. 
From the spectrum, nine separate C peaks (excluding solvent bands) are seen 
which confirms the fact that this compound is correct and pure. No impurity 
carbons are visible in the spectrum shown (appendix 8.1) because each C 
nucleus should have a different environment and thus a single peak. 
3.4.2.1.2 PN508 (Diaspirin) 
PN508 is a diaspirin, made up of two aspirin structures joined together at the 
methyl groups of the acetyl (CH3CO-) parts of the molecule. It also has nine C 
environments all similar to that in aspirin with the exception of C9 due to it 
having a longer carbon chain of –CH2CH2- instead of CH3. The NMR data 
confirm the structure of PN508 (Figure 3.3B). 
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Figure 3.3 13C NMR PN508.  
13C NMR spectrum for PN508 [Appendix Figure 8.2] (A). Chemical structure and 
assigned C atom numbering in relation to C peaks on spectrum for interpretation (B) 
Table for C number assignment and corresponding ppm (C). Molecular Formula: 
C16H14O8, Molecular Weight: 358 g/mol. 
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3.4.2.1.3 PN517 (Fumaryldiaspirin) 
PN517 is also made up two aspirin molecules connected by an alkene grouping 
(Figure 3.4A). 
 
To analyse this NMR (Figure 3.4A), it is helpful to bisect the molecule at the 
centre of symmetry and look for the nine C environments. In comparison to the 
aspirin molecule/chemical structure, two separate C peaks are seen at 165.92 
ppm and 163.54 ppm representing the C nucleus at position 1 and 2 
respectively of the chemical structure. These are lower than aspirin, which 
could be due to the electron donating effect of the double bond found in PN517 
(X=-CH=CH-). 
 
The peak representing position 3 of the chemical structure can be found at 
150.04 ppm as compared to 151.28 ppm in aspirin. C 5 and 6 are found at 
position 132.03 ppm and 127.24 ppm respectively on the spectrum. This leaves 
us with C 4 and 7, which appear as two single peaks at 134.43 ppm and 134.58 
ppm at peak 4 and 124.34 ppm and 124.64 ppm at peak 7. The C 9 in aspirin is 
now an alkene C, which shifts completely away from the 21 ppm methyl position 
to a position between 110 ppm and 140 ppm. This is thus at the 134 ppm region 
close to C 4. At the 124 ppm region, C 7 and 8 can be seen. C 8 has shifted 
from 122.26 ppm in aspirin to either 124.34 ppm or 124.64 ppm. Thus, 9 C 
peaks have been accounted for (Figure 3.4A). 
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Figure 3.4 13C NMR PN517.  
13C NMR spectrum for PN517 [Appendix Figure 8.3] (A). Chemical structure and 
assigned C atom numbering in relation to C peaks on spectrum for interpretation (B) 
Table for C number assignment and corresponding ppm (C). Molecular Formula: 
C16H12O8, Molecular Weight: 356 g/mol. 
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3.4.2.1.4 PN548 (meta-aspirin) 
The difference between PN548 and aspirin is that PN548 has got the carboxylic 
group attached -meta position of the benzene ring (Figure 3.5B). 
 
The large signals seen at 77 ppm are due to the solvent CDCl3 
(deuterochloroform) (Figure 3.5A). Comparing this spectrum to that of aspirin, 
signals 1 and 2 can be seen at 171.19 and 169.32 represent the two C 
contained in the carboxylic groups (C=O). They are probably more apart than in 
aspirin because of the lack of H-bonding between the two groups seen in 
aspirin. This is because in PN548, the groups are too far apart to interact with 
each other. The ring C with the ester (acetoxy) group falls at 150.75 ppm and 
two of C atoms appear as having a weaker signal compared to the others 
(signal 3 and 4). This is because they both do not have a hydrogen (H) atom 
attached to them and this phenomenon is a consequence of the Nuclear 
Overhauser effect (NOE) (Williams and Fleming, 2008). The other four C atoms 
attached to the ring appear between 129.68 and 123.53 ppm. 
The C atom carrying the acetyl group (-CH3) appears at 21.14 ppm, which is 
almost the same frequency as 20.99 ppm in aspirin. 
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Figure 3.5 13C NMR PN548.  
13C NMR spectrum for PN548 [Appendix Figure 8.4] (A). Chemical structure and 
assigned C atom numbering in relation to C peaks on spectrum for interpretation (B) 
Table for C number assignment and corresponding ppm (C). Molecular Formula: 
C9H8O4, Molecular Weight: 180.2 g/mol. 
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3.4.2.1.5 PN549 (para-aspirin) 
Here, the carboxylic group is attached to the benzene ring at the para- position 
(Figure 3.6B). 
 
In PN549 chemical structure, the two C atoms ortho- to the carboxyl group and 
the two C atoms meta- to the carboxyl group are equivalent. This results in an 
extra symmetry and due to this we expect to see only seven and not nine 
signals on the spectrum (Figure 3.6A). At C 7 with the methyl group, which 
corresponds to C 9 in aspirin, the signal appears at 21.25 ppm. The two C=O 
signals are clearly visible at 171.31 ppm and 168.96 ppm. The ring C bearing 
the –CH3COO group at position 3 appears at 155.06 and because it has no H 
atoms (quarternary C) attached to it, the signal is seen to be small. C 5 is also a 
quartenary C at 126.88 ppm. Due to equivalence peaks at 131.96 ppm and 
121.85 ppm each represent 2 Cs at positions 4, 4‘ and 6, 6‘ respectively. 
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Figure 3.6 13C NMR PN549.  
13C NMR spectrum for PN549 [Appendix Figure 8.5] (A). Chemical structure and 
assigned C atom numbering in relation to C peaks on spectrum for interpretation (B) 
Table for C number assignment and corresponding ppm (C). Molecular Formula: 
C9H8O4, Molecular Weight: 180.2 g/mol. 
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3.4.2.1.6 PN590 (ortho-thioaspirin) 
The chemical structure for o-thioaspirin has a sulfur (S) atom attached to the 
C=O instead of an oxygen (O). Nine peaks should be expected with nine 
different C environments (Figure3.7B). 
 
The peak at 171.48 ppm represents C 1 and is pretty much the same as in 
aspirin (170.24 ppm) while the peak at C 2 has shifted significantly to a lower 
field (bigger ppm) at 193.27 ppm. The significant change is because the C atom 
has become much more deshielded because of the S atom not feeding 
electrons to the C=O group as well as the O ester in aspirin. Sulfur has got a 
higher nuclear charge and so shifts the C down the spectrum. C 3 is attached to 
S instead of O found in aspirin. This accounts for the shift away from 151.28 
ppm to 132.66 ppm. C 3 to C 8 fall between 129 ppm and 137 ppm. The 
attachment to S atom also accounts for the shift of C 9 (methyl group) from 21 
ppm to 30.45 ppm. The peak at 77 ppm indicates the CDCl3 solvent used. No 
impurity peaks are evident in the spectrum (Figure 3.7A). 
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Figure 3.7 13C NMR PN590.  
13C NMR spectrum for PN590 [Appendix Figure 8.6] (A). Chemical structure and 
assigned C atom numbering in relation to C peaks on spectrum for interpretation (B) 
Table for C number assignment and corresponding ppm (C). Molecular Formula: 
C9H8O3S, Molecular Weight: 196 g/mol. 
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3.4.2.1.7 PN591 (meta-thioaspirin) 
The S group is attached at the meta- position of the benzene ring (Figure 3.8B). 
Here also nine peaks representing nine separate C environments are expected 
to be seen in the spectrum. 
 
Similar to o-thioaspirin, the C at position 1, 2 and 9 fall at the same position in 
the spectra. However, there are distinct differences at C positions 3 to 8 with C 
3 and 8 showing a smaller signal due to its attachment to the –SCOCH3 and –
COOH groups respectively and thus, are quartenary Cs. Their peaks appear at 
130.43 and 128.88 ppm. C 4, 5, 6 and 7 come at 139.85, 136.16, 131.19 and 
129.46 although hard to ascertain each C environment to its individual peak. 
The peak indicating the solvent CDCl3 used is seen at 77 ppm (Figure 3.8A). 
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Figure 3.8 13C NMR PN591.  
13C NMR spectrum for PN591 [Appendix Figure 8.7] (A). Chemical structure and 
assigned C atom numbering in relation to C peaks on spectrum for interpretation (B) 
Table for C number assignment and corresponding ppm (C). Molecular Formula: 
C9H8O3S, Molecular Weight: 196 g/mol. 
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3.4.2.1.8 PN592 (para-thioaspirin) 
The S group is attached to the para- position of the benzene ring (Figure 3.9B). 
Similar to PN549 (Figure 3.6A), only seven peaks are expected because of the 
extra symmetry of the para isomer. 
 
Two peaks representing the C=O group; C 2 at 192.62 ppm for the thioester 
and C 1 at 166.74 ppm for the COOH nucleus. The relative positions of these 
are for the same reason as PN590 and PN591.  
 
 
In comparison to the aspirins, here the thioester group is significantly 
deshielded at the C=O carbon due to S being a poorer electron donor than O. 
The four ring C environments show peaks at 134.20 ppm (C 4 and 4’), 132.97 
ppm (C 3), 131.54 ppm (C 6) and 129.94 ppm (C 5 and 5’). The two substituted 
ring C nuclei (C 3 and C 6) show as small peaks because they are quatenary C 
atoms while the unsubstituted ring C nuclei appear as larger peaks (C 4, 4’, 5, 
5’) because there are two C nuclei in each band and they have a H attached. 
The only remaining peak is C 7 representing the methyl C nucleus of the acetyl 
group. This was observed to shift upfield to about 30 ppm in PN590 and PN591. 
The same is observed for PN592 at 30.45 ppm (Figure 3.9A). 
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Figure 3.9 13C NMR PN592.  
13C NMR spectrum for PN592 [Appendix Figure 8.8] (A). Chemical structure and 
assigned C atom numbering in relation to C peaks on spectrum for interpretation (B) 
Table for C number assignment and corresponding ppm (C). Molecular Formula: 
C9H8O3S, Molecular Weight: 196 g/mol.  
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3.4.2.2 IR 
IR spectra involve the movement of nuclei between vibrational energy levels. To 
enable identification, many functional groups have characteristic vibration 
frequencies. This method is a simple, quick and reliable method for identifying 
functional groups in chemical compounds (Williams and Fleming, 2008). 
An IR correlation chart 
(https://chem.libretexts.org/Reference/Reference_Tables/Spectroscopic_Param
eters/Infrared_Spectroscopy_Absorption_Table) was used to interpret the 
bands and stretches on the spectra. Spectra of compounds can be found in 
appendix 8.2 [Appendix Figures 8.9 to 8.21].
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Key to band intensities: w = weak band, m = medium band, s = strong band. BA = Benzoic acid. str = stretch. 
Product ID OH/SH 
stretch 
(Phenol/thiol) 
/ cm-1 
OH stretch 
(Carboxylic 
acid) / cm-1 
C=O 
stretch 
Ester / cm-1 
C=O stretch 
Carboxylic 
acid / cm-1 
C=C stretch 
(Alkene) Aromatic / 
cm-1 
Notes 
PN502 - ≈3390-2180 1752 (s) 1680 (s) 1604 (m)  
PN508 - ≈3300-2200 1762 (s) 1681 (s) 1607 (m)  
PN517 - ≈3470-2170 1738 (s) 1685 (s) [≈1575 (w)] 1607 (m)  
PN548 - ≈3400-2200 1758 (s) 1675 (s) 1584 (m)  
PN549 - ≈3500-2200 1754 (s) 1677 (s) 1602 (m)  
PN590 - ≈3380-1960 1694 (s) 1676 (s) 1582 (m)/1565 (m) Overlapping C=O str 
PN591 - ≈3380-1990 1685 (s) 1685 (s) 1593 (m)/1573 (m) Overlapping C=O str 
PN592 - ≈3380-1950 1683 (s) 1683 (s) 1592 (m)/1566 (m) Overlapping C=O str 
Salicylic acid 3230 (OH) (m) ≈3500-1760 - 1656 (s) 1608 (m)  
Thiosalicylic acid 2520 (SH) (m) ≈3300-1750 - 1672 (s) 1586 (m)/1562 (m)  
3-Hydroxy-BA 3330 (OH) (m) ≈3500-1800 - 1680 (s) 1596 (m)  
4-Hydroxy-BA 3510 (OH) (m) ≈3600-1950 - 1670 (s) 1606 (m)/1594 (m)  
3-Mercapto-BA 2548 (SH) (m) ≈3300-2000 - 1678 (s) 1598 (w)/1572 (m)  
4-Mercapto-BA 2555 (SH) (m) ≈3280-1950 - 1670 (s) 1592 (m)/1564 (m)  
Table 3.1 IR interpretation of aspirin analogues and their precursor compounds. All spectra recorded on neat powdered samples using a Genesis II ATR FTIR Spectrometer.
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From the IR table (Table 3.1), it can be seen that the appropriate functional 
groups have been identified in the samples synthesised thus, confirming that 
they are indeed the compounds of interest. 
A hydroxyl (–OH) group (4000-3000 cm-1) belonging to carboxylic acid, C=O 
group also part of carboxylic acid (1870-1540 cm-1) and the C=C (alkene) bonds 
found in aromatic rings (1670-1600 cm-1) have been identified for all of the 
compounds which is very much expected.   
The C=O group as part of the ester group (1870-1540 cm-1) has been identified 
in all but the precursor compounds. This also concurs with the chemical 
structure of the compounds (Table 3.3). 
A distinct feature of the precursor chemical compounds is the presence of a 
thiol (-SH) or –OH group which gets acetylated to a –S and –O producing final 
products of the compounds of interest.  
Last but not least are the thioaspirins with a distinctive feature of having their 
two C=O group stretches (1870-1540 cm-1) overlapping each other (Appendix 
8.13, 8.14 and 8.15). As seen on the table (Table 3.1), only the thioaspirins 
exhibited this feature. 
The differences in the IR specrtra of the precursor compounds from their final 
products confirms that the precursor have been successfully converted into the 
aspirin analogues of interest. And when coupled to NMR evidence there is little 
doubt that this is the case. 
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3.4.3 Purity of aspirin analogues synthesised 
3.4.3.1 TLC 
Thin Layer Chromatography (TLC) and melting point (Table 3.3) was used in 
this chapter to assess the presence of impurities in the compounds synthesised 
and to also find out if the product compound is different from the precursor 
compound. 
Precursor compound Rf Product compound Rf 
SA 1.0 PN502 0.8 
3HBA 0.8 PN548 0.9 
4HBA 0.6 PN549 0.7 
TSA 0.9 PN590 0.8 
3MBA 0.9 PN591 0.8 
4MBA 0.7 PN592 0.6 
SA 0.9 PN517 0.4 
Table 3.2 Rf value of aspirin analogues and their respective precursors with 
solvent system hexane:ethylacetate:acetic acid [65:30:5 (v/v)]. 
The precursors with their corresponding product compounds. Aspirin, Salicylic acid 
(SA), meta-aspirin (PN548), 3-hydoxybenzoic acid (3HBA), para-aspirin (PN549), 4-
hydroxybenzoic acid (4HBA), ortho-thioaspirin (PN590), thiosalicylic acid (TSA), meta-
thioaspirin (PN591), 3-mercaptobenzoic acid (3MBA), para-thioaspirin (PN592), 4-
mercaptobenzoic acid (4MBA), fumaryldiaspirin (PN517). 
 
 
Using qualitative appearance of the spots on the TLC plates, the precursors are 
clearly different from the product compound. The PN502 is light grey in 
appearance (Figure 3.10A) and has Rf value of 0.8 (Table 3.2). This is clearly 
different from the blue spot of SA (Figure 3.10A) with 1.0 as its Rf value (Table 
3.2). 
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Figure 3.10 TLC of aspirin analogues assessing purity.  
Samples were chromatographed on silica-coated plates developed with 
hexane/ethylacetate/acetic acid (65:30:5, v/v), and the spots were visualised under UV254 light. 
Separation and detection of aspirin (o-A), Salicylic acid (SA), PN548 (m-A) and 3-
hydroxybenzoic acid (3HBA) (A). Separation and detection of PN549 (p-A), 4-hydroxybenzoic 
acid (4HBA), PN517 (517) and SA (B). Separation and detection of PN590 (o-T), Thiosalicylic 
acid (TSA), PN591 (m-T) and 3-mercaptobenzoic acid (3MBA) (C). Separation and detection of 
PN592 (p-T) and 4-mercaptobenzoic acid (4MBA) (D).  
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PN548 appears as a light grey spot (Figure 3.10A) with Rf value of 0.9 (Table 
3.2) while its precursor, 3HBA appears as a darker shade of grey with Rf value 
of 0.8 (Table 3.2). PN549 spot colour appeared as grey and its precursor 
compound as a charcoal grey (Figure 3.10B). Rf values for PN549 and 4HBA 
are 0.7 and 0.6 respectively (Table 3.2). PN517 appeared as a light grey spot 
against a blue spot for its precursor, SA (Figure 3.10B) with 0.4 and 0.9 as their 
respective Rf values. TSA and 3MBA appear as darker spots than their 
respective product compounds, PN590 and PN591 (Figure 3.10C). The Rf value 
was 0.9 for TSA and 3MBA; and 0.8 for PN590 and PN591 (Table 3.2). PN592 
spot appeared as the same colour shade as that of its precursor 4MBA (Figure 
3.10D) with the distinguishing difference between the two being the Rf value of 
0.6 and 0.7 respectively (Table 3.2). Both PN592 and 4MBA appear as multiple 
spots (Figure 3.10D). The multiple spots could be due to impurities in the 
precursor compound, which was commercially purchased, that have also been 
transferred to the product compound PN592. 
In summary, salicylic acid shows up as blue (Figure 3.10A and 3.10B), but the 
aspirin analogues (Figure 3.10A, 3.10B, 3.10C and 3.10D) are all shades of 
grey varying from quite pale for PN517 to deep grey-almost charcoal for 4-MBA. 
This is probably due, partly, to loading on the plate as well as natural colour 
variation. 
Note also that one of the commercial samples (4MBA in Figure 3.10D) show 
significant amounts of impurity and is not a single spot. The ‘in-house’ 
synthesised compounds are pretty good by comparison. 
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3.4.3.2 Melting point analysis 
The melting point of compounds was determined using the Stuart® SMP 10 
melting point apparatus. The individual melting points taken all correlate with 
the melting points in the literature with the exception of PN592, whose melting 
point was lower (Table 3.3) than that found in the literature indicating presence 
of impurities stemming from the precursor compound, 4MBA (Figure 3.10D).
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ID 
number 
Chemical name Structure Molecular 
weight 
(g/mol) 
Melting point (°C) TLC IR NMR 
PN502 ortho-aspirin [2-acetoxybenzoic acid] OOH
O
O
 
180 134-136 
✓ 
PN548 meta-aspirin [3-acetoxybenzoic acid] O
OH
O
O  
180 132-134 
Lit. 129-131 (Edwin et al., 1942) ✓ 
PN549 para-aspirin [4-acetoxybenzoic acid] O
OH
O
O
 
180 183-185 
Lit. 188.7-189.4 (Nelander, 1964) ✓ 
PN590 ortho-thioaspirin [2-acetylthiobenzoic 
acid] 
OH
O
S
O  
196 122-125 
Lit. 125.5-126 (Nelander, 1964) ✓ 
PN591 meta-thioaspirin [3-acetylthiobenzoic 
acid] 
OH
O
S
O  
196 153-156 
Lit. 152-153 (Bordwell, 1956) ✓ 
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PN592 para-thioaspirin [4-acetylthiobenzoic 
acid] 
OH
O
S
O
 
196 189-190 
Lit. 202.8-203.6 (Nelander, 1964) ✓ 
PN517 fumaryldiaspirin, F-DiA [bis-(2-
carboxyphenyl) fumarate] 
O
OOH
O
X
O
O
OOH
 
X= -CH=CH- (trans) 
356 190-192 
Lit. 178-180 (Zaugg et al., 1980) ✓ 
PN508 diaspirin, DiA [bis-(2-carboxyphenyl) 
succinate] 
O
OOH
O
X
O
O
OOH
 
X= -CH2-CH2- 
358 169-171 
Lit. 160-165 (Aldrich) 
 
✓ 
PN524 m-bromobenzoylsalicylate [(3-
bromobenzoyl)salicylic acid] 
O OH
O
O
Br
 
321 Lit. 140-142 (Claudius et al., 2014)  
✓ 
 
PN528 benzosalin, [methyl-
bromobenzoylsalicylate]  O
O
O
O
 
256 84-86 
Lit. 83.8-84 (Claudius et al., 2014)  
 
✓ 
 
PN529 Isopropyl (3-bromobenzoyl)salicylate 
O
O
O
O
Br
 
363 Lit. 49-51 (Claudius et al., 2014)  
✓ 
 
Table 3.3 Structure and Properties of aspirin analogues. Lit. (Literature), ✓  = Analysis carried out on compounds.
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3.4.4 Stability/Breakdown of aspirin analogues 
3.4.4.1 Salicylic Acid Analysis 
The salicylic acid analysis assay was based on fluorescence enhancement of 
the As (III)-salicylic acid system (Karim et al., 2006). 
3.4.4.1.1 Dilution Curve for Salicylic Acid 
A dilution curve was plotted for SA and aspirin boiled in the presence of sodium 
hydroxide (NaOH) for 1 h in order to hydrolyse aspirin into salicylic acid. SA 
caused fluorescence in a concentration dependant manner within the 
concentrations used. Aspirin was without effect. Alkaline hydrolysis of aspirin, 
caused by boiling for 1 h in the presence of NaOH caused quantitative cleavage 
of aspirin, as determined by the curve overlaying the SA standard curve (Figure 
3.11). The purpose of this dilution curve is to make sure that the assay is robust 
enough. 
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Figure 3.11 Standard curve for salicylic acid detection using the As(III)-SA 
system.  
SA, aspirin broken down into salicylic acid when boiled with NaOH for 1 h and aspirin 
alone were serially diluted (from 5mM) in wells and fluorescence taken at 315 nm 
excitation and 408 nm emission wavelenghths. 
 
 
The standard curve shows that the assay is specific for salicylic acid and does 
not react with aspirin (Figure 3.11). 
To further test the robustness of the assay, the fluorescence reading of different 
concentrations of salicylic acid (SA) was taken at different time points. 
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Figure 3.12 Fluorescence reading of salicylic acid (SA) at different time points. 
Twelve time points were taken every 3 min. Fluorescence scale is at Log10. 
 
 
The fluorescence reading for SA remained constant for over 30 min when 
assessed at four different concentrations (Figure 3.12). Thus, indicating a 
robust assay for measuring salicylic acid. 
A major setback that was encountered with this assay is its reducing property. 
The reducing property of the assay rendered it insensitive to most of the 
compounds in this study, which also possess reducing characteristics. This 
assay was only sensitive to PN502, PN517 and PN548. The reason for its 
insensitivity to PN549 is unclear. 
3.4.4.1.2 Assessment of breakdown of compounds into salicylic acid 
using salicylic acid assay 
Aspirin is hydrolysed into SA, also known as 2-hydroxybenzoic acid as soon as 
it enters the circulatory system (Elliot Cham et al., 1982, Karim et al., 2006). 
The serum concentration of SA is found to be 20-30 times higher than aspirin 
after 5 min of administration with aspirin being 20 times more potent (Higgs et 
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al., 1987). The aspirin analogues used in this chapter have been observed to 
exert their antiproliferative effect when cells were treated for 48 h. It was 
therefore, rational to study and observe the rate at which they metabolise to 
salicylic acid during this duration of treatment. In this case the supernatant cell 
media was used to assess the percentage of SA present after 48 h because 
levels of intracellular SA was difficult to measure using the As (III)-SA system. 
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Figure 3.13 Percentage of salicylic acid (SA) produced by aspirin analogues. 
SW480 cells were treated at 1 mM of aspirin analogues for 48 h at 37°C. Control 
contains no compound, SA [salicylic acid], PN502 [ortho-aspirin], PN508 [diaspirin], 
PN517 [fumaryldiaspirin], P524 [m-bromobenzoylsalicylate], PN528 
[methyl(benzoylsalicylate](benzosalin) and PN529 [isopropyl(m-
bromobenzoylsalicylate)]. The other compounds not included in this figure did not show 
any sensitivity to the SA analysis. Data plotted as mean ± SEM (n=5), ★★p<0.01, 
★★★p<0.001,★★★★p<0.0001. 
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PN528 and PN529 showed the least amount of SA (Figure 3.13), which 
indicates that they are not easily metabolised into SA. Although PN502 and 
PN517 showed some level of SA after 48 h, the levels were still significantly 
different from the positive control (SA). If PN502 and PN517 metabolised into 
same levels of SA after 48 h (Figure 3.13), was it also at the same rate? This 
prompted a comparison between PN502 and PN517 of the rate of breakdown 
into salicylate with time. 
The reading for salicylate was therefore measured for PN502 and PN517 at 
nine time points for duration of 90 min. 
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Figure 3.14 Percentage of salicylic acid (SA) produced by aspirin analogues. 
SW480 cells were treated with 1mM of PN502 [aspirin] and PN517 [fumaryldiaspirin] 
for 90 min at 37°C. Readings were taken every 10 min using the As (III)-SA system.  
 
 
Results show for PN517, metabolism slows down with time. The rate of 
breakdown of PN517 into SA is seen to be much higher than PN502 (Figure 
3.14) because it appears to be metabolised to the same level of SA after 48 h 
(Figure 3.13) but then PN517 appearing to be metabolised into higher levels of 
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SA than PN502 for the first 90 min. However, metabolism into SA is still 
significantly different from SA alone after 48 h (Figure 3.13). 
Due to this salicylic acid analysis being insensitive to thioaspirins and para-
aspirin, it was decided to use a different approach in investigating the 
breakdown of the mentioned aspirin analogues. The approach taken was TLC. 
3.4.4.1.3 Assessment of breakdown of compounds using TLC 
TLC of supernatant containing compounds of treated cells was run against 
salicylates (precursors) of the aspirin analogues. Prior to spotting, the 
supernatant was acidified using conc. HCl after which ether was added in order 
to extract the compounds of interest (ether layer). Ether layers containing 
aspirin (o-A), PN548 (m-A), PN549 (p-A), PN590 (o-T), PN591 (m-T) and 
PN592 (p-T) were named S1, S2, S3, S4, S5 and S6 respectively. 
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Figure 3.15 TLC of aspirin analogues against their salicylates and extracts (S).  
Samples were chromatographed on silica-coated plates developed with 
hexane/ethylacetate/acetic acid (65:30:5, v/v), and the spots were visualised under 
UV254 light. Separation and detection of PN502 (o-A), Salicylic acid (SA) and extract 
of supernatant media of cells after treatment with PN502 (S1) (A). Separation and 
detection of PN548 (m-A), 3-hydroxybenzoic acid (3HBA) and extract after treatment 
with PN548 (S2) (B). Separation and detection of PN549 (p-A), 4-hydroxybenzoic acid 
(4HBA) and extract after treatment with PN549 (S3) (C). Separation and detection of 
PN590 (o-T), Thiosalicylic acid (TSA) and extract after treatment with PN590 (S4) (D). 
PN591 (m-T), 3-mercaptobenzoic acid (3MBA) and extract after treatment with PN591 
(S5) (E). Separation and detection of PN592 (p-T), 4-mercaptobenzoic acid (4MBA) 
and extract after treatment with PN592 (S6) (F).  
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The spot for PN502 appears to be black in colour with its precursor, SA as blue 
and closer to the solvent front. Extract S1 appears to be made up of SA due to 
the colour and distance from the solvent front being the same as in SA (Figure 
3.15A). Extract S2 appears to have the same Rf value as 3HBA, which 
suggests that PN548 has broken down into its salicylate (Figure 3.15B). Extract 
S3 also share the same Rf value as the salicylate of PN549, 4HBA (Figure 
3.15C). Extract S4 show two spots suggesting that PN590 has been broken 
down into two compounds, which corresponds to the separation into two spots 
by TSA (Figure 3.15D). For PN591, the extract, S5 appears to be about 10% of 
the salicylate, 3MBA and 90% of something else which could be a dimer (Figure 
3.15E). The same effect is seen with PN592 with the extract and salicylate both 
separating into two spots suggesting two different compounds (Figure 3.15F). 
3.4.4.1.4 Stability of PN502 
In order to carry out experiments/assays using these aspirin analogues, 
knowledge of their stability in solution is of utmost importance. PN502 was used 
as a ‘benchmark’ to find out the relative stability of these compounds at room 
temperature (RT), at +4°C and at -20°C. 
PN502 dissolved in acetone at 50mM was stored at RT, +4°C and -20°C for 24 
h and the level of salicylic acid measured from each sample. 
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Figure 3.16 Salicylate formation from PN502 in solution at different storage 
conditions. 
PN502 was dissolved in acetone and stored at the temperature stated for 24 h before 
testing for the presence of SA using the As (III)-SA system. Data are from n=3 
performed in duplicate. Error bars represent SEM. 
 
 
Using the SA assay, over 20% of PN502 had been hydrolysed to SA when in 
solution in acetone and kept at RT for 24 h. At +4°C, hydrolysis was slowed 
down and only about 5% was hydrolysed to salicylic acid and about 2% was 
hydrolysed when stored at -20°C (Figure 3.16). 
3.5  Discussion 
The aspirin analogues synthesised were identified and chemical structure 
verified using NMR spectroscopy (Figure 3.1 to 3.9) in combination with IR 
spectroscopy (Table 3.1). In order to make sure that the compounds were free 
of impurities, an assessment was made using TLC (Table 3.2 and Figure 3.10) 
where it was observed that the compounds of interest separated as a single 
spot distinct from the precursor salicylate compound with the exception of 
PN592 of which even its commercially bought precursor, 3MBA (Figure 3.10D) 
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showed significant amounts of impurity. Melting point was also used to assess 
the state of purity for these compounds and found to be close to the readings 
given in literature (Table 3.3). Signs of impurities present in the PN592 sample 
can also be confirmed by the melting point which was low at 189-190°C (Table 
3.3) as compared to the melting point found in the literature as a reference point 
(202.8-203.6°C). However, the other ‘in-house’ synthesised compounds show 
high purity. The rate and extent of hydrolysis or breakdown of these compounds 
were studied using a newly developed salicylic acid assay based on a 
published paper (Karim et al., 2006). The assay was also tested for its 
sensitivity to SA and robustness (Figure 3.11 and 3.12) before commencing 
with the aspirin analogues of interest (Figure 3.13). It was observed that PN528 
and PN529 were the least affected by hydrolysis with only about 5% 
metabolised to SA. PN502 and PN517 were metabolised quantitatively at the 
same level to SA, which raised the question to whether this hydrolysis was also 
at the same rate. Assessment of the rate of hydrolysis at nine time points 
suggested that PN517 is hydrolysed at a faster rate than PN502 (Figure 3.14). 
A major set back was encountered in that the assay developed is enhanced by 
the reducing property of As(III) to the salicylic system (Karim et al., 2006) and 
so thioaspirins due to their reducing property could not be used in this assay. 
Thioaspirins have a sulfhydryl group attached to their benzene rings which 
reacts with As(III) and reduces it (Scott et al., 1993) thereby rendering the 
assay null and void. 
Thus, TLC was adopted to assess the breakdown of the thioaspirins into their 
respective thiosalicylate forms (Figure 3.15). In PN502, the hydroxyl bond (-OH) 
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is more strongly bonded to the carboxy group as compared to its affinity to the 
TLC plate (Watson, 2005). This is why its distance from the solvent front is 
more than that of Salicylic acid, thus, moves at a slower rate as compared to its 
meta- and para- isomer. It was observed that the extracts for the cells treated 
with thioaspirins separated into two spots, as the salicylates. Thiols are known 
to lose a proton above a given pH, this being relevant to the biological system, 
which leads to the formation of disulphide bonds (Rowland et al., 2011). An 
increase in pH leads to a 50% oxidation to 2-2’-disulfanediyldibenzoic acid (2,2’-
DSBA), which contains a disulphide bond/bridge (Rowland et al., 2011). 
However, the experimental conditions differ.  There might be a formation of 
disulphide bonds by 3MBA and 4MBA (Rowland et al., 2010), which explains 
the multiple spots for the extracts observed on the TLC plate. The oxidation of 
thioaspirins is likely to make the products more polar.  
Using PN502 as a ‘benchmark’ (Figure 3.16), it can be said that these aspirin 
analogues are not very stable when in solution especially at RT (Kim et al., 
2013) and as such are always freshly prepared before each experiment.  
The aspirin analogues synthesised were thus declared fit for use in  
experimental studies.
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Chapter 4. Cytotoxicity and Synergy of Aspirin 
analogues with platinum compounds 
4.1 Introduction 
The discovery of a positive effect of aspirin on CRC (Kune et al., 1988) was a 
stepping stone for the study of aspirin on various cancers. Evidence later 
emerged that indeed the daily intake of aspirin reduced mortality (Rothwell et al., 
2011), incidence and metastasis of CRC (Algra and Rothwell, 2012). These 
discoveries geared studies carried out on the effects caused by aspirins in 
different cancers (Drew et al., 2016, Nan et al., 2015, Thorat and Cuzick, 2015). 
4.1.1 Cytotoxicity of Aspirin analogues 
The cell line primarily used in this study was the SW480 CRC cell line, which 
has been well characterized by Leibovitz et al., (1976) and more recently 
genetically characterized (Ahmed et al., 2013) . The cell line was isolated from 
the primary adenocarcinoma in the colon of a 50-year-old Caucasian male 
(Ahmed et al., 2013, Leibovitz et al., 1976). The cells are polygonal in shape 
with microvilli on their cell surfaces when viewed under an electron microscope 
(Leibovitz et al., 1976) with an intermediate growth rate (Ahmed et al., 2013). 
They are also known to be hyperdiploid and a low producer of CEA and are 
considered a good candidate for experimental studies in CRC research 
(Leibovitz et al., 1976). 
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The SW480 cell line is DNA MMR proficient (Din et al., 2004) and thus a good 
model for the study of changes involved in the progression of late CRC (Hewitt 
et al., 2000). Semi quantitative analysis reveals the SW480 cell line to express 
low levels of COX1 and undetectable levels of COX2 (Li et al., 2001, Richter et 
al., 2001), thus making it a good model for the study of mechanism of action of 
compounds following COX-independent pathways. 
 
The cytotoxicity of aspirin and its analogues have been reported in various 
cancers (Claudius et al., 2014, Din et al., 2004, Gurpinar et al., 2013). In this 
study, it has been found out that aspirin and several synthesised novel 
analogues have cytotoxic effects on the SW480 cell line and oesophageal 
cancer cell lines OE33 and FLO1.  
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Figure 4.1 Morphology of the cell lines used in this study. 
SW480 CRC cell line (A), OE33 Oesophageal cell line (B), FLO1 Oesophageal cell line 
(C) and U251 MG tumour cell line. Phase Contrast images of cell lines taken at 100X 
Magnification. Bar scale is at 100 μm. 
 
4.1.2 Synergy 
The adaption of combined therapy using several active ingredients to produce a 
desired effect in the treatment of different diseases by both traditional and 
modern medical practitioners (Foucquier and Guedj, 2015) dates back 
thousands of years when the Chinese and African herbalists used a 
combination of naturally occurring herbs to treat ailments (Odugbemi et al., 
2007, Yuan and Lin, 2000). One of the reasons behind the increased interest in 
the development of combination therapies can be attributed to the enhanced 
understanding that cancer as a disease involves the disruption of different 
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molecular pathways, which are all connected and better tackled with the 
combined action of two or more drugs (Podolsky and Greene, 2011, 
Zimmermann et al., 2007). Another reason for the increased interest in 
combination therapy is the desire to achieve therapeutic effects at reduced 
doses, which will result in toxicity reduction and also delay or minimize the 
induction of drug resistance (Chou, 2010). Drug combination therapy has 
increased in popularity for the treatment of complicated diseases such as 
cancer and AIDS (Chou, 2006). 
  
Synergy can be defined as the greater effect for drugs in combination than in 
the simple additive effect produced by each drug individually (Foucquier and 
Guedj, 2015). For example, 1+1 should be >2 for a synergistic effect while an 
antagonistic effect is less than an additive effect (Foucquier and Guedj, 2015). 
The term ‘combination index’ (CI) is used to quantitatively depict synergism 
(CI<1), additive effect (CI=1) or antagonism (CI>1) (Chou and Talalay, 1984). 
With emphasis on the treatment of CRC involving platinum compounds, 
oxaliplatin has been used in several combinations with other drugs. As far back 
as 1992, a study was published on the effects that resulted from the 
combination of oxaliplatin, folinic acid and 5-FU with an objective response from 
58% of the patients (Levi et al., 1992). FOLFOX was later introduced which 
comprises of 5-FU, folinic acid (leucovorin) and oxaliplatin, which resulted in a 
high response rate in CRC patients (Andre et al., 2009, de Gramont et al., 
1997). Bevacizumab, a VEGF antagonist is also used in combination with 
FOLFOX, the oxaliplatin-containing regimen in the treatment of metastatic CRC 
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and has produced promising results (Saltz et al., 2008). EGFR antagonists, 
cetuximab or panitumumab have also produced improved response rates when 
used in combination with FOLFOX in patients harbouring the KRAS gene 
mutation (Alcindor and Beauger, 2011).  Unfortunately, these combinations do 
not improve overall survival (Bendell et al., 2017, Saltz et al., 2008). 
Oxaliplatin, as part of a neoadjuvant chemotherapy regimen is administered to 
CRC patients in order to shrink tumours before surgery/main treatment (Andre 
et al., 2004, Yang et al., 2016). However resistance to oxaliplatin is an 
encroaching menace especially in cancers that harbour a mutation of the TP53 
gene of the tumour suppressor protein p53 (Lowe et al., 1993). p53 as a 
transcription factor acts as guard to the cell in response to stress signals and  is 
responsible for the regulation of the cell cycle (Brown et al., 2009) and several 
metabolic enzymes, which are in turn responsible for drug metabolism (Lowe et 
al., 1993, Yang et al., 2016). For example, mutations found in the TP53 gene 
affect cytochrome P450, an enzyme involved in the metabolism of drugs such 
as oxaliplatin (Lee et al., 2008, Yang et al., 2016), thereby leading to resistance. 
It was therefore aimed to establish whether these aspirin analogues used in 
combination with platinum compounds could have an effect in either a 
synergistic, additive or antagonistic manner.  
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4.1.2.1 Terminologies and plots used in the interpretation of drug 
combination results 
There are certain terminologies and graph plots used to interpret whether a 
certain combination of drugs result in synergy, additive effect or antagonism. 
They include CI, which has been earlier mentioned, an isobologram, which is “a 
graph with equipotency sum of doses” (Chou, 2006), Fa-CI and Fa-DRI plots. 
The Fa-CI plot (Figure 4.2A) is a graph showing the CI of each combination in 
relation to the fraction affected (Fa), which means the growth inhibitory effect of 
each drug [Fa = 1 − (%growth ⁄ 100)] (Bijnsdorp et al., 2011). Isobologram is a 
plot that indicates synergism, antagonism or additive effect depending on 
whether the data points fall on the left, right or on the curve (Chou, 2006). Chou 
(2006) further explains that if the data points fall on the left side, right side or on 
the curve, the combination is synergistic, antagonistic or additive respectively 
(Figure 4.2B). Another plot found in both the CalcuSyn and CompuSyn software 
is the Fa-dose-reduction index (Fa-DRI) plot (Figure 4.2C). As alluded before, 
one of the main reason for synergistic studies is to develop drug combinations 
with desired effects at reduced doses in order to decrease toxicity effects (Chou, 
2006). The dose-reduction-index, DRI>1 indicate favourable dose-reduction 
while DRI<1 indicate unfavourable dose-reduction. For example (Table 4.1), 
Fa=0.5 means at 50% inhibition of cell proliferation; 
 
Fa Dose A Dose B DRI A DRI B 
0.5 3.7260 4.1938 3.2163 3.5924 
Table 4.1 Example of a DRI Data for Drug Combination involving drugs A and B. 
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For a 50% inhibition of cell growth, 3.7 μM of drug A and 4.2 μM of B is required. 
However, 3.2163-fold less A plus 3.5924-fold less B is required to achieve the 
same 50% inhibition at the chosen combination ratio (i.e., 3.7260 μM/3.2163 = 
1.1585 μM of drug A plus 4.1938 μM/3.5924 = 1.1674 μM of drug B). 
CI values can also be interpreted as descriptive words or by symbols (Table 
4.2). 
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Figure 4.2 Drug combination plots and their interpretations based on the Chou 
and Tatalay combination index (CI) theorem.  
Fa-CI plot (A), Isobologram at ED50, ED75 and ED90 (B), Fa-DRI plot (C) (Chou, 2006). 
These plots are generated automatically by using the CompuSyn (Chou and Martin, 
2005) or CompuSyn (Chou, 2005) software. Fa = fraction affected. 
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Combination Index (CI) Graded Symbols Interpretation 
<0.1 +++++ Very strong synergism 
0.1-0.3 ++++ Strong synergism 
0.3-0.7 +++ Synergism 
0.7-0.85 ++ Moderate synergism 
0.85-0.9 + Slight synergism 
0.9-1.1  Nearly additive 
1.1-1.2 − Slight antagonism 
1.2-1.45 −− Moderate antagonism 
1.45-3.3 −−− Antagonism 
3.3-10 −−−− Strong antagonism 
>10 −−−−− Very strong antagonism 
Simplified CI values and their interpretation 
<0.8 Synergism 
0.8-1.2 Additive 
>1.2 Antagonism 
Table 4.2 Description and Interpretation of CI values. 
A table showing the description and interpretation of synergism or antagonism in 
combination studies using CI method of analysis [Adapted from (Bijnsdorp et al., 2011, 
Chou, 2006)]. 
 
The synergy experiments carried out in this chapter involved the combination of 
aspirin analogues and DNA-damaging platinum compounds in SW480 CRC 
and OE33 oesophageal cell lines. 
Based on their respective IC50, compounds were combined at different ratios. 
Doses and FA of individual compounds and combinations were fed into the 
CompuSyn software, which calculated CI and DRI at ED50, ED75 and ED90. 
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4.2 Aims and Objectives 
Kankipati (2014) and Kilari (2014) have reported cytotoxic effects of some of 
these aspirin analogues on colorectal and oesophageal cell lines respectively. 
In this chapter, it was aimed to investigate the cytotoxic effects of a wider range 
of these analogues, which include the meta- and para- isomers of aspirin and 
thioaspirin. It was also aimed to study if their cytotoxic effect against SW480 
CRC and OE33 oesophageal cell lines will result in a synergistic effect when in 
combination with DNA-damaging platinum compounds known to be used as 
chemotherapeutic agents using the CalcuSyn® and CompuSyn® softwares. 
4.3 Methodology 
The methodology used in this chapter is given in detail in chapter two for 
materials and methods (2.2.6 and 2.2.17). The MTT assay was later adopted to 
investigate cytotoxic effects of compounds after it was discovered that the MTS 
reagent became insensitive to the thioaspirins because of their reducing effect 
(Mert et al., 2006), which rendered the MTS reagent inactive. There is evidence 
for the dimerization of thiosalicylic acid which varies with pH (Rowland et al., 
2011) and thus has the capacity to interfere with any assay that utilises 
reagents capable of undergoing a redox reaction (For example, MTS assays 
and SA assays using As(III) or Fe(III) salts). MTT assay was preferred in this 
case because there was a step in the procedure that enabled the washing out 
of compounds before addition of MTT reagent thus avoiding/minimizing 
interaction, whereas the MTS reagent is used as a single solution added 
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directly to assay wells. The combination ratios for the synergy experiments were 
based on the individual IC50 values for each compound. 
4.4 Results 
4.4.1 Cytotoxicity results 
A standard curve for the MTS solution was plotted, which resulted in a very 
good R-square value indicating that absorbance readings were directly 
proportional to the concentration or percentage of MTS solution. 
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Figure 4.3 Standard curve for MTS solution.  
MTS solution was serially diluted with acetone. Linear regression analysis shows  “R-
square” value as 0.98, which indicates it is a good fit. Absorbance was used in relation 
to cell activity/viability. 
 
The MTS solution was thus fit for determining cell viability in accordance with 
the absorbance readings at 490 nm (Figure 4.3). 
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The standard curve for the MTT assay was also determine to make sure that 
the concentration of formazan was directly proportional to the absorbance at 
540 nm (Figure 4.4). 
 
0 50 100 150
0
1
2
3
4
5
% MTT
A
b
s
 (
5
4
0
n
m
)
r2= 0.99
 
Figure 4.4 Standard curve for MTT solution.  
Formazan crystals were diluted with DMSO to make a solution. Linear regression 
analysis shows “R-square” value as 0.99, which indicates it is a very good fit. 
Absorbance was used in relation to cell activity/viability. 
 
The absorbance recorded at 540nm appears to be directly proportional to the 
percentage of MTT solution thus rendering the assay fit for purpose (Figure 4.4). 
The percentage viability of cells was assessed using this MTT assay and IC50 
values calculated using GraphPad Prism. 
 
Prior to analysing the cell viability of cells after treatment with aspirin analogues, 
the most appropriate dissolution solvent for these compounds had to be 
determined. Assays had initially been carried on these compounds using DMSO 
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as a dissolution solvent. It was thus decided to compare other organic solvents 
with DMSO based on their ability to dissolve the aspirin analogues and their 
effect on cell viability. Acetone, THF, DMSO and water were chosen to test 
solubility of compounds and effect on cell viability. 
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Figure 4.5 Percentage cell viability of SW480 CRC cells in different organic 
solvents. 
SW480 cells were incubated with organic solvents in media to different final 
concentrations at 37°C for 48 h. Mean ± SEM (n=3).  
 
Although ultrapure water had no cytotoxic effect on the cells at the 
concentrations tested, water was a poor dissolution solvent for the compounds 
used in this study. Likewise, THF also failed to dissolve some of the aspirin 
analogues. The aspirin analogues completely dissolved in acetone and DMSO, 
with less toxicity to cell viability noted with acetone in particular (Figure 4.5). 
Although DMSO is generally known as the ‘universal solvent’ for biological 
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experiments due to its ability to dissolve most molecules at high concentrations 
of up to 100 mM (Pereira and Williams, 2007), acetone was found to have a 
lesser effect on cell viability. Acetone was thus chosen as the dissolution 
solvent for the experiments carried out with aspirin analogues in this thesis. 
Compounds were always dissolved in acetone to a concentration of 50 mM, 
which was further diluted with a buffer and finally diluted to the desired final 
concentration with cell culture media (e.g. L-15, DMEM, etc). 
 
SW480 CRC cells were treated with aspirin analogues dissolved in acetone and 
NSAIDs for 48 h at doses between 1 μM and 3 mM. Platinum compounds were 
treated at doses between 0.1 μM and 0.3 mM. The IC50 values were then 
determined from the dose response curves plotted. 
Acetone was used to dissolve aspirin analogues and NSAIDs with the exception 
of diflunisal, which was only soluble in DMSO. Dissolution with DMSO was also 
avoided in platinum compounds; cisplatin, oxaliplatin and carboplatin as DMSO 
react with platinum complexes thereby decreasing their cytotoxic effect (Hall et 
al., 2014). The nucleophilic sulphur in DMSO reacts with platinum complexes 
thereby displacing their ligands, which result in a structure change, and thus 
making the compounds unstable in DMSO (Farrell et al., 1990, Kerrison and 
Sadler, 1985). Due to these facts, cisplatin was dissolved using PBS while both 
oxaliplatin and carboplatin were dissolved using water as suggested by Hall et 
al., (2014). SW480 cells were also treated with aspirin analogues and platinum 
compounds for 12 days in order to determine if cytotoxicity of compounds will 
follow the same pattern, slow down or come to a halt. Furthermore, increased 
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cytotoxic effect of any of these compounds over long period of time means such 
compounds have a longer duration of action than expected. 
The oesophageal cancer cell lines, OE33 and FLO1 are both from human and 
originate from the oesophagus. OE33 is originally from the adenocarcinoma of 
the lower oesophagus (Barrett’s metaplasia) in a 73-year-old female patient 
(ECACC). FLO1 is originally from the primary distal oesophageal 
adenocarcinoma in a 68-year-old Caucasian male (ECACC). 
OE33 and FLO1 oesophageal cell lines were also treated with a few of the 
aspirin analogues and platinum compounds in order to determine the IC50 as a 
base needed for synergy experiments later carried out. The same dissolution 
conditions for compounds used to treat SW480 cells were also applied for 
oesophageal cancer cell lines. 
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Figure 4.6 Dose response curves of aspirin analogues in SW480 CRC cell line. 
SW480 CRC cell lines were treated with compounds (1 μM-3 mM) and incubated at 37°C for 48 h. The 
anti-proliferative effects were measured using MTT assay. Data plotted as mean ± SEM (n=3). Where 
error are absent, SEM is smaller than size of data point. IC50 was calculated using GraphPad Prism. 
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SW480 CRC cells treated with aspirin and its analogues for 48 h resulted in an 
inhibitory concentration of 50% of the cell population for aspirin as 1.8 mM 
(Figure 4.6A). PN548 (meta-aspirin) and PN549 (para-aspirin) had IC50 at 3.8 
mM and 4.9 mM respectively when cells were treated for 48 h (Figure 4.6A), 
which appears to not have much cytotoxicity. This could be due to the short 
duration of treatment. In comparison to PN502, PN517 (fumaryldiaspirin) and 
PN524 (m-bromo benzoylsalicylate), both ‘diaspirins’ were very cytotoxic 
against SW480 cells with an IC50 of 0.24 mM and 0.44 mM respectively (Figure 
4.6A). PN508, also one of the ‘diaspirins’ was quite cytotoxic with 0.75 mM as 
its IC50 which suggests that even though ‘diaspirins’ are dimers of aspirin, they 
are more than twice more potent. Cytotoxicity against SW480 cells was higher 
when cells were treated with the thioaspirins as compared to aspirin with IC50 
for PN590 (ortho-thioaspirin), PN591 (meta-thioaspirin) and PN592 (para-
thioaspirin) as 0.16 mM, 0.48 mM and 0.75 mM respectively (Figure 4.6B). 
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Figure 4.7 Dose response curves of NSAIDs and platinum compounds in SW480 CRC cell line. 
SW480CRC cell lines were treated with compounds (0.1 μM-0.3 mM) and incubated at 37°C for 48 h. The 
anti-proliferative effects were measured using MTT assay. Data plotted as geometric mean ± SEM (n=3). 
Where error are absent, SEM is smaller than size of data point. IC50 was calculated using GraphPad Prism. 
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SW480 cells were also treated with NSAIDs for 48 h, which resulted in diflunisal 
as the most cytotoxic NSAID against this cell line with an IC50 of 0.08 mM 
(Figure 4.7A). Treatment with diclofenac, indomethacin and naproxen resulted 
in IC50 of 0.1 mM, 0.15 mM and 0.49 mM respectively (Figure 4.7A). 
Cytotoxicity of NSAIDs against SW480 cells is much higher than aspirin and 
‘diaspirins’ with the exception of PN517 (Figure 4.6A). The DNA-damaging 
platinum compounds had IC50 of 0.02 mM for cisplatin, 0.05 mM for oxaliplatin 
and 0.21 mM for carboplatin, all of which were more cytotoxic than aspirin 
(Figure 4.7B). 
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Figure 4.6 Dose response curves of aspirin analogues and platinum compounds 
in OE33 (A) and FLO1 (B) oesophageal cell lines. 
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Figure 4.8 Dose response curves of aspirin analogues and platinum compounds 
in OE33 (A) and FLO1 (B) oesophageal cell lines. 
Oesophageal cells were treated with aspirin analogues (1 μM-3 mM) and platinum 
compounds (0.1 μM-0.3 mM) and then incubated at 37°C for 48 h. The anti-proliferative 
effects were measured using MTT assay. Data plotted as geometric mean ± SEM 
(n=3). Where error are absent, SEM is smaller than size of data point. IC50 was 
calculated using GraphPad Prism. 
 
 
 
The oesophageal cell lines, OE33 and FLO1 were also treated with some of the 
aspirin analogues and DNA-damaging platinum compounds for 48 h. PN502 
(aspirin) appeared not to be very cytotoxic against FLO1 cells with 4.64 mM as 
IC50 (Figure 4.8B) as compared to OE33 cells (Figure 4.8A) and SW480 cells 
(Figure 4.6) with 1.95 mM and 1.8 mM as IC50 respectively. PN524 was also 
found to be more cytotoxic in OE33 cells, IC50 as 0.47 mM (Figure 4.8A) than in 
FLO1 cells, IC50 as 0.87 mM (Figure 4.8B). However, PN517 and the platinum 
compounds had similar cytotoxic effects in both oesophageal cell lines. In OE33 
cells, PN517, cisplatin, oxaliplatin and carboplatin had IC50 at 0.84 mM, 0.01 
mM, 0.04 mM and 0.05 mM respectively (Figure 4.8A). While in FLO1 cells, 
PN517, cisplatin, oxaliplatin and carboplatin resulted in IC50 values of 0.79 mM, 
0.01 mM, 0.02 mM and 0.04 mM respectively (Figure 4.8B). 
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Compounds Geometric mean of IC50 values (mM)  
SW480 OE33 FLO1 
PN502 1.8  1.95 4.64  
PN548 3.8  - - 
PN549 4.9  - - 
PN517 0.24  0.84 0.79  
PN508 0.75  - - 
PN524 0.44  0.47 0.87 
Salicylic acid 2.55  - - 
PN590 0.16  - - 
PN591 0.48  - - 
PN592 0.75  - - 
Diclofenac 0.10  - - 
Naproxen 0.49  - - 
Diflunisal 0.08  - - 
Indomethacin 0.15  - - 
Cisplatin 0.02  0.01  0.01 
Oxaliplatin 0.05  0.04  0.02 
Carboplatin 0.21  0.05  0.04  
Table 4.3 IC50 values of aspirin analogues, NSAIDs and platinum compounds on SW480 CRC cell 
line, OE33 and FLO1 oesophageal cell lines. 
Cells were treated for 48 h. IC50 values were obtained by non-linear regression analysis from dose-
response curves using Graphpad Prism. Data are presented as geometric mean (n=4),  
 
Compounds Geometric mean of IC50 values (mM)  
PN502 0.10 
PN508 0.16 
PN517 0.06 
PN590 0.08 
PN591 0.04 
PN592 0.03 
Diclofenac 0.05 
Naproxen 0.09 
Indomethacin 0.05 
Cisplatin 0.003 
Oxaliplatin 0.0004 
Carboplatin 0.009 
Table 4.4 IC50 values of some aspirin analogues, NSAIDs and platinum compounds on SW480 CRC 
cell line after 12- day cytotoxicity assay. 
Cells were treated for 12 days with cells replenished on the sixth day. IC50 values were obtained by non-
linear regression analysis from dose-response curves using Graphpad Prism. Data are presented as 
geometric mean (n=3). 
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4.4.2 DEREK analysis 
Aspirin and its analogues were analysed in silico for their toxicity profile. The 
toxicological endpoints assessed include hepatoxicity, nephrotoxicity, 
mitochondrial dysfunction and skin sensitisation in humans. The knowledge 
database used is the DEREK KB 2015 2.0, version 1.0, certified by Lhasa 
Limited, Leeds, Yorshire, UK. 
 
A major setback in this analysis is that the software did not recognise the 
chemical structures of some of the compounds and so did not produce any 
predictions for its toxicological profile. 
 
The aspirin analogues that the programme did recognise were identified as 
salicylates and thus produced predictions for their toxicological profile as that of 
salicylic acid. Salicylates have anti-inflammatory, analgesic and antipyretic 
effects and are known to cause liver injury that could lead to fatality in humans 
at doses that exceed 4g orally (Cao et al., 2015, Hamdan et al., 1985, Seaman 
et al., 1974). Mitochondrial dysfunction is also included in the toxicological 
profile of the salicylates (Zhang et al., 2009). 
Nephrotoxicity have also been reported to be caused by salicylates in the form 
of renal failure, nephrotic syndrome and interstitial nephritis (Perazella and 
Markowitz, 2010). 
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Compound Endpoint Result 
PN502 (ortho-aspirin) Hepatotoxicity Positive 
Mitochondrial 
dysfunction 
Positive 
Nephrotoxicity Positive 
Skin sensitisation Plausible 
PN548 (meta-aspirin) Hepatotoxicity ‘The query structure 
does not match any 
structural alerts or 
examples in Derek’ 
Mitochondrial 
dysfunction 
Nephrotoxicity 
Skin sensitisation 
PN549 (para-aspirin) Hepatotoxicity ‘The query structure 
does not match any 
structural alerts or 
examples in Derek’ 
Mitochondrial 
dysfunction 
Nephrotoxicity 
Skin sensitisation 
PN590 (ortho-thioaspirin) Hepatotoxicity ‘The query structure 
does not match any 
structural alerts or 
examples in Derek’ 
Mitochondrial 
dysfunction 
Nephrotoxicity 
Skin sensitisation 
PN591 (meta-thioaspirin) Hepatotoxicity ‘The query structure 
does not match any 
structural alerts or 
examples in Derek’ 
Mitochondrial 
dysfunction 
Nephrotoxicity 
Skin sensitisation 
PN592 (para-thioaspirin) Hepatotoxicity ‘The query structure 
does not match any 
structural alerts or 
examples in Derek’ 
Mitochondrial 
dysfunction 
Nephrotoxicity 
Skin sensitisation 
PN508 (diaspirin) Hepatotoxicity Positive 
Mitochondrial 
dysfunction 
Positive 
Nephrotoxicity Positive 
Skin sensitisation Plausible 
PN517 (fumaryldiaspirin) Hepatotoxicity Positive 
Mitochondrial 
dysfunction 
Positive 
Nephrotoxicity Positive 
Skin sensitisation Plausible 
Table 4.5 List of compounds, endpoints and results produced by in silico 
analysis using the DEREK software. 
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4.4.3 Drug combinations 
Platinum compounds in combination with aspirin and its analogues were used 
to treat SW480 CRC cells and OE33 oesophageal cancer cells for 72 h. The 
cytotoxic effect and fraction of cells affected (Fa) was then calculated and fed 
into the CompuSyn software where The CI was determined at ED50, ED75 and 
ED90. The dose-effect graph to compare the fraction of cells affected by single 
compounds with the fractions of cells affected by drug combinations; Fa-log 
(DRI) graphs to show the effective ED50 of compounds decreased or increased 
when in combination were also plotted by the software. Against the colorectal 
cell line, SW480, cisplatin had synergistic effects when combined with all the 
aspirin analogues with the exception of the meta- (PN591) and para- (PN592) 
thioaspirin (Figure 4.16 and 4.17 respectively). Oxaliplatin in combination with 
PN548, PN524 and PN592 had synergistic effects at lower doses i.e. ED50 and 
lower. Although there appears to be a synergistic effect, antagonism sets in at 
ED75 and ED90. PN517 also has a synergistic effect with carboplatin at ED50, 
which decreased and effect became antagonistic at ED90 (Table 4.5). 
Carboplatin and PN549 [1:50] was the only combination that had a favourable 
synergistic effect. These combination effects between aspirin and its analogues 
with platinum compounds have been summarised on Table 4.5.  
Against the oesophageal cell line, OE33, cisplatin had synergistic effects when 
used in combination with PN517, PN524 and PN528. PN528 (methyl-
bromobenzoylsalicylate) was included in this study against the OE33 cell line 
because of its high cytotoxic effects and specificity against three different 
oesophageal cell lines namely; FLO1, OE33 and OE21 (Kilari, 2014). The other 
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platinum compounds however, did not show any synergistic effects when used 
in combination with PN502 (aspirin), PN517, PN524 and PN528.
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Figure 4.7 Drug combination plots for cisplatin and ortho-aspirin (CP+PN502[1:200]) in SW480 
CRC cells. 
Dose response curve (A). Dose-effect curve as plotted by CalcuSyn (B). Bar chart representation of 
IC50 by single compounds and their combination (C). Fa-log(DRI) plot as plotted by CompuSyn (D). 
CI values as calculated by CompuSyn at ED50, ED75 and ED90. CP=Cisplatin. 
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Figure 4.8 Drug combination plots for cisplatin and meta-aspirin (CP+PN548[1:400]) in SW480 
CRC cells. 
Dose response curve (A). Dose-effect curve as plotted by CalcuSyn (B). Bar chart representation of 
IC50 by single compounds and their combination (C). Fa-log(DRI) plot as plotted by CompuSyn (D). 
CI values as calculated by CompuSyn at ED50, ED75 and ED90. CP=Cisplatin. 
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Figure 4.9 Drug combination plots for cisplatin and para-aspirin (CP+PN549[1:250]) in SW480 
CRC cells. 
Dose response curve (A). Dose-effect curve as plotted by CalcuSyn (B). Bar chart representation of 
IC50 by single compounds and their combination (C). Fa-log(DRI) plot as plotted by CompuSyn (D). 
CI values as calculated by CompuSyn at ED50, ED75 and ED90. CP=Cisplatin. 
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Cisplatin was used in combination with aspirin and its isomers, PN502 (aspirin), 
PN548 (meta-aspirin) and PN549 (para-aspirin) at 1:200 (Figure 4.9A, B, C, D 
and E), 1:400 (Figure 4.10A, B, C, D and E) and 1:250 (Figure 4.11A, B, C, D 
and E) respectively.  
Combination index (CI) values for cisplatin and PN502 [1:200] indicated a 
synergistic effect (Figure 4.9E) with ED50 for cisplatin when used in combination 
with PN502 reduced from 51.9μM to 6.2μM (Figure 4.9D). The DRI calculated 
by CompoSyn software for SW480 CRC cells showed that cisplatin and PN548 
[1:400] resulted in a decrease in concentration to kill 50% of the cell population 
(ED50) for cisplatin and PN548 from 51.9μM and 2265.0μM to 5.2μM and 
2097.6μM respectively in combination (Figure 4.10D). The ED50 for cisplatin 
when used in combination with PN549 [1:250] reduced from 51.9μM to 4.2μM 
(Figure 4.11D). 
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Figure 4.10 Drug combination plots for cisplatin and fumaryldiaspirin (CP+PN517[1:10]) in 
SW480 CRC cells. 
Dose response curve (A). Dose-effect curve as plotted by CalcuSyn (B). Bar chart representation of 
IC50 by single compounds and their combination (C). Fa-log(DRI) plot as plotted by CompuSyn (D). 
CI values as calculated by CompuSyn at ED50, ED75 and ED90. CP=Cisplatin. 
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Figure 4.11 Drug combination plots for cisplatin and diaspirin (CP+PN508[1:17.5]) in SW480 
CRC cells. 
Dose response curve (A). Dose-effect curve as plotted by CalcuSyn (B). Bar chart representation of 
IC50 by single compounds and their combination (C). Fa-log(DRI) plot as plotted by CompuSyn (D). 
CI values as calculated by CompuSyn at ED50, ED75 and ED90. CP=Cisplatin. 
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Figure 4.12 Drug combination plots for cisplatin and m-bromobenzoylsalicylate 
(CP+PN524[1:40]) in SW480 CRC cells. 
Dose response curve (A). Dose-effect curve as plotted by CalcuSyn (B). Bar chart representation of 
IC50 by single compounds and their combination (C). Fa-log(DRI) plot as plotted by CompuSyn (D). 
CI values as calculated by CompuSyn at ED50, ED75 and ED90. CP=Cisplatin. 
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Cisplatin used in combination with the ‘diaspirins’, PN517, PN508 and PN524 
against SW480 cells at 1:10 (Figure 4.12A, B, C, D and E), 1:17.5 (Figure 4.13A, 
B, C, D and E) and 1:40 (Figure 4.14A, B, C, D and E) concentrations 
respectively resulted in synergistic effects at ED50, ED75 and ED90. 
When cisplatin was used in combination with PN517 [1:10], PN508 [1:17.5] and 
PN524 [1:40], the ED50 of the platinum compound reduced from 51.9 μM to 
10.7μM (Figure 4.12D), 20.1μM (Figure 4.13D) and 7.1μM (Figure 4.14D) 
respectively. PN517 in combination with cisplatin had its ED50 reduced from 
751.1μM to 107.1μM (Figure 4.12). The ED50 of PN508 in combination with 
cisplatin was decreased from 838μM as calculated by CompuSyn to 352.1μM 
(Figure 4.13). PN524 also had ED50 reduced from 382.1μM to 282.8μM (Figure 
4.14).  
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Figure 4.13 Drug combination plots for cisplatin and ortho-thioaspirin (CP+PN590[1:20]) in 
SW480 CRC cells. 
Dose response curve (A). Dose-effect curve as plotted by CalcuSyn (B). Bar chart representation of 
IC50 by single compounds and their combination (C). Fa-log(DRI) plot as plotted by CompuSyn (D). 
CI values as calculated by CompuSyn at ED50, ED75 and ED90. CP=Cisplatin. 
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Figure 4.14 Drug combination plots for cisplatin and meta-thioaspirin (CP+PN591[1:20]) in 
SW480 CRC cells . 
Dose response curve (A). Dose-effect curve as plotted by CalcuSyn (B). Bar chart representation of 
IC50 by single compounds and their combination (C). Fa-log(DRI) plot as plotted by CompuSyn (D). 
CI values as calculated by CompuSyn at ED50, ED75 and ED90. CP=Cisplatin.  
 
  
 
 
173 
 
-6 -5 -4 -3
0
20
40
60
80
100
log[conc] M
%
 C
e
ll
 v
ia
b
il
it
y
CP 
592
CP+592 [1:70]
0 200 400 600 800
0
0.2
0.4
0.6
0.8
1.0
D os e
D os e-effec t	c urve
E
ff
e
c
t
C P PN592 C P +PN592
C
P
59
2
C
P
+5
92
 [1
:7
0]
1
10
100
1000
lo
g
1
0
 IC
5
0
 (
m
M
)
CP
592
CP+592 [1:70]36.3
254.6
14.4
(A) (B) 
(C) (D) 
(E) 
Figure 4.15 Drug combination plots for cisplatin and para-thioaspirin (CP+PN592[1:70]) in 
SW480 CRC cells. 
Dose response curve (A). Dose-effect curve as plotted by CalcuSyn (B). Bar chart representation of 
IC50 by single compounds and their combination (C). Fa-log(DRI) plot as plotted by CompuSyn (D). 
CI values as calculated by CompuSyn at ED50, ED75 and ED90. CP=Cisplatin. 
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Cisplatin when used in combination with thioaspirin, PN590 and its isomers, 
PN591 (meta-thioaspirin), PN592 (para-thioaspirin) resulted in different effects, 
which ranged from antagonistic, additive and synergistic effects. 
The DNA-damaging platinum compound, cisplatin in combination with PN590 
[1:20] (Figure 4.15A, B, C, D and E), resulted in its ED50 reduced from 51.9μM 
to 5.9μM (Figure 4.15D). The combination effect of cisplatin and PN590 was 
slightly antagonistic at ED50 and progressed to additive effect at ED75 and ED90 
(Figure 4.15, Table 4.5). Strong antagonistic effects (Figure 4.16D) resulted 
when cisplatin was used in combination with PN591 [1:20] (Figure 4.16A, B, C, 
D and E) and also when used in combination with PN592 [1:70] (Figure 4.17A, 
B, C, D and E). The ED50 of cisplatin was not reduced in combination with either 
of the thioaspirin isomers, which defeats the purpose of drug combinations. 
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Figure 4.16 Drug combination plots for oxaliplatin and ortho-aspirin (OX+PN502[1:80]) in 
SW480 CRC cells. 
Dose response curve (A). Dose-effect curve as plotted by CalcuSyn (B). Bar chart representation of 
IC50 by single compounds and their combination (C). Fa-log(DRI) plot as plotted by CompuSyn (D). 
CI values as calculated by CompuSyn at ED50, ED75 and ED90. OX=Oxaliplatin. 
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Figure 4.17 Drug combination plots for oxaliplatin and meta-aspirin (OX+PN548[1:80]) in 
SW480 CRC cells. 
Dose response curve (A). Dose-effect curve as plotted by CalcuSyn (B). Bar chart representation of 
IC50 by single compounds and their combination (C). Fa-log(DRI) plot as plotted by CompuSyn (D). 
CI values as calculated by CompuSyn at ED50, ED75 and ED90. OX=Oxaliplatin. 
 
  
 
 
177 
 
O
X
54
9 
O
X
+5
49
[1
:1
00
]
1
10
100
1000
10000
lo
g
1
0
 IC
5
0
 (
m
M
)
OX
549 
OX+549[1:100]
61.1
1826.0
13.7
0 1000 2000 3000 4000 5000
0
0.2
0.4
0.6
0.8
1.0
D os e
D os e-effec t	c urve
E
ff
e
c
t
OX PN549 O X +PN549
(A) (B) 
(C) (D) 
(E) 
-6 -5 -4 -3 -2
0
20
40
60
80
100
log[conc] M
%
 C
e
ll
 v
ia
b
il
it
y
OX 
549 
OX+549 [1:100]
 
Figure 4.18 Drug combination plots for oxaliplatin and para-aspirin (OX+PN549[1:100]) in 
SW480 CRC cells. 
Dose response curve (A). Dose-effect curve as plotted by CalcuSyn (B). Bar chart representation of 
IC50 by single compounds and their combination (C). Fa-log(DRI) plot as plotted by CompuSyn (D). 
CI values as calculated by CompuSyn at ED50, ED75 and ED90. OX=Oxaliplatin. 
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Oxaliplatin was used in combination with aspirin and its isomers, PN502 
(aspirin), PN548 (meta-aspirin) and PN549 (para-aspirin) at 1:80 (Figure 4.18A, 
B, C, D and E), 1:80 (Figure 4.19A, B, C, D and E) and 1:100 (Figure 4.20A, B, 
C, D and E) respectively.  
Oxaliplatin in combination with PN548 had synergistic effects at lower doses i.e. 
ED50 and lower, but the combinations became antagonistic with increase in 
concentration at ED75 and ED90 (Table 4.5). This is unfavourable in anticancer 
therapy because high cytotoxicity to the cancer cells is needed for the 
combination to be effective (Chou, 2010). However, there was a synergistic 
effect when oxaliplatin was combined with PN502 [1:80] against SW480 CRC 
cells (Figure 4.18) and the ED50 of oxaliplatin was decreased from 72.9μM to 
10.6μM. The ED50 for oxaliplatin when in combination with PN549 [1:100] also 
decreased from 72.9μM to 11.7μM (Figure 4.20).  
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Figure 4.19 Drug combination plots for oxaliplatin and fumaryldiaspirin (OX+PN517[1:8]) in 
SW480 CRC cells. 
Dose response curve (A). Dose-effect curve as plotted by CalcuSyn (B). Bar chart representation of 
IC50 by single compounds and their combination (C). Fa-log(DRI) plot as plotted by CompuSyn (D). 
CI values as calculated by CompuSyn at ED50, ED75 and ED90. OX=Oxaliplatin. 
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Figure 4.20 Drug combination plots for oxaliplatin and diaspirin (OX+PN508[1:14]) in SW480 
CRC cells. 
Dose response curve (A). Dose-effect curve as plotted by CalcuSyn (B). Bar chart representation of 
IC50 by single compounds and their combination (C). Fa-log(DRI) plot as plotted by CompuSyn (D). 
CI values as calculated by CompuSyn at ED50, ED75 and ED90. OX=Oxaliplatin. 
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Figure 4.21  Drug combination plots for oxaliplatin and m-bromobenzoylsalicylate 
(OX+PN524[1:8]) in SW480 CRC cells. 
Dose response curve (A). Dose-effect curve as plotted by CalcuSyn (B). Bar chart representation of 
IC50 by single compounds and their combination (C). Fa-log(DRI) plot as plotted by CompuSyn (D). 
CI values as calculated by CompuSyn at ED50, ED75 and ED90. OX=Oxaliplatin. 
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Oxaliplatin used in combination with the ‘diaspirins’, PN517, PN508 and PN524 
against SW480 cells at 1:8 (Figure 4.21A, B, C, D and E), 1:14 (Figure 4.22A, B, 
C, D and E) and 1:8 (Figure 4.23A, B, C, D and E) concentrations respectively 
resulted in a combination of synergistic and antagonistic effects at ED50, ED75 
and ED90. 
Oxaliplatin in combination with PN517 [1:8] had a synergistic effect on SW480 
CRC cells (Figure 4.21) with a decrease in oxaliplatin ED50 from 72.9 μM to 8.8 
μM (Figure 4.21D). ED50 for oxaliplatin in combination with PN580 [1:14] and in 
combination with PN524 [1:8] decreased from 72.9 μM to 25.2 μM (Figure 
4.22D) and 17.7 μM (Figure 4.23D) respectively. 
PN517 (Figure 4.21) had synergistic effects at ED50, ED75 and ED90 with PN508 
(Figure 4.22) and PN524 (Figure 4.23) having synergistic effects at ED50 but 
antagonistic when the dose was increased to ED90. 
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Figure 4.22 Drug combination plots for oxaliplatin and ortho-thioaspirin (OX+PN590[1:8]) in 
SW480 CRC cells. 
Dose response curve (A). Dose-effect curve as plotted by CalcuSyn (B). Bar chart representation of 
IC50 by single compounds and their combination (C). Fa-log(DRI) plot as plotted by CompuSyn (D). 
CI values as calculated by CompuSyn at ED50, ED75 and ED90. OX=Oxaliplatin. 
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Figure 4.23 Drug combination plots for oxaliplatin and meta-thioaspirin (OX+PN591[1:10]) in 
SW480 CRC cells. 
Dose response curve (A). Dose-effect curve as plotted by CalcuSyn (B). Bar chart representation of 
IC50 by single compounds and their combination (C). Fa-log(DRI) plot as plotted by CompuSyn (D). 
CI values as calculated by CompuSyn at ED50, ED75 and ED90. OX=Oxaliplatin. 
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Figure 4.24  Drug combination plots for oxaliplatin and para-thioaspirin (OX+PN592[1:14]) in 
SW480 CRC cells. 
Dose response curve (A). Dose-effect curve as plotted by CalcuSyn (B). Bar chart representation of 
IC50 by single compounds and their combination (C). Fa-log(DRI) plot as plotted by CompuSyn (D). 
CI values as calculated by CompuSyn at ED50, ED75 and ED90. OX=Oxaliplatin. 
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Oxaliplatin when used in combination with thioaspirin, PN590 (Figure 4.24A, B, 
C, D and E) and its isomers [PN591 (Figure 4.25A, B, C, D and E) and PN592 
(Figure 4.26A, B, C, D and E)] resulted in synergistic and antagonistic effects 
respectively. 
Oxaliplatin in combination with PN592 had synergistic effects at lower doses i.e. 
ED50 and lower, but the combinations became antagonistic with increase in 
concentration at ED75 and ED90 (Table 4.5). This is unfavourable in anticancer 
therapy because high cytotoxicity to the cancer cells is needed for the 
combination to be effective. Synergistic effects between two compounds when 
used in combination at ED50 and above is favourable in the treatment of cancer 
as a maximum kill of the cancer cells accompanied by a decrease in dose 
required to make that kill is required for an ideal combination for cancer therapy 
(Chou, 2010).  
The ED50 for oxaliplatin when used in combination with PN590 was reduced 
from 72.9 μM to 12.9 μM (Figure 4.24D). However, combinations with PN591 
(Figure 4.25) and PN592 (Figure 4.26) had antagonistic effects.  
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Figure 4.25 Drug combination plots for carboplatin and ortho-aspirin (CB+PN502[1:20]) in 
SW480 CRC cells. 
Dose response curve (A). Dose-effect curve as plotted by CalcuSyn (B). Bar chart representation of 
IC50 by single compounds and their combination (C). Fa-log(DRI) plot as plotted by CompuSyn (D). 
CI values as calculated by CompuSyn at ED50, ED75 and ED90. CB=Carboplatin. 
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Figure 4.26 Drug combination plots for carboplatin and meta-aspirin (CB+PN548[1:20]) in 
SW480 CRC cells. 
Dose response curve (A). Dose-effect curve as plotted by CalcuSyn (B). Bar chart representation of 
IC50 by single compounds and their combination (C). Fa-log(DRI) plot as plotted by CompuSyn (D). 
CI values as calculated by CompuSyn at ED50, ED75 and ED90. CB=Carboplatin. 
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Figure 4.27 Drug combination plots for carboplatin and para-aspirin (CB+PN549[1:50]) in 
SW480 CRC cells. 
Dose response curve (A). Dose-effect curve as plotted by CalcuSyn (B). Bar chart representation of 
IC50 by single compounds and their combination (C). Fa-log(DRI) plot as plotted by CompuSyn (D). 
CI values as calculated by CompuSyn at ED50, ED75 and ED90. CB=Carboplatin. 
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Carboplatin was used in combination with aspirin and its isomers, PN502 
(aspirin), PN548 (meta-aspirin) and PN549 (para-aspirin) at 1:20 (Figure 4.27A, 
B, C, D and E), 1:20 (Figure 4.28A, B, C, D and E) and 1:50 (Figure 4.29A, B, C, 
D and E) respectively. 
Amongst the aspirin isomers, PN549 stood out as the only one that had a 
synergistic effect when used in combination with carboplatin against SW480 
CRC cells (Figure 4.29). The ED50 for carboplatin in combination with PN549 
[1:50] reduced from 100.6μM to 28μM. Carboplatin in combination with aspirin 
and PN548 had antagonistic effects (Figure 4.27 and 4.28 respectively). 
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Figure 4.28 Drug combination plots for carboplatin and fumaryldiaspirin (CB+PN517[1:2]) in 
SW480 CRC cells. 
Dose response curve (A). Dose-effect curve as plotted by CalcuSyn (B). Bar chart representation of 
IC50 by single compounds and their combination (C). Fa-log(DRI) plot as plotted by CompuSyn (D). 
CI values as calculated by CompuSyn at ED50, ED75 and ED90. CB=Carboplatin. 
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Figure 4.29 Drug combination plots for carboplatin and diaspirin (CB+PN508[1:1.75]) in 
SW480 CRC cells. 
Dose response curve (A). Dose-effect curve as plotted by CalcuSyn (B). Bar chart representation of 
IC50 by single compounds and their combination (C). Fa-log(DRI) plot as plotted by CompuSyn (D). 
CI values as calculated by CompuSyn at ED50, ED75 and ED90. CB=Carboplatin. 
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Figure 4.30 Drug combination plots for carboplatin and m-bromobenzoylsalicylate 
(CB+PN524[1:1]) in SW480 CRC cells . 
Dose response curve (A). Dose-effect curve as plotted by CalcuSyn (B). Bar chart representation of 
IC50 by single compounds and their combination (C). Fa-log(DRI) plot as plotted by CompuSyn (D). 
CI values as calculated by CompuSyn at ED50, ED75 and ED90. CB=Carboplatin. 
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Carboplatin used in combination with the ‘diaspirins’, PN517 (Figure 4.30A, B, C, 
D and E), PN508 (Figure 4.31A, B, C, D and E) and PN524 (Figure 4.32A, B, C, 
D and E) against SW480 cells resulted in a combination of synergistic and 
antagonistic effects at ED50, ED75 and ED90.  
PN517, PN508 and PN524 did not have favourable anticancer effects against 
SW480 CRC cells when used in combination with carboplatin (Figure 4.30, 4.31 
and 4.32 respectively). Although, there was what seemed to be a synergistic 
effect between carboplatin with PN508 and PN524 at ED50, the doses of 
carboplatin at ED50 increased rather than decrease when used in combination 
with the diaspirins. This increase in ED50 of carboplatin when in combination 
defeats one of the main reasons of combination therapy, which is to achieve a 
decrease in effective dose in order to reduce or alleviate side effects (Chou, 
2010). 
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Figure 4.31 Drug combination plots for carboplatin and ortho-thioaspirin (CB+PN590[1:2]) in 
SW480 CRC cells. 
Dose response curve (A). Dose-effect curve as plotted by CalcuSyn (B). Bar chart representation of 
IC50 by single compounds and their combination (C). Fa-log(DRI) plot as plotted by CompuSyn (D). 
CI values as calculated by CompuSyn at ED50, ED75 and ED90. CB=Carboplatin. 
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Figure 4.32 Drug combination plots for carboplatin and meta-thioaspirin (CB+PN591[1:5]) in 
SW480 CRC cells. 
Dose response curve (A). Dose-effect curve as plotted by CalcuSyn (B). Bar chart representation of 
IC50 by single compounds and their combination (C). Fa-log(DRI) plot as plotted by CompuSyn (D). 
CI values as calculated by CompuSyn at ED50, ED75 and ED90. CB=Carboplatin. 
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Figure 4.33 Drug combination plots for carboplatin and para-thioaspirin (CB+PN592[1:1.75]) in 
SW480 CRC cells. 
Dose response curve (A). Dose-effect curve as plotted by CalcuSyn (B). Bar chart representation of 
IC50 by single compounds and their combination (C). Fa-log(DRI) plot as plotted by CompuSyn (D). 
CI values as calculated by CompuSyn at ED50, ED75 and ED90. CB=Carboplatin. 
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Carboplatin when used in combination with thioaspirins, PN590, PN591 (meta-
thioaspirin) and PN592 (para-thioaspirin) resulted in antagonistic effects. 
Carboplatin, in combination with PN590 (Figure 4.33A, B, C, D and E), PN591 
(Figure 4.34A, B, C, D and E) and PN592 (Figure 4.35A, B, C, D and E) all had 
strong synergistic effects against the colorectal cell line. Some of the 
combinations showed strong antagonism due to very high CI values. This is 
possible in some combinations as the synergy scale is from 1 to 0 and the 
antagonism scale is from 1 to infinity (Chou, 2010). 
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Figure 4.34 Drug combination plots for cisplatin and ortho-aspirin (CP+PN502[1:100]) in OE33 
oesophageal cancer cells. 
Dose response curve (A). Dose-effect curve as plotted by CalcuSyn (B). Bar chart representation of 
IC50 by single compounds and their combination (C). Fa-log(DRI) plot as plotted by CompuSyn (D). 
CI values as calculated by CompuSyn at ED50, ED75 and ED90. CP=Cisplatin. 
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Figure 4.35 Drug combination plots for cisplatin and fumaryldiaspirin (CP+PN517[1:50]) in 
OE33 oesophageal cancer cells. 
Dose response curve (A). Dose-effect curve as plotted by CalcuSyn (B). Bar chart representation of 
IC50 by single compounds and their combination (C). Fa-log(DRI) plot as plotted by CompuSyn (D). 
CI values as calculated by CompuSyn at ED50, ED75 and ED90. CP=Cisplatin. 
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Figure 4.36 Drug combination plots for cisplatin and m-bromobenzoylsalicylate 
(CP+PN524[1:50]) in OE33 oesophageal cancer cells. 
Dose response curve (A). Dose-effect curve as plotted by CalcuSyn (B). Bar chart representation of 
IC50 by single compounds and their combination (C). Fa-log(DRI) plot as plotted by CompuSyn (D). 
CI values as calculated by CompuSyn at ED50, ED75 and ED90. CP=Cisplatin. 
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Figure 4.37 Drug combination plots for cisplatin and methyl-benzoylsalicylate 
(CP+PN528[1:160]) in OE33 oesophageal cancer cells. 
Dose response curve (A). Dose-effect curve as plotted by CalcuSyn (B). Bar chart representation of 
IC50 by single compounds and their combination (C). Fa-log(DRI) plot as plotted by CompuSyn (D). 
CI values as calculated by CompuSyn at ED50, ED75 and ED90. CP=Cisplatin. 
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Cisplatin in combination with PN502 [1:100] against OE33 oesophageal cancer 
cells had an additive effect (Figure 4.36A, B, C, D and E). Synergistic effects 
were achieved when cisplatin was combined with PN517 [1:50] with the ED50 
for cisplatin reduced from 5.36μM to 1.49μM (Figure 4.37A, B, C, D and E). 
Synergistic effects at ED50, ED75 and ED90 were also observed when cisplatin 
was combined with PN524 [1:50] against the oesophageal cell line and 
accompanied by a reduction in the ED50 of cisplatin from 5.36μM to 2.25μM 
(Figure 4.38A, B, C, D and E). PN528 in combination with cisplatin had an 
additive effect at ED50, however, at higher doses, synergistic effects were 
achieved (Figure 4.39A, B, C, d and E) with a drop in ED50 for cisplatin from 
5.36μM to 3.54μM. 
In OE33 oesophageal cancer cell line, the ED50 for cisplatin when used in 
combination with PN517 [1:50] reduced from 5.4μM to 1.5μM while that of 
PN517 reduced from 599.7μM to 74.6μM. ED50 reduced from 5.4μM and 
407.7μM to 2.3μM and 112.6μM respectively for cisplatin and PN524 [1:50] 
when in combination. 
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Figure 4.38 Drug combination plots for oxaliplatin and ortho-aspirin (OX+PN502[1:20]) in 
OE33 oesophageal cancer cells. 
Dose response curve (A). Dose-effect curve as plotted by CalcuSyn (B). Bar chart representation of 
IC50 by single compounds and their combination (C). Fa-log(DRI) plot as plotted by CompuSyn (D). 
CI values as calculated by CompuSyn at ED50, ED75 and ED90. OX=Oxaliplatin. 
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Figure 4.39 Drug combination plots for oxaliplatin and fumaryldiaspirin (OX+PN517[1:20]) in 
OE33 oesophageal cancer cells. 
Dose response curve (A). Dose-effect curve as plotted by CalcuSyn (B). Bar chart representation of 
IC50 by single compounds and their combination (C). Fa-log(DRI) plot as plotted by CompuSyn (D). 
CI values as calculated by CompuSyn at ED50, ED75 and ED90. OX=Oxaliplatin. 
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Figure 4.40 Drug combination plots for oxaliplatin and m-bromobenzoylsalicylate 
(OX+PN524[1:10]) in OE33 oesophageal cancer cells. 
Dose response curve (A). Dose-effect curve as plotted by CalcuSyn (B). Bar chart representation of 
IC50 by single compounds and their combination (C). Fa-log(DRI) plot as plotted by CompuSyn (D). 
CI values as calculated by CompuSyn at ED50, ED75 and ED90. OX=Oxaliplatin. 
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Figure 4.41 Drug combination plots for oxaliplatin and methyl-benzoylsalicylate 
(OX+PN528[1:32]) in OE33 oesophageal cancer cells. 
Dose response curve (A). Dose-effect curve as plotted by CalcuSyn (B). Bar chart representation of 
IC50 by single compounds and their combination (C). Fa-log(DRI) plot as plotted by CompuSyn (D). 
CI values as calculated by CompuSyn at ED50, ED75 and ED90. OX=Oxaliplatin. 
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Oxaliplatin in combination with PN502 [1:20] against OE33 oesophageal cancer 
cells had synergistic effects at ED50 and below, which indicates synergy at low 
doses with little cytotoxic effects. This is not relevant in cancer therapy (Figure 
4.40A, B, C, D and E). The platinum compound, oxaliplatin in combination with 
PN517 (Figure 4.41A, B, C, D and E) and PN524 (Figure 4.42A, B, C, D and E) 
against OE33 oesophageal cancer cell line had antagonistic effects ED75 and 
ED90 with synergy at ED50 and below. The platinum compound in combination 
with PN528 (Figure 4.43A, B, C, D and E) had antagonistic effects with CI 
values above 0.9 at ED50, ED75 and ED90. 
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Figure 4.42 Drug combination plots for carboplatin and ortho-aspirin (CB+PN502[1:40]) in 
OE33 oesophageal cancer cells. 
Dose response curve (A). Dose-effect curve as plotted by CalcuSyn (B). Bar chart representation of 
IC50 by single compounds and their combination (C). Fa-log(DRI) plot as plotted by CompuSyn (D). 
CI values as calculated by CompuSyn at ED50, ED75 and ED90. CB=Carboplatin. 
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Figure 4.43 Drug combination plots for carboplatin and fumaryldiaspirin (CB+PN517[1:40]) in 
OE33 oesophageal cancer cells. 
Dose response curve (A). Dose-effect curve as plotted by CalcuSyn (B). Bar chart representation of 
IC50 by single compounds and their combination (C). Fa-log(DRI) plot as plotted by CompuSyn (D). 
CI values as calculated by CompuSyn at ED50, ED75 and ED90. CB=Carboplatin. 
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Figure 4.44 Drug combination plots for carboplatin and m-bromobenzoylsalicylate 
(CB+PN524[1:20]) in OE33 oesophageal cancer cells. 
Dose response curve (A). Dose-effect curve as plotted by CalcuSyn (B). Bar chart representation of 
IC50 by single compounds and their combination (C). Fa-log(DRI) plot as plotted by CompuSyn (D). 
CI values as calculated by CompuSyn at ED50, ED75 and ED90. CB=Carboplatin. 
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Figure 4.45 Drug combination plots for carboplatin and methyl-benzoylsalicylate 
(CB+PN528[1:32]) in OE33 oesophageal cancer cells. 
Dose response curve (A). Dose-effect curve as plotted by CalcuSyn (B). Bar chart representation of 
IC50 by single compounds and their combination (C). Fa-log(DRI) plot as plotted by CompuSyn (D). 
CI values as calculated by CompuSyn at ED50, ED75 and ED90. CB=Carboplatin.  
 
  
 
 
213 
 
Antagonistic effects were observed when carboplatin was used in combination 
with PN502 (Figure 4.44A, B, C, D and E), PN517 (Figure 4.45A, B, C, D and E) 
and PN528 (Figure 4.47A, B, C, D and E) against the oesophageal cancer cell 
line. The platinum compound in combination with PN524 [1:20], however, had a 
synergistic effect at ED50 and below but combinations had antagonistic effects 
at ED75, ED90 and above (Figure 4.46A, B, C, D and E). The ED50 of carboplatin 
was combined with PN524 reduced from 40.77μM to 11.67μM, which is about a 
4-fold reduction in dose to kill 50% of the oesophageal cancer cells. 
PN524 in combination with oxaliplatin and carboplatin have synergistic effects 
at ED50 and lower. This is not favourable in cancer chemotherapy because 
drugs are needed to be highly cytotoxic to the cancer cells in order to ensure 
maximal kill. The DRI for cisplatin and PN528 combination resulted in a 
decrease in ED50 for cisplatin from 5.4μM to 3.5μM.  
A summary of the effects of all the combinations in this thesis as determined by 
their CI values against SW480 CRC cell line and OE33 oesophageal cancer cell 
line calculated by CompuSyn and CalcuSyn can be found on Table 4.6 and 4.7.
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Compounds Cisplatin (CP) Oxaliplatin (OX) Carboplatin (CB) 
CI values at 
ED50 ED75 ED90 ED50 ED75 ED90 ED50 ED75 ED90 
PN502 +++ +++ ++ +++ +++ ++ −− −− −−− 
PN548 + + ++ + − −−  −−− −−−− 
PN549 +++ +++ +++ ++ ++ +  +++ +++ 
PN517 +++ ++++ ++++ ++++ ++++ +++ +++ + −−− 
PN508 ++ +++ +++ ++ ++  −−−− −− +++ 
PN524 + +++ +++ +++ −−− −−−−−  + +++ 
PN590 − −  − + +++ −−− −−−  
PN591 −−−− −−−− −−−−−   −− −−− −−−−− −−−−− 
PN592 −−−− −−−  + −−−− −−−−− − −−−−− −−−−− 
Table 4.6 Summary of drug combination CI values in SW480 CRC cell line. 
Drug combinations with CI values at effective dose for 50% kill of the cell population (ED50), 75% of the population (ED75) and 
90% of the population (ED90). Effect for each combination is synergistic [+], additive [] or antagonistic [−] (Table 4.2).
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Compounds Cisplatin (CP) Oxaliplatin (OX) Carboplatin (CB) 
CI values at 
ED50 ED75 ED90 ED50 ED75 ED90 ED50 ED75 ED90 
PN502 − −  +++ −− −−− −−− −−− − 
PN517 +++ +++ +++ ++ −−− −−−− −−− −−− −− 
PN524 +++ +++ +++ ++ −−− −−−− ++ −− −−− 
PN528 − + ++ −−− −−− −−− −−− −−− −−− 
Table 4.7 Summary of drug combination CI values in OE33 oesophageal cancer cell line. 
Drug combinations with CI values at effective dose for 50% kill of the cell population (ED50), 75% of the population (ED75) and 
90% of the population (ED90). Effect for each combination is synergistic [+], additive [] or antagonistic [−] (Table 4.2).   
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4.5 Discussion 
In comparison to PN502 (aspirin), the other aspirin analogues and NSAIDs with 
the exception of meta- (PN548) and para- (PN549) isomers of aspirin appear to 
be more cytotoxic to SW480 CRC cells (Figure 4.5 and 4.6). The IC50 for PN502 
after buffering with HEPES and treating for 48 h is found to be at 1.8 mM with 
the meta- and para-isomers, PN548 and PN549 at 3.8 mM and 4.9 mM 
respectively (Figure 4.5A). However, higher cytotoxic effects of aspirin (PN502) 
have been reported; for example, the IC50 for aspirin has been found to be 1.48 
mM (Din et al., 2004). This difference in cytotoxicity could be as a result of the 
difference in dissolution solvent used for stock solutions, buffers used to adjust 
pH or duration of treatment. Din et al., (2004) used distilled water to make up 
stock solutions of aspirin at a concentration of 500 mM and further diluted to 
desired concentrations using media. However, stocks were made up at 
concentrations of 50 mM with acetone, diluted down to 25 mM (1:1) using 
HEPES buffer (pH8) and then further diluted to the desired concentration using 
media, after which cells were treated for 48 h. The ‘diaspirins’ PN517 and 
PN508, caused a 50% growth inhibition at 0.24 mM and 0.75 mM respectively 
(Figure 4.5A), which is substantially more cytotoxic than 0.87 mM and 2.43 mM 
respectively (Claudius et al., 2014). These differences in cytotoxicity may be 
due to different reasons such as dissolution solvents used; for example acetone 
or DMSO, buffering solutions used such as HEPES or PBS to adjust pH of 
compounds and duration of treatment. The IC50 of salicylic acid is higher than 
that of aspirin at 2.55 mM (Figure 4.5A), which suggests that the cytotoxic effect 
of aspirin does not solely depend on its salicylate moiety but on the parent 
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compound. Thioaspirin (PN590) and its meta- (PN591) and para- (PN592) 
appear to be very cytotoxic with their IC50 as 0.16 mM, 0.48 mM and 0.75 mM 
respectively. The mutational status of TP53 gene in SW480 CRC, OE33 and 
FLO1 oesophageal cancer cells (Din et al., 2004, Liu et al., 2017), indicate that 
cancers made up such cell lines will have reduced sensitivity to platinum 
compounds and thus cytotoxicity is reduced (Perego et al., 1996, Toscano et al., 
2007, Yang et al., 2016, Zhang et al., 2014) in cancers. This could explain why 
the cytotoxic effect of the platinum compounds was not very high (Table 4.3) 
and possibly due to the p53 dependence for sensitivity to oxaliplatin (Toscano 
et al., 2007, Yang et al., 2016) and other platinum compounds (Perego et al., 
1996, Zhang et al., 2014) in other cancers. Likewise, in CRC cell lines, p53 is 
essential for chemotherapy-induced cytotoxicity exhibited by oxaliplatin (Yang 
et al., 2016). In addition, MMR proficient CRC cells are known to survive high 
doses of cisplatin or oxaliplatin (Sergent et al., 2002). Aspirin was found to have 
higher cytotoxicity in SW480 cells with IC50 of 1.8 mM as compared to in FLO1 
with IC50 of 4.1 mM (Table 4.3). Sensitivity to these aspirin analogues clearly 
differ from cell type to cell type due to differences in specific targets by different 
compounds (Din et al., 2004). Din et al. (2004) compared sensitivity to aspirin in 
CRC cell lines to non-CRC cell lines and found out that the dose of aspirin used 
was inversely proportional to cell viability in CRC cells while non-CRC cells did 
not show this relationship. 
In regards to the 12-day cytotoxicity assay (Table 4.4), it was observed that the 
degree of cytotoxicity for some of these compounds was not the same as when 
cells were treated for 48 h (Table 4.3). The 12-day IC50 values for cisplatin and 
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oxaliplatin (Table 4.4) are similar to 2.22 μM and 0.34 μM respectively 
(McPherson et al., 2014). Based on their respective IC50 values determined at 
48 h compared to that determined after 12 days of treatment, cisplatin and 
carboplatin both had about 10-fold increase in cytotoxicity after 12 days while 
oxaliplatin had about 100-fold increase in cytotoxicity, thus increase in 
cytotoxicity varies from compound to compound. PN502 and naproxen had a 8-
fold and 5-fold increase in cytotoxicity after 12 days of treatment. The 12-day 
cytotoxicity assay revealed PN517, PN590, diclofenac and indomethacin to 
have a 3-fold increase in cytotoxicity against SW480 CRC cells. The thioaspirin 
isomers, PN591 and PN592 had a big increase in cytotoxicity after 12 days of 
treatment against SW480 CRC cells. The increase in cytotoxicity is about 12-
fold and 25-fold for PN591 and PN592 respectively with the cytotoxic effects 
overtaking that of their ortho- isomer, which is usually more cytotoxic. This 
unusual finding suggests that meta- and para- isomers of thioaspirin are more 
cytotoxic against SW480 CRC cells after treatment for lengthy periods, thus 
exhibiting a longer duration of action for reasons that are not known. 
Furthermore, increase in cytotoxicity of these compounds could be due to 
replenishment of cells on day six of treatment, which will lead to an increase in 
drug concentration. 
The combination of cisplatin and PN548 [1:400] in SW480 CRC cells (Figure 
4.10) had a slight synergistic effect at ED50 and ED75 with the synergistic effect 
increasing to moderate at a higher dose of ED90. In addition, the ED50 for 
cisplatin in this combination reduced by about 10-fold, which is favourable in 
cancer therapy (Chou, 2010). The ED50 of cisplatin reduced by almost 10-fold 
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when in combination with PN549 (para-aspirin) [1:250] accompanied by a 
synergistic effect at ED50, ED75 and ED90 (Figure 4.11). Strong synergy was 
observed when cisplatin was combined with PN517 [1:10] with a 5-fold 
decrease in ED50 for cisplatin (Figure 4.12). Cisplatin in combination with 
PN508 [1:18] (Figure 4.13) and PN524 [1:40] (Figure 4.14) had synergistic 
effects in SW480 CRC cells with about a 2-fold and 7-fold decrease in ED50 for 
cisplatin respectively. In addition, the synergistic effects of these combinations 
increased at higher dose, which is advantageous in chemotherapy (Chou, 
2010). Cisplatin in combination with PN590 [1:20] (Figure 4.15) had an additive 
effect in SW480 CRC cells with both of its isomers, PN591 (Figure 4.16) and 
PN592 (Figure 4.17) having an antagonistic effect when used in combination 
with all three platinum compounds. This antagonism between the isomers of 
thioaspirin and the platinum compounds could be because they had low 
cytotoxic effects against these CRC cells after 72 h (Table 4.1), which later on 
greatly improved overtaking PN590 after cells were treated for a period of 12 
days (Table 4.2). 
 
In this study, combinations of oxaliplatin with PN548 [1:80] (Figure 4.19) and 
PN524 [1:8] (Figure 4.23) had antagonistic effects at ED75 and ED90. Even 
though there was synergistic effects at ED50 and below, this is unfavourable in 
cancer therapy because maximum cytotoxicity against the cancer cells is key to 
effective therapy (Chou, 2010). Oxaliplatin combination with PN548 [1:80] 
(Figure 4.19) resulted in slight synergistic effects at ED50 and ED75 increasing to 
moderate synergism at ED90 with a 4-fold decrease in oxaliplatin ED50. The 
ED50 for the platinum compound, oxaliplatin had a 7-fold decrease when 
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combined with PN549 (Figure 4.20), PN590 (Figure 4.24) and PN517 (Figure 
4.21) with strong synergistic effects with PN517 and synergistic effects with 
PN549 and PN590 (Table 4.5). Although there was a synergistic effect when 
oxaliplatin was combined with PN508 [1:14] (Figure 4.22) and PN524 [1:8] 
(Figure 4.23) at ED50, the effect regressed to antagonism with dose increase 
(ED75 and ED90). This effect will not produce the maximum cytotoxicity needed 
in cancer therapy (Chou, 2010). With the prominent side effect of oxaliplatin 
being peripheral neuropathy (Alcindor and Beauger, 2011), a reduction in its 
ED50 as a result of the combinations with aspirin (Figure 4.18), PN549 (Figure 
4.20), PN517 (Figure 4.21) and PN590 (Figure 4.24) may reduce or totally 
alleviate this side effect because a reduction in drug concentration will result in 
toxicity reduction and also delay or minimize the induction of drug resistance 
(Chou, 2010). Although, there was what seemed to be a synergistic effect 
between carboplatin with PN508 (Figure 4.31) and PN524 (Figure 4.32) at ED50, 
the doses of carboplatin at ED50 increased rather than decreased when used in 
combination with the ‘diaspirins’. This increase in ED50 of carboplatin when in 
combination defeats one of the main reasons of combination therapy, which is 
to achieve a decrease in effective dose in order to reduce or alleviate side 
effects. Carboplatin, in combination with the thioaspirins, PN590 (Figure 4.33), 
PN591 (Figure 4.34) and PN592 (Figure 4.35) also had strong synergistic 
effects against the colorectal cell line. Some of the combinations showed strong 
antagonism due to very high CI values. This is possible in some combinations 
as the synergy scale is from 1 to 0 and the antagonism scale is from 1 to infinity 
(Chou, 2010). PN549 [1:50] (Figure 4.29) was the only aspirin analogue that 
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showed synergistic effects against the colorectal cell line when in combination 
with carboplatin. There was a 3-fold decrease in carboplatin ED50.  
 
In the OE33 oesophageal cancer cell line, none of the platinum compounds 
synergised with aspirin (Figure 4.36, 4.40 and 4.44). Although there was 
synergy when oxaliplatin and aspirin [1:20] were combined at ED50, this effect 
regressed at ED75 and ED90 and thus is not favourable in the treatment of 
cancer. In gastric cancer cells however, cell growth was significantly inhibited 
when cisplatin was used in combination with aspirin (Dong et al., 2014). 
Combinations of cisplatin and aspirin were also seen to have synergistic effects 
in human cervical carcinoma HeLa cells (Wang et al., 2010). The combination 
of cisplatin and PN517 [1:50] (Figure 4.37) maintained its synergistic effects 
through ED50, ED75 and ED90, which make this a promising combination for the 
treatment of cancer. Oxaliplatin and carboplatin in combination with PN517 
(Figure 4.41 and 4.45 respectively) had an antagonistic effect. Although there 
was moderate synergy between oxaliplatin and PN517 at ED50, the positive 
effect decreased as doses increased, which is thus not favourable. Cisplatin 
and PN524 [1:50]  (Figure 4.38) had synergistic effect at ED50, ED75 and ED90. 
Even though oxaliplatin and carboplatin also had synergistic effects with PN524 
at ED50, this was not maintained at ED75 and ED90 (Figure 4.42 and 4.46 
respectively). Slight synergy was observed when cispaltin was in combination 
with PN528 [1:160] (Figure 4.39). Oxaliplatin and carboplatin in combination 
with PN528 had antagonistic effects (Figure 4.43 and 4.47 respectively). The 
decrease in doses needed for these platinum compounds are of utmost 
importance because of their narrow therapeutic index (Alcindor and Beauger, 
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2011). The differences in outcomes for each drug combination in different cell 
lines may be due to differences in specific targets by different compounds (Din 
et al., 2004). 
 
In the treatment of CRC, oxaliplatin has been used in combination with a variety 
of cytotoxic agents producing different levels of desired effects (Alcindor and 
Beauger, 2011). Due to oxaliplatin not having any effect on the drug 
biotransformation enzyme, P450, its combination with commonly used drugs 
such as aspirins does not raise any concerns (Masek et al., 2009). Some of 
these aspirin analogues thus show promising results when combined with 
platinum compounds for the treatment of cancer and should be investigated   
further in vivo.
  
223 
 
Chapter 5.  Apoptosis or Necrosis? 
5.1 Introduction 
Regulation of various cellular processes such as proliferation, differentiation 
and apoptosis have been linked to activation of mitogen-activated protein 
kinase (MAPK), Akt, PI 3-K and STAT proteins, all found in the EGFR signalling 
pathway (Grant et al., 2002). 
There are a series of published studies linking activation of pro-apoptotic 
mechanisms with inhibition of the EGFR signalling pathway as a mechanism of 
action found in established anti cancer compounds (Mendelsohn and Baselga, 
2000), which resulted in the extension of these studies to the possible effects of 
aspirin analogues on the EGFR found in the next chapter of this thesis. It has 
already been established that the diaspirins (PN508, PN517 and PN524) induce 
apoptotic death in cancer cells (Claudius et al., 2014). Here, in this chapter, it 
was investigated whether the isomers of aspirin namely PN502 (aspirin), PN548 
(meta-aspirin), PN549 (para-aspirin) and isomers of thioaspirin namely PN590 
(ortho-thioaspirin), PN591 (meta-thioaspirin) and PN592 (para-thioaspirin) 
induce apoptotic, necrotic cell death or a mixture of both in SW480 CRC cell 
line was investigated. 
5.1.1 Apoptosis 
Cell death was classified as occurring via two separate morphological patterns, 
one of which is known as ‘coagulative necrosis’ where there is swelling and 
rupture of organelle membranes and disintegration of their structure and the 
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other pattern is known as apoptosis. In apoptosis, the cell organelles maintain 
their integrity with the membrane forming different bulges that eventually 
separate and form membrane-bound globules ready to be phagocytized (Wyllie 
et al., 1980). However, it is now believed that programmed cell death (PCD) 
occurs via different pathways with more than one of these pathways triggered 
simultaneously (Leist and Jaattela, 2001, Nikoletopoulou et al., 2013).  
 
 
Figure 5.1 Morphological features of the different types of PCD. 
Healthy cell (a). Necrotic cell (b). Apoptotic cell (c). Autophagic cell (d) (Edinger and 
Thompson, 2004, Nikoletopoulou et al., 2013). 
 
Cell death could be as a result of apoptosis, necrosis or autophagy (Leist and 
Jaattela, 2001, Nikoletopoulou et al., 2013). PCD is particularly important in the 
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life cycle of a cell as a balance between cell proliferation and cell death is 
essential for the maintenance of homeostasis (Schwartzman and Cidlowski, 
1993). During apoptosis, the phosphatidylserine (PS) normally found in the 
inner leaflet of the phospholipid cell membrane flips and is exposed (Leist and 
Jaattela, 2001, van Engeland et al., 1996). 
5.1.1.1 Cell cycle and apoptosis 
The cell cycle was initially divided into two stages; mitosis and interphase with 
the mitosis stage made up of prophase, metaphase, anaphase and telophase. 
This division was later on reviewed, which included G1, S, G2 and M phases as 
part of interphase (Norbury and Nurse, 1992). Cells undergo DNA replication in 
the G1 phase before which some enter the G0 phase also known as the resting 
phase where cells are dormant and thus do not proliferate (Vermeulen et al., 
2003). 
 
In cancer, mutations normally occur in two classes of genes known as the 
proto-oncogenes and the tumour suppressor genes. The proto-oncogenes are 
responsible for the stimulation of cell proliferation. However, when mutated this 
process is uncontrolled and promotes tumour growth. As the name implies, 
tumour suppressor genes are responsible for inhibiting the cell cycle 
progression where and when necessary. When mutated, these get inactivated 
(McDonald and El-Deiry, 2000). 
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The cyclin-dependent kinase inhibitor p21, also known as WAF1 controls many 
biological activities by functioning as an anti-apoptotic protein, promoting cell 
cycle arrest by inhibiting proliferating cell nuclear antigen (PCNA) via binding to 
it and thus, inhibiting DNA synthesis at G1 phase of the cell cycle, which then 
allows for DNA repair and this correlates with an increase in expression (Abbas 
and Dutta, 2009, Karimian et al., 2016, Pan et al., 1995). However, in certain 
conditions, p21 can also act as an oncogene (Gartel, 2006, Roninson, 2002), 
thus not having classical tumour suppressor activities (Abbas and Dutta, 2009). 
The expression of p21 is dependent on p53, a tumour suppressor gene (el-
Deiry et al., 1993). Nevertheless, there is evidence of it being activated 
independently of p53 (Abbas and Dutta, 2009, Gartel, 2005, Halevy et al., 1995). 
p21 expression is found to be inversely related to the expression of the p53 
protein (Zirbes et al., 2000). The p53 protein regulates DNA repair, cell arrest 
and apoptosis after treatment with cytotoxic drugs (Goldstein et al., 2011, 
Vousden and Prives, 2009). Activation of TP21 gene leads to cell cycle arrest 
halting replication of damaged DNA (Abbas and Dutta, 2009, Ko and Prives, 
1996). This is necessary particularly in human CRCs (Polyak et al., 1997). 
 
BAX (BCL2 associated X protein) is an important member of the BCL2 family 
located in the cytosol and translocates to the mitochondria after an apoptotic 
stimulus (Wolter et al., 1997). However, in cases where BAX is overexpressed, 
apoptosis is triggered even in the absence of stimuli (Jurgensmeier et al., 1998). 
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The BCL2 family is important for regulating apoptosis because too little or too 
much apoptosis leads to the progression of cancer or ischaemic conditions 
respectively (Czabotar et al., 2014). BCL2 regulates apoptosis by exhibiting 
anti-apoptotic functions and it is regulated either by other proteins in the BCL2 
family or phosphorylation which could also inactivate it (Haldar et al., 1995). 
Interestingly, very high levels of BCL2 reverse its role, thus making it cause cell 
death (Shinoura et al., 1999). BCL2 also causes cells to exit the cell cycle and 
enter into the resting phase and prevents re-entry (Adams and Cory, 1998, 
Mazel et al., 1996) as well as inhibiting BAX, which is a promoter of cell 
apoptosis (Mazel et al., 1996). This suggests it has multiple functions. However, 
its main function is prolonging G1 to S phase transition in the cell cycle to 
enable supplementary time for the cell to either synthesise or repair damaged 
DNA (Mazel et al., 1996). 
PCNA is a protein responsible for DNA replication and damage repair (Wang et 
al., 2006). 
5.1.2 Beta catenin 
The adenomatous polyposis coli suppressor (APC) gene is responsible for the 
regulation and destruction of β-catenin (Munemitsu et al., 1995).  Mutation in 
the APC gene occurs in CRC and colorectal adenomas, which leads to the 
accumulation of β-catenin in the cell cytoplasm, thus, activation of the Wnt/β-
catenin pathway (Schror, 2011). β-catenin is normally degraded by 
phosphorylation in its amino terminus which leads to a reduction in its signalling 
(Yost et al., 1996) and absence of phosphorylatable residues due to mutation 
leads to an increase in its signalling (Morin et al., 2016). 
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The translocation of β-catenin to the nucleus leads to its interaction with DNA-
bound transcription factor proteins (TCF1, TCF2 or TCF3) which in turn causes 
the activation of several target genes such as Cyclin D1 (Thorstensen et al., 
2005). 
5.2 Aims and Objectives 
As opposed to necrosis, apoptosis is the preferred method for drug-induced cell 
death, otherwise the leaked cell contents cause damage to neighbouring cells 
in an uncontrolled manner. However, more often these patterns of cell death go 
hand in hand (Leist and Jaattela, 2001). 
These aspirin analogues have been found to have cytotoxic effects on SW480 
CRC cells. Thus, it was planned to find out if the mode of cell death was caused 
via apoptosis, necrosis or a mixture of both and whether a change in the 
isomeric positions of the acetyl group to the benzene ring might be responsible 
for this change in behaviour.  
5.3 Methodology 
The effect of aspirin analogues on pro-apoptotic and anti-apoptotic proteins was 
tested using SDS-PAGE resolution and western blot analysis (2.2.9.2.3). 
Annexin-V dye to detect apoptotic cells and PI to detect necrotic cells using flow 
cytometry (2.2.9) was also used. To further confirm these findings, YO-PRO®-1 
and PI dyes to detect apoptosis and necrosis respectively were later employed 
using confocal microscopy (2.2.10). 
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5.4 Results 
5.4.1 Effects of aspirin analogues on p21 expression  
The effect on the expression of p21 was first of all observed using a drug in 
chemotherapy as control. The fluoropyrimidine, 5-fluorouracil (5-FU), is the 
most common drug used in the treatment of colorectal cancer and has been in 
use for almost 60 years (Chu et al., 2009), thus, it was a the drug of choice to 
use in order to compare with the compounds in this study. 
Interestingly, p21 protein was repeatedly downregulated by high doses of 5-FU 
(Figure 5.2). 
 
Figure 5.2 Effect of 5-FU on the expression of p21 using different antibodies.  
SW480 CRC cells were treated with increasing doses of 5-FU for 24 h, lysed with 
Laemelli buffer, resolved using SDS-PAGE and probed with different antibodies to p21 
(21 kDa) from Abcam. -Tubulin (55 kDa) was used as loading control. 
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In comparison to the untreated cells (C), 5-FU at 0.1 μM and 1.0 μM 
upregulated the expression of p21 protein. However, at higher concentrations 
the expression was reduced and ultimately abolished (Figure 5.2). 
With this consistent result across different p21 antibodies, it was decided to 
compare this with the effects to p21 expression caused by some of the aspirin 
analogues. 
 
 
Figure 5.3 Effect of aspirin analogues on p21, BAX and BCL2 expression in 
SW480 CRC cells. 
Effect of aspirin analogues on p21 expression in SW480 CRC cells (A). Effect of 
aspirin analogues on BAX and BCL2 expression in SW480 CRC cells (B). Cells were 
treated with compounds at 0.5 mM for 24 h. The concentration of 5-FU used was 100 
M. Lysed cells were resolved and probed with p21 (ab109520), BAX (sc-493) or BCL2 
(ab32124) antibodies. -Tubulin was used as loading control. 
 
 
  
231 
 
There was complete suppression of p21 expression by 5-FU and PN590. 
However, PN548 and PN549 caused an increase in p21 expression with a 
decrease in expression by PN502, PN591 and PN592 (Figure 5.3A). 
Similarities in effects to p21, BAX and BCL2 have been consistent between the 
meta- and para- isomers of these aspirin analogues [PN548 and PN549] and 
[PN591 and PN592] (Figure 5.3A and 5.3B). 
5.4.2 Effects of aspirin analogues on BAX and BCL2 expression 
The effect of these compounds on the expression of the BAX and BCL2 
proteins, which are pro-apoptotic and anti-apoptotic proteins respectively, were 
also studied. 
It was observed that the expression of BAX was increased when cells were 
treated with PN548 and PN549. All the other compounds did not have any 
effect on BAX expression (Figure 5.3B). Similarly, only PN548 and PN549 
decreased the expression of BCL2 with the others having no effect (Figure 
5.3B). 
To further study the effects of these compounds on apoptosis, it was decided to 
use flow cytometry and immunocytochemistry (ICC). 
5.4.3 Effects of aspirin analogues on apoptosis 
SW480 CRC cells were treated with the isomers of these aspirin analogues at 
0.5 mM with the exception of PN590, which was treated at 0.3 mM because of 
its high cytotoxic effect (Table 4.3) for 16 h and 40 h, using staurosporine as a 
control for apoptosis and hydrogen peroxide (H2O2) as control for necrosis. 
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Staurosporine is a potent kinase protein inhibitor (Kiyoto et al., 1987), which has 
been shown to induce apoptosis in a number of cell lines (Bertrand et al., 1994, 
del Solar et al., 2015, McKeague et al., 2003) while H2O2, a reactive oxygen 
species is produced naturally during metabolism and high levels causes 
necrosis (McKeague et al., 2003, Miyoshi et al., 2006). 
A large number of late apoptotic/dead cells were detected using flow cytometry 
after treatment with compounds and even in samples of untreated cells.  
 
 
Figure 5.4 Representation of flow cytometric analysis and ICC for negative 
control (untreated) and control for apoptosis. 
SW480 cells were treated with 500 nM of staurosporine for 16 h and 40 h. This is 
compared with a control (untreated cells). The fluorescent dyes used for flow cytometry 
are Annexin-V-FITC (green) for apoptotic cells and PI (red) for necrotic cells. The 
fluorescent dyes used for ICC were YO-PRO®-1 (green) for apoptotic cells and PI (red) 
for late apoptotic/necrotic cells. Representative confocal images were taken at 40X 
oil/1.30 oil immersion objective. n=3. 
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Flow cytometric analysis of untreated cells detects the presence of dead cells 
after 16 h and the percentage increases after 40 h of incubation. However, 
using ICC, dead cells are not detected in the untreated cells after 16 h and 40 h 
(Figure 5.4). This could be because only adherent cells were analysed as the 
dead cells get washed off during washes. The treatment with staurosporine in 
both flow cytometry and ICC detected a significant amount of apoptotic cells 
after 16 h. Both methods also detected a combination of apoptotic and late 
apoptotic/necrotic cells after 40 h of treatment (Figure 5.4). 
 
Figure 5.5 Representation of flow cytometric analysis and ICC for negative 
control (untreated) and control for necrosis. 
SW480 cells were treated with 5 mM of H2O2 for 16 h and 40 h. This is compared with 
a control (untreated cells). The fluorescent dyes used for flow cytometry are Annexin-
V-FITC (green) for apoptotic cells and PI (red) for necrotic cells. The fluorescent dyes 
used for ICC were YO-PRO®-1 (green) for apoptotic cells and PI (red) for late 
apoptotic/necrotic cells. Representative confocal images were taken at 40X oil/1.30 oil 
immersion objective. n=3. 
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Both the flow cytometric analysis and ICC experiments indicate a few apoptotic 
cells with most being late apoptotic/necrotic in samples treated with H2O2 for 16 
h. The SW480 cells all turn necrotic after 40 h of treatment with 5 mM H2O2 
(Figure 5.5).   
Using staurosporine and H2O2 in both analysis produced very similar outcomes 
and thus good controls for detecting apoptotic and late apoptotic/necrotic cells 
respectively in SW480 CRC cell line. 
 
Figure 5.6 Representation of flow cytometric analysis and ICC for PN502 (aspirin). 
SW480 cells were treated with 0.5 mM of PN502 for 16 h and 40 h. The fluorescent 
dyes used for flow cytometry are Annexin-V-FITC (green) for apoptotic cells and PI 
(red) for late apoptotic/necrotic cells. The fluorescent dyes used for ICC were YO-
PRO®-1 (green) for apoptotic cells and PI (red) for late apoptotic/necrotic cells. 
Representative confocal images were taken at 40X oil/1.30 oil immersion objective. 
n=3. 
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The flow cytometric analysis detected a large number of necrotic cells after 
treatment with 0.5 mM of PN502 after 16 h and a larger percentage of necrotic 
cells after 40 h of treatment. About 8% of cells were apoptotic after the 16 h 
treatment, which increased to about 35% after 40 h of treatment with PN502. 
The levels of apoptotic cells detected correlates with the ICC method however, 
in the ICC method, late apoptotic/necrotic cells were not detected (Figure 5.6). 
This could be because a dominant number of the cells analysed have 
undergone early apoptosis and a negligible number of necrotic cells are present. 
 
 
Figure 5.7 Representation of flow cytometric analysis and ICC for PN548 (meta-
aspirin). 
SW480 cells were treated with 0.5 mM of PN548 for 16 h and 40 h. The fluorescent dyes 
used for flow cytometry are Annexin-V-FITC (green) for apoptotic cells and PI (red) for late 
apoptotic/necrotic cells. The fluorescent dyes used for ICC were YO-PRO®-1 (green) for 
apoptotic cells and PI (red) for late apoptotic/necrotic cells. Representative confocal images 
were taken at 40X oil/1.30 oil immersion objective. n=3. 
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About 8% of the SW480 cells became apoptotic after treatment with 0.5 mM of 
PN548 after 16 h, which increased to about 20% after 40 h of treatment and 
accompanied with over 50% of necrotic cells. A lot of the cells can be seen to 
be apoptotic after 16 h of treatment and analysed using the ICC method with 
some of the cells showing some necrosis after 40 h of treatment (Figure 5.7). 
 
 
Figure 5.8 Representation of flow cytometric analysis and ICC for PN549 (para-
aspirin). 
SW480 cells were treated with 0.5 mM of PN549 for 16 h and 40 h. The fluorescent 
dyes used for flow cytometry are Annexin-V-FITC (green) for apoptotic cells and PI 
(red) for late apoptotic/necrotic cells. The fluorescent dyes used for ICC were YO-
PRO®-1 (green) for apoptotic cells and PI (red) for late apoptotic/necrotic cells. 
Representative confocal images were taken at 40X oil/1.30 oil immersion objective. 
n=3. 
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Apoptotic cell cells increased from about 5% after being treated with 0.5 mM of 
PN549 for 16 h to about 37% after 40 h of treatment. Although a large number 
of late apoptotic/necrotic cells are detected by the flow cytometric analysis, this 
is also reflected by the qualitative results shown from the ICC method after 40 h 
of treatment with this isomer (Figure 5.8), which is more similar to the 
staurosporine image (Figure 5.4) than the H2O2 image (Figure 5.5). Cells 
treated with H2O2 went straight to dead (red fluorescence) unlike staurosporine 
and PN549 where there was accumulation of cells in the early apoptotic region. 
 
 
 
 
 
Figure 5.9 Representation of flow cytometric analysis and ICC for PN590 (ortho-
thioaspirin). 
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SW480 cells were treated with 0.3 mM of PN590 for 16 h and 40 h. The fluorescent 
dyes used for flow cytometry are Annexin-V-FITC (green) for apoptotic cells and PI 
(red) for late apoptotic/necrotic cells. The fluorescent dyes used for ICC were YO-
PRO®-1 (green) for apoptotic cells and PI (red) for necrotic cells. Representative 
confocal images were taken at 40X oil/1.30 oil immersion objective. n=3. 
 
The flow cytometric analysis here again detects a large percentage of necrotic 
cells after treatment with 0.3 mM PN590 for 16 h and 40 h. The apoptotic cells 
seem to decrease in percentage with increase duration of treatment. This can 
also be seen in the ICC slides where the cells after 40 h treatment start to turn 
necrotic [yellow fluorescence] (Figure 5.9) unlike the brownish/red fluorescence 
when cells were treated with H2O2 (Figure 5.5). 
 
 
 
Figure 5.10 Representation of flow cytometric analysis and ICC for PN591 (meta-
thioaspirin). 
SW480 cells were treated with 0.5 mM of PN591 for 16 h and 40 h. The fluorescent 
dyes used for flow cytometry are Annexin-V-FITC (green) for apoptotic cells and PI 
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(red) for late apoptotic/necrotic cells. The fluorescent dyes used for ICC were YO-
PRO®-1 (green) for apoptotic cells and PI (red) for necrotic cells. Representative 
confocal images were taken at 40X oil/1.30 oil immersion objective. n=3. 
 
Treatment with 0.5 mM PN591 after a duration of 16 h resulted in about 8% of 
apoptotic cells, which increased to about 14% after 40 h as shown by flow 
cytometry. The increase in apoptotic cells with time is reflected by the ICC 
confocal images by fluorescing bright green apoptotic cells (Figure 5.10). 
 
 
Figure 5.11 Representation of flow cytometric analysis and ICC for PN592 (para-
thioaspirin). 
SW480 cells were treated with 0.5 mM of PN592 for 16 h and 40 h. The fluorescent 
dyes used for flow cytometry are Annexin-V-FITC (green) for apoptotic cells and PI 
(red) for late apoptotic/necrotic cells. The fluorescent dyes used for ICC were YO-
PRO®-1 (green) for apoptotic cells and PI (red) for necrotic cells. Representative 
confocal images were taken at 40X oil/1.30 oil immersion objective. n=3. 
 
Apoptotic cells increased after treatment with 0.5 mM PN592 from about 8% 
after 16 h to about 15% after treatment for 40 h as shown by flow cytometric 
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analysis. About 10% of necrotic cells were detected using flow cytometry. 
However, necrotic cells were not detected using the ICC method with apoptotic 
cells also increasing with duration of treatment with PN592 [from 16 h to 40 h] 
(Figure 5.11). 
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Figure 5.12 Flow cytometric analysis of aspirin analogues showing induced 
apoptosis in SW480 CRC cell line. 
SW480 CRC cells were treated with compounds for 16 h and 40 h, stained with 
Annexin-V-Fluos and counterstained with PI fluorescence dye and analysed using flow 
cytometry. Data plotted as mean ± SEM (n=3), ★★★★p<0.0001. 
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Figure 5.13 Flow cytometric analysis of aspirin analogues showing induced 
necrosis in SW480 CRC cell line. 
SW480 CRC cells were treated with compounds for 16 h and 40 h, stained with 
Annexin-V-Fluos and counterstained with PI fluorescence dye and analysed using flow 
cytometry. Data plotted as mean ± SEM (n=3) ★p<0.05,★★p<0.01,★★★p<0.001. 
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Using flow cytometric analysis, the percentage of induced apoptosis in SW480 
cells was quite low after treatment with all aspirin analogues. However, the 
percentage apoptosis did increase after 40 h of treatment with the exception of 
staurosporine, the compound used as a positive control to apoptosis (Figure 
5.12). Necrotic/dead cells also increased in percentage with duration of 
treatment. The longer the cells were under treatment, the more necrotic cells 
appeared (Figure 5.13). This also applies to control cells, which could be 
attributed to the nature of the cells or the methodology/protocol followed. 
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5.4.4 Effect of ortho-thioaspirin on the localization of β-catenin 
 
 
Figure 5.14 Effect of PN590 (ortho-thioaspirin) on β-catenin localization.  
DMSO as vehicle control [untreated cells] (A) Cells treated with PN590 dissolved in 
DMSO (B) Acetone as vehicle control [untreated cells] (C) Cells treated with PN590 
dissolved in acetone (D). SW480 CRC cells were treated with PN590 dissolved in 
either acetone or DMSO for 24 h.  
 
Translocation of β-catenin towards the nucleus from the cytoplasmic membrane 
can be seen when the cells were treated with PN590 dissolved in DMSO 
(Figure 5.14B). The translocation of β-catenin from the cytoplasmic membrane 
when cells were treated with PN590 dissolved in acetone was more to the 
cytoplasm and not towards the nucleus (Figure 5.14D). Acknowledging that 
PN590 has a very reactive sulfhydryl group (Scott et al., 1993), reaction with 
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DMSO may be possible which eventually leads to translocation of β-catenin 
towards the nucleus.  
5.5 Discussion 
Programmed cell death (PCD), also known as apoptosis, occurs via different 
pathways with more than one of these pathways triggered simultaneously (Leist 
and Jaattela, 2001, Nikoletopoulou et al., 2013). As mentioned in section 
1.3.2.1, the SW480 cell line contains a mutation at TP53 gene of the p53 
protein (Din et al., 2004), which p21 is dependent on in its expression and 
status (el-Deiry et al., 1993). Although p21 is not a reliable protein to conclude 
induction of apoptotic or anti-apoptotic cell death caused by compounds due to 
its multiple functions, it does control cell proliferation by causing cell cycle arrest 
at G1/S transition of the cell cycle. (Abbas and Dutta, 2009, Karimian et al., 
2016). Thus, its application to cancer therapy must be approached with caution 
with emphasis on inhibiting only the oncogenic activities of p21 (Karimian et al., 
2016). There was a decrease in p21 expression when SW480 CRC cell line 
was treated with aspirin (PN502), PN591, PN592 and completely abolished 
when treated with 100 μM 5-FU, a known anti-cancer drug used in the 
treatment of CRC (Chu et al., 2009) and PN590 (Figure 5.2 and 5.3A). Contrary 
to the results obtained in regards to p21 expression after treatment of cells with 
5-FU, Li et al. found p21 to be up-regulated in oral cancer cell lines, NA and 
HSC-4 treated with 10 mg/ml and 1 mg/ml 5-FU respectively for a period of 12 h 
(Li et al., 2004). This could be due to different cell lines having different 
responses to 5-FU or a difference in dose or duration of treatment. In this study, 
SW480 CRC cells were treated with 100 μM of 5-FU for a period of 24 h while 
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Li et al. (2004) treated NA and HSC-4 cells with 10 mg/ml and 1 mg/ml, which is 
equivalent to 76.9 mM and 7.69 mM of 5-FU respectively. Lee et al. (2005) also 
found an increase in p21 expression after treatment of hypopharyngeal cancer 
cell line, PNUH-12 with 5-FU. However, lung cancer cells, Calu-6 and colon 
cancer cells, HCT 116 treated with 100 μM of 5-FU for a period of 24 h also 
down-regulated p21 expression (Esposito et al., 2014), which concurs with the 
findings in this study. Clinically, investigations by immunohistochemistry in pre- 
and post-therapeutic tumour samples in patients with rectal carcinoma revealed 
a decrease in p21 expression to be related to better disease-free survival, 
indicating the induction of p21 to be linked with lower proliferative activity but 
poor prognosis after treatment (Noske et al., 2009, Rau et al., 2003). 
Furthermore, it was observed that the untreated cells (control) expressed p21, 
which is consistent with p21 being overexpressed in a variety of cancers (Abbas 
and Dutta, 2009) and could be due to DNA damage and subsequent induction 
of cell cycle arrest (Karimian et al., 2016) . Expression of p21 is also found to be 
inversely related to the expression of the p53 protein (Zirbes et al., 2000) and in 
this study could be due to TP53 gene mutations harboured by SW480 cells. A 
number of studies have linked the overexpression of p21 to inhibition of 
apoptosis. An example includes a study in breast cancer cell lines that revealed 
a decrease in sensitivity to IR-induced apoptosis when p21 was overexpressed 
(Soria and Gottifredi, 2010). An increase in the expression of p21 therefore 
suggests inhibition of apoptosis thus promoting cell survival and cell cycle arrest 
due to potential DNA damage, while a decrease in the expression of p21 
suggests either induction of apoptosis or non-interference in the cell cycle. The 
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isomers of aspirin, PN548 and PN549 did not seem to have an effect in the 
expression of p21 (Figure 5.3A). This suggests that PN548 and PN549 may 
maintain stable biological activity through cell cycle arrest. These isomers of 
aspirin again stand out when SW480 cells were treated (Figure 5.3B) with them 
and appeared to be the only compounds that had an effect on the proteins that 
suggests induction of apoptosis via the BAX-BCL2 pathways. The expression of 
BAX was increased and the expression of BCL2 decreased simultaneously by 
both the meta- and para-isomers of aspirin. It can thus be concluded that 
PN548 and PN549 induce apoptosis via BAX-BCL2 pathways but not through 
the p21 pathways. However, decrease in the expression of p21 caused by 
treatment with 5-FU, PN502, PN590, PN591 and PN592 is favourable in cancer 
therapy because researchers have found out that the knockdown of p21 by 
radiation leads to a decrease in tumourigenesis suggesting that p21 functions 
as an oncogene by inhibiting apoptosis (Prives and Gottifredi, 2008). It was 
therefore concluded that p21 can have dual outcomes in regards to cell 
proliferation. It can have inhibitory or stimulatory effect on cell division either 
through apoptosis or cell cycle arrest (Karimian et al., 2016).  
 
The comparison between the quantitative apoptotic status of cell populations 
using flow cytometry and ICC led to the rise of two main concerns about flow 
cytometry in the quantitative determination of adherent cells. 
The first concern is false PI staining as a result of damaged cells due to 
trypsinization in order to make a suspension out of the monolayers ready for 
analysis using the flow cytometer. It was found out that some of the cells got 
  
248 
 
damaged due to the addition of trypsin thereby taking up PI and thus giving a 
false result for necrotic/dead cells. Further investigation revealed that all 
manufacturers of apoptosis kits use cells that are in suspension as sample cells 
for quantitative analysis of their products found on the protocol sheets (Table 
5.1). 
 
 
Product Company Type of cells Culture 
properties 
★Annexin V-
FLUOS kit 
Roche® Life 
Sciences 
U937 lymphocyte 
cells 
Suspension 
FITC Annexin 
V/PI 
invitrogen® 
Molecular 
probes® 
Jurkat cells (T-cell 
Leukaemia,human) 
Suspension 
Annexin V 
Reagents for 
apoptosis 
IncuCyte® Jurkat cells Suspension 
FITC Annexin V 
apoptosis 
detection kit with 
7-AAD 
Biolegend® Jurkat cells Suspension 
PE Annexin V 
apoptosis kit I 
BDPharminogen™ Jurkat cells Suspension 
Annexin V-CF 
Blue 7-AAD 
apoptosis 
staining/detection 
kit 
Abcam Jurkat cells Suspension 
Annexin V 
apoptosis 
detection kit PE 
e Bioscience™ Mouse thymocytes Suspension 
Annexin V/7-AAD 
apoptosis kit 
Abnova Jurkat cells Suspension 
Table 5.1 List of various apoptosis detection kits from different companies with 
the type of cell used in the documentation/protocol sheet. 
(★Product used for this study). 
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The inclusion of adherent cells in samples used for quantitative analysis of 
apoptosis detection kits will make the product more versatile for use and false 
PI staining will surely be taken care of by the manufacturers due to damage 
inflicted on the cell membranes during harvesting in order to produce more 
robust and reliable data. Some protocols suggest harvesting the cells by 
incubation in standard trypsin with EDTA, trypsin without EDTA, EDTA without 
trypsin or mechanical scraping with a rubber policeman. However, all these 
methods result in damage of the cell membrane (van Engeland et al., 1996). 
Such damage is likely to happen when attempts are made to harvest adherent 
cells from the surface of tissue culture plates and was thus suggested to allow 
for Annexin V binding to cells before harvesting (van Engeland et al., 1996). 
The second concern is that late apoptotic cells also appear in the UR quadrant 
positive for PI staining. This means that the analysis is unable to differentiate 
between late apoptotic, necrotic and dead cells. Part of this issue is raised by 
Rieger et al., (2011) in that about 40% of PI stain results could be due to 
staining of RNA within the cytoplasm and thereby producing false positive 
events (Rieger et al., 2010). They suggest a protocol, which includes the 
addition of 16 μl of 1:100 diluted RNase A (Sigma, R4642) to give a final 
concentration of 50 μg/ml and incubated before analysis (Rieger et al., 2011). 
This enables the removal of cytoplasmic RNA and thus eliminates any false 
necrotic values due to PI staining. 
 
Results from ICC confocal images after treatment with isomers of aspirin and 
thioaspirins revealed that SW480 CRC cells treated with 0.5 mM of PN502 
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(aspirin), PN591 and PN592 for 16 h caused few cells to undergo early 
apoptosis, which increased substantially after 40 h of treatment (Figures 5.6, 
5.10 and 5.11 respectively). Aspirin has previously been reported to cause cell 
death in SW480 cells via apoptosis (Stark et al., 2001). Treatment of this cell 
line with 0.5 mM of PN548, 0.5 mM of PN549 and 0.3 mM of PN590 caused the 
cells to undergo early apoptosis after treatment for 16 h and then progressed to 
late apoptosis and necrosis after 40 h of treatment (Figures 5.7, 5.8 and 5.9 
respectively). Here again the same trend is followed by the isomers of aspirin, 
PN548 and PN549 and the isomers of thioaspirin, PN591 and PN592. 
 
Inactivation of the pathways that involves APC tumour suppressor gene and β-
catenin is usually the beginning of a chain of genetic changes involved in 
colorectal cancer development (Morin et al., 2016, Morin et al., 1997). These 
changes include translocation of β-catenin to the nucleus which leads to its 
interaction with DNA-bound transcription factor proteins (TCF1, TCF2 or TCF3), 
which in turn causes the activation of several target genes such as Cyclin D1 
(Thorstensen et al., 2005). Thus, the ability of PN590 to drive β-catenin towards 
the nucleus is a disadvantage to its properties as a compound with cytotoxic 
effects. However, this translocation towards the nucleus is seen more clearly 
when PN590 is dissolved in DMSO, which suggests that PN590 dissolution in 
DMSO should be avoided (Figure 5.15B).
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Chapter 6. Effect of Aspirin analogues on the EGFR 
6.1 Introduction 
6.1.1 The EGF Receptor 
EGF was discovered while in the process of isolating and characterizing a 
salivary gland protein that caused growth developments in new-born mice back 
in 1960 (Cohen, 1962). In 1975, Graham Carpenter published his findings of a 
receptor, as a membrane protein with a molecular weight of 170-kDa 
(Carpenter et al., 1975). 
The EGF receptor (EGFR) is one of the 20 subfamilies of the receptor tyrosine 
kinases (RTKs), which are the main mediators of many cell signals in living 
organisms. The EGFR family, also known as ErbB tyrosine kinase receptors or 
type I receptor tyrosine kinases (Mendelsohn and Baselga, 2000) is made up of 
four receptors; namely, EGFR (ErbB1), HER2 (ErbB2/neu), HER3 (Erb3) and 
HER4 (ErbB4) (Hackel et al., 1999, Klapper et al., 2000, Olayioye et al., 2000). 
Levels of EGFR in the neoplastic tissue of the colorectal mucosa in comparison 
to the surrounding unaffected mucosa, assessed by enzyme immunoassay and 
Western blotting procedure are raised in up to 80% of CRC cases (Messa et al., 
1998, Porebska et al., 2000). EGFR overexpression in cancer cells is primarily 
due to mRNA instability caused by a mutation that lead to mononucleotide or 
dinucleotide deletions within the A13/A14 repeat sequence in the 3’-
untranslated region of the EGFR gene (Yuan et al., 2009). This condition can 
be reversed by treatment with anti-EGFR agents that bind competitively with 
EGF to the receptor such as cetuximab (Cunningham et al., 2004) and more 
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recently by aspirin treatment, leading to improved clinical outcomes (Algra and 
Rothwell, 2012, Chan and Lippman, 2011, Li et al., 2015). In about 10% of lung 
tumours however, mutation occurs as a result of threonine being substituted 
with methionine at amino acid 790 (T790M). This mutation enables activation of 
EGFR even after drug-receptor interaction, thus, causing resistance to EGFR 
inhibitor drug, gefitinib and leads to poor prognosis (Kobayashi et al., 2005, Pao 
et al., 2005).  
The percentage of EGFR expression and its significance in clinical outcomes 
differ quite widely in the literature as a result of the absence of a standardized 
methodology for assessment (Krasinskas, 2011). For example, while EGFR is 
reported to be overexpressed in about 80% of CRC cases with no correlation to 
increased patient mortality (Spano et al., 2005), it is also reported to be 
overexpressed in 35% of CRC cases which has been related to increased 
patient mortality (Resnick et al., 2004). In comparison to lung cancer, the defect 
found in CRC is mainly due to overexpression of the EGFR and rarely 
protein/gene mutation (Barber et al., 2004, Lee et al., 2005). However, the 
prevalence in Korean CRC patients is 22.4% in a small clinical study of 58 
patients (Oh et al., 2011). 
Thus, overexpression of the EGFR is often found in a number of cancers and 
related to the development and enhancement of tumourigenesis. 
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6.1.1.1 Structure of the EGFR 
The EGF receptor is made up of three domains. The extracellular ligand binding 
domain, the transmembrane lipophilic domain and the intracellular protein 
kinase domain that consists of a regulatory carboxyl terminal segment 
(Mendelsohn and Baselga, 2000), which harbours the different phosphorylation  
sites (Wheeler et al., 2010) (Figure 6.1). 
 
 
Figure 6.1 Structure of the EGFR, sites of phosphorylation and effector 
signalling pathways triggered.  
Homodimerization or heterodimerization occurs after ligand binding to the EGFR. This 
leads to autophosphorylation of the tyrosine kinase residues located on the 
cytoplasmic tail of the receptor. The tyrosine kinase sites include Y992, Y1045, Y1068, 
Y1101 and Y1173 and their biological activities indicated after the arrows [(Adapted  
from (Nyati et al., 2006) and (Wheeler et al., 2010)].
  
254 
 
Proteins that connect the RTKs to downstream signalling pathways include Shc, 
Grb2, Grb7 and Nck while the enzymes include phospholipase Cγ (PLCγ), PI 3-
K and Src, which is phosphorylated and thus activated (Hackel et al., 1999). 
6.1.1.2 Epidermal Growth Factor (EGF) 
Epidermal growth factor (EGF) was first discovered while in the process of 
isolating and characterizing a salivary gland protein that caused growth 
developments in new-born mice back in 1960 and was found out to make up 
about 0.5% of the protein content of the submaxillary gland (Carpenter and 
Cohen, 1979, Cohen, 1962). 
Endogenous EGF in normal cells has a positive function that is wound healing 
(Schultz et al., 1991, Werner and Grose, 2003). The EGF family members are 
considered as one of the most important growth factors responsible for the 
growth and differentiation of keratinocytes, which is a process involved in 
wound healing of the skin (Shirakata et al., 2005). 
EGF only has a negative effect in cancer due to the overexpression and 
deregulation of its signalling pathway. 
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6.1.1.3 The phosphorylation sites 
Upon stimulation of the EGF receptor, phosphorylation is activated on its 
various tyrosine residues (Margolis, 1992, Wheeler et al., 2010). 
 
EGFR 
phosphorylation 
sites/Tyrosine 
residues 
Function 
Tyr 1068 The activation of EGFR leads to a series of protein-protein 
interactions involving Grb2, a protein found in the site’s 
downstream signalling pathway. This serves as an adaptor 
protein, which binds to the phosphorylated Tyr 1068. This is 
particularly important in the protein kinase-signalling 
pathway. Phosphorylation at this site is responsible for the 
activation of Ras and Mitogen-activated protein kinase 
(MAPK) pathway (Nyati et al., 2006, Rojas et al., 1996, 
Wheeler et al., 2010). 
Tyr 992 PLCγ has two SH2 domains which both bind to this 
phosphorylation site to activate PLCγ mediated downstream 
signalling (Emlet et al., 1997, Wheeler et al., 2010). 
Tyr 1045 The EGFR is downregulated by c-Cbl adaptor proteins via 
mobilizing ubiquitin-activating and ubiquitin-cojugating 
enzymes. This leads to endocytosis (internalisation) and 
degradation of ligand-receptor complexes (Levkowitz et al., 
1998, Nyati et al., 2006) 
Tyr 1173 This provides the docking site for Shc and Grb2 adaptor 
proteins in which its phosphorylation causes the activation of 
the Ras oncogene after Erk phosphorylation (Jorissen et al., 
2003) 
Tyr 1101 The function of this phosphorylation site is uncertain 
(Biscardi et al., 1999). However, Wheeler et al. described it 
as having an effect on the activation of PI3K and 
subsequently Akt (Wheeler et al., 2010). 
Table 6.1 EGFR phosphorylation sites used in this study and their functions. 
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6.1.1.4 Biological function of the EGFR 
In healthy cells, dimerization occurs when the EGFR becomes activated as a 
result of ligand binding to the receptor or overexpression of the receptor 
(Cochet et al., 1988, Lemmon and Schlessinger, 1994, Yarden and 
Schlessinger, 1987). This leads to the formation of homo or heterodimeric 
complexes for Src homology (SH2) and phosphotyrosine binding (PTB) domain-
containing proteins by phosphorylation of specific tyrosine residues (Lemmon 
and Schlessinger, 2010). An asymmetric dimer with only one bound ligand is 
created when the first ligand binds to the receptor and the idle site of the dimer 
becomes structurally unable to interact with any ligand. Thus, reducing the 
possibility of a second ligand to bind onto the same receptor. This process is 
known as negative co-operativity (Alvarado et al., 2010).  
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Figure 6.2 EGFR signalling pathway.  
Dimerization occurs after ligand binding to the receptor. Autophosphorylation of 
tyrosine kinase residues leads to a cascade of downstream signalling. [Adapted from 
(Krasinskas, 2011, Schlessinger, 2000)]. 
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Activation of the protein tyrosine kinases is then set-off with subsequent 
autophosphorylation of the sites resulting in the activation of different signalling 
pathways and cellular activities (Alroy and Yarden, 1997), which include 
apoptosis, gene expression, cellular differentiation and proliferation (Chan et al., 
1999). These phosphorylated tyrosines cause a change in charge and shape of 
the receptors, permitting the recruitment of particular signalling protein. Adaptor 
proteins that contain Src homology 2 domains (SH2) or phosphotyrosine-
binding domains such as c-Cbl (Y1045) or Grb2 (Y1068) are later recruited 
(Levkowitz et al., 1998, Ushiro and Cohen, 1980). One of the branches of the 
EGFR signalling pathway is the Ras-Raf-MEK-MAPK pathway (Figure 6.2).  
It should be mentioned that there are different conflicting theories and 
explanations on endocytosis of the EGFR, which could be due to differences in 
experimental designs or possibly different clones of the same cell type 
(Benmerah and Lamaze, 2007). 
PTEN, a tyrosine phosphatase enzyme, is known to inhibit PI 3-K by 
dephosphorylating phosphatidylinositol 3,4,5-trisphosphate (PIP3) in the 3-
position, which ultimately results in Akt inactivation and cell death (Krasinskas, 
2011). 
The EGFR pathway is complicated, and signalling needs to be strictly controlled 
due to different negative and positive feedback mechanisms linked to the 
pathway and activation of different transcription factors all with different 
outcomes depending on which type of cell it is (Citri and Yarden, 2006). 
Otherwise, this results in anti-apoptosis, cell proliferation, angiogenesis and 
metastasis (Mitsudomi and Yatabe, 2010). Tumour formation or progression is 
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especially due to the activation of EGFR downstream regulators such as the Akt, 
KRAS and MAPK (Krasinskas, 2011). The inhibition of these 
effectors/regulators will be beneficial in therapy. However, study of these 
individual regulators commonly results in different outcomes (Krasinskas, 2011). 
For example, KRAS proto-oncogene encodes a GTPase at the beginning of the 
MAPK pathway. Mutation of KRAS leads to the prolonged activation of the 
MAPK pathway. Samowitz et al., (2000), Belly et al., (2001) and Andreyev et al., 
(2010) reported KRAS mutation status to be linked with shorter patient survival 
whereas Roth et al., (2010) and Tejpar et al., (2010) reported otherwise.  
EGFR stimulation also leads to the continuous activation of certain STAT 
(Signal transducers and activators of transcription) proteins, which include Stat-
3 having anti-apoptotic effects (Grandis et al., 2000). Thus, its inhibition will lead 
to the activation of the apoptotic process. 
Currently, seven STATs are recognised, namely STAT 1, -2, -3, -4, -5A, -5B 
and -6 (Garcia and Jove, 1998). In comparison to normal human cells, Stat-3 
activation is greatly increased in a range of human cancer cells and have been 
linked to poor prognosis in breast and colon cancers (Khazaie et al., 1993). 
Activation of Stat-3 subsequently leads to activation of Bcl-2 (Catlett-Falcone et 
al., 1999), which is also anti-apoptotic. EGFR degradation is one of two results 
of its stimulation by EGF (Decker, 1990). 
A number of studies have found out that the internalization of the EGFR 
induced by ligand binding is a crucial step in the EGFR signalling pathway 
(Schlessinger, 2000, Weiner and Zagzag, 2000). 
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6.1.1.5 Medical relevance 
The epidermal growth factor receptor (EGFR) is one of the numerous molecular 
targets suggested as candidate targets for cancer therapy (Mendelsohn and 
Baselga, 2000) and is one of four receptor tyrosine kinases with its 
overexpression resulting in poor prognosis (Madshus and Stang, 2009). A 
number of human cancers have been identified to show overexpression, 
mutations and gene amplification of the receptor (Zwang and Yarden, 2006) 
with colorectal cancer amongst those known to exhibit such characteristics 
(Ciardiello et al., 2001). 
Apart from observed mutations in receptor tyrosine kinase (RTK) pathways in 
different subtypes of human CRC, which are one of the main oncogenic 
mechanisms, there is also overexpression in some oncogenic RTKs (Yao et al., 
2013). Thus, a complete understanding on the EGFR signalling pathway will be 
of great use to researchers (Hynes and Lane, 2005). In patients undergoing 
cancer therapy using gefitinib, mutations at the tyrosine kinase domain were 
found in those that responded to the therapy and none of these mutations were 
seen in those that did not (Jorissen et al., 2003). Stimulation of these 
downstream pathways can lead to different pathways responsible for cell 
migration, proliferation and cell survival and their alterations can lead to positive 
prognostic effects (Krasinskas, 2011). 
6.1.2 Early Endosome Antigen1 (EEA1) 
The early endosome antigen1 (EEA1) is an effector protein required at the early 
endosome, which is a compartment responsible for the sorting of ligand-
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receptor complexes into late endosomes and lysosomes for degradation or 
back to the cell surface for recycling (Mu et al., 1995, Shepherd, 1989). This 
compartmentalization takes place after endocytosis of a receptor, which is part 
of the signalling pathway of the EGFR (Schlessinger, 2000). Two models have 
been proposed for transition from early endosomes to late endosomes, one of 
which proposes that early endosomes progressively mature into late 
endosomes and lysosomes (Murphy, 1991). However, Griffiths and Gruenberg 
(1991) disagrees and proposes that early and late endosomes are ‘two distinct 
pre-existing cellular organelles’ and linked by a microtubule communicating 
system. Proteins specific to these compartments include Rab5, a GTP-binding 
rab protein (Chavrier et al., 1990) and EEA1 both localizing to the early 
endosome, Rab4 or Rab11 localizing the recycling compartments and Rab7, 
localizing to the late endosome and are all GTP-binding rab proteins (Flores-
Rodriguez et al., 2015, Mu et al., 1995). Ligand stimulation of the EGFR leads 
to it being rapidly internalised and transported to the early endosomes with 
some of the receptor recycled back to the cell membrane but most of it 
delivered into intraluminal vesicles (ILVs) within the endosome, which matures 
into the multivesicular body (MVB) (Flores-Rodriguez et al., 2015, Sorkin and 
Goh, 2009). The endosomes then undergoes biochemical changes via fusion 
and fission leading to development into late endosomes that eventually delivers 
the EGFR to the lysosomes where it undergoes degradation (Foret et al., 2012).  
Within the early endosome network, the EGFR is delivered to the Rab5 situated 
at the periphery of the early endosomes enriched with APPL1 (adaptor protein, 
phosphotyrosine interaction, PH domain and leucine zipper containing 1), an 
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adaptor protein that regulates AKT signalling before being delivered to EEA1-
positive endosomes (Schenck et al., 2008). However, it is also reported that the 
receptor employs endosomal-sorting complex required for transport (ESCRT), 
protein complexes that deliver the receptor into ILVs (Hanson and Cashikar, 
2012) before being sorted to EEA1-positive endosomes (Flores-Rodriguez et al., 
2015). 
CHMP4C and CAV1, genes essential in the endosomal-sorting network are 
regulated by the transcription factor, P53 (Yu et al., 2009). CHMP4C is 
harboured by one of the ESCRT protein complex situated on the MVB 
(Woodman, 2009) while CAV1 is harboured by caveolin-1 protein involved in 
the caveolae-mediated pathway for EGFR endocytosis (Le Roy and Wrana, 
2005, Yu et al., 2009). 
6.2 Aims and Objectives 
In the previous chapters of this thesis and previous publications, it has been 
seen that the cytotoxic effects of aspirin and its analogues on SW480 CRC cell 
lines in varying degrees. Their capacity to induce apoptosis (Deb et al., 2011), 
inhibit NF-κB in vitro and cyclin D1 expression and also suppress tumour 
growth in vivo in a murine model of colorectal cancer with no evidence of 
toxicity observed (Claudius et al., 2014). Cytotoxic effects on oesophageal 
cancer cell lines have also been reported by Kilari, R.S. (2014) Roles of Inositol 
Diphosphate in DNA Repair And Effects of Aspirin Analogues on Oesophageal 
Cancer. Ph.D. Thesis, University of Wolverhampton. 
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In this chapter, it was intended to find out if these compounds have an effect on 
the molecular pharmacology of the EGFR; namely its internalization, its co-
localization with EEA1 and the effect of these analogues on the different 
tyrosine kinase phosphorylation sites responsible for its ubiquitination and 
recycling. The pursuit to study whether the EGFR phosphorylation state was 
altered, leading to regulation of downstream effects, was determined using 
selective antibodies prepared against particular targets. Fluorescent dyes and 
selective antibodies have been used to study this signalling pathway. SW480 
CRC cell line is a good candidate for this study because it is known to over-
express EGFR (Goetz et al., 2010). 
The ability of aspirins and analogues to alter tyrosine phosphorylation may be a 
general effect, or it may target specific tyrosines. Selective sites were looked at 
in order to determine (i) whether the EGFR is a target for these drugs and (ii) 
whether all phosphorylation sites are affected. 
6.3  Methodology 
The experimental methods used in this chapter are as stated in chapter two 
(2.2.12 to 2.2.16). 
6.4 Results 
6.4.1  Perturbation of EGF internalization and effect on its co-localization 
with EEA1 by aspirin and its analogues 
A long standing proposal has been that the internalization of the EGFR is a way 
of attenuating the signalling pathway as the receptor is removed from the cell 
surface (Wells, 1999). However, evidences from von Zastrow and Sorkin, 
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(2007) generated by observations made in 1996 by Vieira et al., show that 
internalization is an essential part of the signalling pathway in which inhibition 
could lead to disruption of a number of mechanisms in the signalling pathway 
(Sigismund et al., 2008). Internalization removes the EGFR from the cell 
surface and routes it to either be recycled or degraded in endosomes and 
lysosomes (Sorkin and von Zastrow, 2009). Nuclear EGFR has been found to 
act as a transcription factor, activating genes such as cyclin D1 responsible for 
cell proliferation (Lin et al., 2001). A recent study from Ortega et al., discovered 
that the phosphorylation of PCNA by EGFR in the nucleus led to the inhibition 
of DNA MMR thereby promoting proliferation of cells with damaged DNA 
(Ortega et al., 2015) and thus tumour growth.  
Effects of these compounds could be due to the salicylate moiety of the 
chemical structure. Diflunisal, containing salicylate as part of its substructure is 
an NSAID, and also included in this study. Diflunisal works similarly to salicylic 
acid as an anti-inflammatory and has been found to inhibit the growth of cancer 
cells in vitro and in vivo (Shirakawa et al., 2016). 
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Figure 6.3 Structure of diflunisal and salicylic acid.  
Diflunisal has a salicylic acid moiety as part of its chemical structure. 
 
 
The compounds used were dissolved in acetone and either buffered in HEPES 
(pH8) or PBS (pH7.4) and then made up to the required 0.5 mM final 
concentration as in all the experiments prior to this chapter. The cells were 
initially treated with the compounds and EGF without ‘chasing’ (Activating 
internalization) at 37°C to ensure that there was no competitive binding 
between the compounds and EGF to the receptor. 
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Figure 6.4 Quantification of the effect on aspirin analogues on EGF binding. 
The effect of aspirin analogues on EGF binding was quantified using Image J software. 
50 cells were analysed per compound and data plotted as mean ± SEM (n=3). 
 
The difference in EGF bound along the membrane of the cytoplasm in 
untreated SW480 CRC cells was not significantly different from the cells treated 
with the aspirin analogues (Figure 6.4). Intensity of EGF-Alexafluor 555 
measured for treated cells is relative to the intensity of EGF in the control 
(untreated cells). 
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Figure 6.5 Effect of aspirin analogues on EGF binding.  
Confocal images of SW480 CRC cells treated with or without compounds; Control [untreated] 
(A), PN502 [ortho-aspirin] (B), PN508 [diaspirin] (C), PN517 [fumaryldiaspirin] (D), PN524 [m-
bromobenzoylsalicylate] (E), PN590 [ortho-thioaspirin] (F). Cells (with the exception of control) 
were treated with 0.5 mM (pH adjusted with PBS) for 30 min. The EGF used is complexed to 
Alexa Fluor® 555 (100 ng/ml) for 1 h on ice and fixed. Images were acquired at 405 nm-DAPI 
(blue) and 561 nm-Alexa Fluor (red) for EGF. Representative images are shown taken at 40X 
oil/1.30 oil immersion objective. Scale bar represents 10 μm. 
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Semi-quantitative (Figure 6.4) and qualitative (Figure 6.5) analysis revealed that 
there was no significant difference between the intensity of EGF bound to the 
control cells that were untreated (Figure 6.5A) with the cells that were treated 
with PN502 (Figure 6.5B), PN517 (Figure 6.5D), PN524 (Figure 6.5E), PN590 
(Figure 6.5F) and PN508 (Figure 6.5C). This enabled further experiments to be 
carried out with the knowledge that these compounds do not alter EGF binding. 
The images below have been grouped into aspirins, diaspirins, thioaspirins and 
salicylate-like compounds for easy visualisation using the same positive and 
negative controls to all aspirin analogues for same experimental conditions. 
 
In the controls where there was only ligand stimulation and no treatment with 
compounds for the EGF-EEA1 co-localization experiments, the EGF was 
observed not to have co-localized with EEA1 even though internalization had 
taken place. This suggests that degradation did not take place but perhaps the 
receptors were recycled back to the cell surface and so signalling pathways  
remained activated. 
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Figure 6.6 (A – F) Effect of aspirins with PBS on EGF-100 ng/ml internalization 
and EGF co-localization with EEA1. 
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Figure 6.6 Effect of aspirins with PBS on EGF-100 ng/ml internalization and EGF 
co-localization with EEA1. 
Confocal images of SW480 CRC cells treated with or without compounds, negative 
control [EGF receptor unstimulated] (A), negative control with EEA1 (B), positive 
control [EGF receptor stimulated] (C), positive control with EEA1 (D), PN502 [ortho-
aspirin] (E), PN502 showing EEA1 (F), PN548 [meta-aspirin] (G), PN548 showing 
EEA1 (H), PN549 [para-aspirin] (I), PN549 showing EEA1 (J). Cells were treated with 
0.5 mM aspirin analogue (pH adjusted with PBS) for 30 min. The EGF used is 
complexed to Alexa Fluor® 555 (100 ng/ml) for 1 h on ice after which it was ‘chased’ at 
37°C for 30 min. The cells were then fixed for 5 min. For EEA1 co-localization, the 
slides were then treated with EEA1 primary antibody and a corresponding secondary 
antibody. Images were acquired at 405 nm-DAPI (blue) for nucleus, 561 nm-Alexa 
Fluor (red) for EGF and 488 nm-FITC for EEA1 (green). Representative images are 
shown taken at 40X oil/1.30 oil immersion objective (n=3). Scale bar represents 10 μm.
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EGF can be seen along the cell membrane for the negative control cells (Figure 
6.6A) because the receptor has not been stimulated by incubation at 37°C. As 
EGF binds to EGFR, this represents the EGFR along the cell membrane before 
internalization when stimulated. The positive control represents the state of the 
EGF after it has been ‘chased’, which means stimulating the receptor by 
incubating the cells for 30 min at 37°C stimulating the receptor leads to its 
internalization towards the nucleus as seen in Figure 6.4C.  
The presence of yellow fluorescence signifies co-localization. Upon observation, 
the EGF, with the receptor not stimulated showed no signs of co-localization 
with EEA1 (Figure 6.6B). This was expected. However, what was not expected 
was the stimulated receptor to also show no signs of co-localization with EEA1 
(Figure 6.6D). 
Internalization of EGF (100ng/ml) was clearly perturbed by PN502 (Figure 6.6E), 
PN548 (Figure 6.6G) and PN549 (Figure 6.6I) in varying degrees with the 
perturbation strongest in cells treated with PN502. Downregulation of EGFR 
internalization is a significant process in regulating its signalling (Roepstorff et 
al., 2009). However, effect on the co-localisation of EGF and EEA1 in the cells 
treated with PN548 (Figure 6.6H) and PN549 (Figure 6.6J) was no different 
from the unstimulated (Figure 6.6B) and stimulated (Figure 6.6G) receptors with 
slight co-localization seen in the cells treated with PN502 (Figure 6.6F). 
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Figure 6.7 (A – F) Effect of thioaspirins with PBS on EGF-100 ng/ml 
internalization and EGF co-localization with EEA1. 
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Figure 6.7 Effect of thioaspirins with PBS on EGF-100 ng/ml internalization and 
EGF co-localization with EEA1.  
Confocal images of SW480 CRC cells treated with or without compounds, negative 
control [EGF receptor unstimulated] (A), negative control with EEA1 (B), positive 
control [EGF receptor stimulated] (C), positive control with EEA1 (D), PN590 [ortho-
thioaspirin] (E), PN590 showing EEA1 (F), PN591 [meta-thioaspirin] (G), PN591 
showing EEA1 (H), PN592 [para-thioaspirin] (I), PN592 showing EEA1 (J). Cells were 
treated with 0.5 mM aspirin analogue (pH adjusted with PBS) for 30 min. The EGF 
used is complexed to Alexa Fluor® 555 (100 ng/ml) for 1 h on ice after which it was 
‘chased’ at 37°C for 30 min. The cells were then fixed for 5 min. For EEA1 co-
localization, the slides were then treated with EEA1 primary antibody and a 
corresponding secondary antibody. Images were acquired at 405 nm-DAPI (blue) for 
nucleus, 561 nm-Alexa Fluor (red) for EGF and 488 nm-FITC for EEA1 (green). 
Representative images are shown taken at 40X oil/1.30 oil immersion objective (n=3).  
Scale bar represents 10 μm.
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PN590 clearly perturbs EGF internalization with the formation of small rounded 
vesicle-like structures (Figure 6.7E) and in comparison to the positive and 
negative controls; this compound causes slight co-localization between EGF 
and EEA1. 
Disruption of EGF internalization was not as significant when the cells were 
treated with PN591 (Figure 6.7G) and PN592 (Figure 6.7E). Co-localization of 
EGF and EEA1 was also not observed in cells treated with PN591 (Figure 6.7H) 
and PN592 (Figure 6.7J). This indicated that the thioaspirins also perturbed the 
EGF signalling pathway by inhibiting or delaying the internalization of the 
stimulated receptor.  
 
The cells were then treated with the diaspirins, namely, PN517, PN508 and 
PN524.
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Figure 6.8 (A – F) Effect of diaspirins with PBS on EGF-100 ng/ml internalization 
and EGF co-localization with EEA1. 
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Figure 6.8 Effect of diaspirins with PBS on EGF-100 ng/ml internalization and 
EGF co-localization with EEA1.  
Confocal images of SW480 CRC cells treated with or without compounds, negative 
control [EGF receptor unstimulated] (A), negative control with EEA1 (B), positive 
control [EGF receptor stimulated] (C), positive control with EEA1 (D), PN517 
[fumaryldiaspirin] (E), PN517 showing EEA1 (F), PN508 [diaspirin] (G), PN508 showing 
EEA1 (H), PN524 [m-bromobenzoylsalicylate] (I), PN524 showing EEA1 (J). Cells were 
treated with 0.5mM aspirin analogue (pH adjusted with PBS) for 30 min. The EGF used 
is complexed to Alexa Fluor® 555 (100 ng/ml) for 1 h on ice after which it was ‘chased’ 
at 37°C for 30 min. The cells were then fixed for 5 min. For EEA1 co-localization, the 
slides were then treated with EEA1 primary antibody and a corresponding secondary 
antibody. Images were acquired at 405 nm-DAPI (blue) for nucleus, 561 nm-Alexa 
Fluor (red) for EGF and 488 nm-FITC for EEA1 (green). Representative images are 
shown taken at 40X oil/1.30 oil immersion objective (n=3). Scale bar represents 10 μm.
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PN517 clearly perturbed EGF internalization along with the formation of small 
round vesicle-like structures (Figure 6.8E). EGF and EEA1 highly co-localized 
when the SW480 CRC cells were treated with PN517 (Figure 6.8F). The yellow 
colouring is clearly seen due to the overlapping of red for EGF and green for 
EEA1. Cells treated with PN508 also showed EGF internalization being 
perturbed (Figure 6.8G). However, EGF co-localization with EEA1 was ever so 
slight (Figure 6.8H). PN524 perturbed EGF internalization as well with the 
formation of small rounded vesicle-like structures (Figure 6.8I) but did not cause 
any co-localization between EGF and EEA1 (Figure 6.8J). 
Overall, all the aspirin analogues pH adjusted with PBS perturbed EGF 
internalization with PN517 and PN590 causing significant co-localization 
between EGF and EEA1. These results raised a few questions. Why did PN517 
and PN590 cause co-localization of EGF and EEA1? Could these aspirin 
analogues be forcing the EGF back into the appropriate signalling pathway? In 
other words, is it a pharmacological effect? 
 Could this just be a pH effect? This question was raised because aspirins are 
known to be acidic in nature. Even though the pH had been adjusted with PBS, 
it was decided to use another buffer just to make sure that the effect was not 
due to pH. This is important because an appropriate pH of between 6 and 8 is 
required for tissue culture preparations (Good et al., 1966) and it has been 
asserted that ligand binding can be affected by low pH due to the EGF 
dissociating itself from the receptor (Roepstorff et al., 2009). 
Good et al. (1966) described N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic 
acid (HEPES) as an effective buffering agent for biological research. Thus, 
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HEPES was also used as a buffering agent and the above experiments 
repeated accordingly to confirm if the effects seen are consistent. 
 
 
Figure 6.9 Aspirin analogues dissolved in acetone to 50 mM and further diluted 
with buffer to adjust pH.  
C represents L-15 media without any aspirin analogue. Compounds dissolved in 
acetone to 50 mM concentration and further diluted to 0.5 mM with media (A) 
Compounds dissolved in acetone to an initial 50 mM concentration, diluted to adjust pH 
to 25 mM with HEPES (pH8) and further diluted to a concentration of 0.5 mM with 
media (B). 
 
Compounds dissolved in acetone without a buffering agent clearly changed the 
colour of the media indicating a change in pH (Figure 6.9A). The pH of these 
compounds were therefore adjusted, only this time with HEPES (pH8) (Figure 
6.9B) instead of PBS to see if the same effects on EGF internalization and 
EEA1 co-localization will be seen. All the compounds of interest were studied 
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for effect on EGF internalization; however, only the compounds that had some 
effect on EGF co-localization with EEA1 in previous experiments were included 
for this experimental condition to confirm the effects seen. Thus, PN524, PN517, 
PN508, PN590 and PN502 for comparison were included for the EGF-EEA1 co-
localization experiments with pH being adjusted with HEPES.  
To find out if the effects these aspirin analogues have on the EGF are due to its 
metabolite, salicylate, salicylic acid and diflunisal were also included in the 
experiments. Diflunisal, having salicylate as part of its chemical structure works 
similarly to salicylic acid as an anti-inflammatory and has been found to have  
anticancer properties (Shirakawa et al., 2016)
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Figure 6.10 (A – F) Effect of aspirins and thioaspirins with HEPES on EGF-100  
ng/ml internalization and EGF co-localization with EEA1.
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Figure 6.10 (G – L) Effect of aspirins and thioaspirins with HEPES on EGF-100 
ng/ml internalization and EGF co-localization with EEA1. 
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Figure 6.10 Effect of aspirins and thioaspirins with HEPES on EGF-100 ng/ml 
internalization and EGF co-localization with EEA1.  
Confocal images of SW480 CRC cells treated with or without compounds, negative 
control [EGF receptor unstimulated] (A), negative control with EEA1 (B), positive 
control [EGF receptor stimulated] (C), positive control with EEA1 (D), PN502 [ortho-
aspirin] (E), PN502 showing EEA1 (F), PN590 [ortho-thioaspirin] (G), PN590 showing 
EEA1 (H), PN548 [meta-aspirin] (I), PN549 [para-aspirin] (J), PN591 [meta-thioaspirin] 
(K), PN592 [para-thioaspirin] (L). Cells were treated with 0.5 mM aspirin analogue (pH 
adjusted with HEPES, pH8) for 30 min. The EGF used is complexed to Alexa Fluor® 
555 (100 ng/ml) for 1 h on ice after which it was ‘chased’ at 37°C for 30 min. The cells 
were then fixed for 5 min. For EEA1 co-localization, the slides were then treated with 
EEA1 primary antibody and a corresponding secondary antibody. Images were 
acquired at 405 nm-DAPI (blue) for nucleus, 561 nm-Alexa Fluor (red) for EGF and 488 
nm-FITC (green) for EEA1. Representative images are shown taken at 40X oil/1.30 oil  
immersion objective (n=3). Scale bar represents 10 μm. 
 
Cells labelled as negative control were not subjected to incubation at 37°C 
following EGF binding so as not to stimulate the receptor into internalization. 
Images representing this had the EGF (red dye) seen along the surface of the 
cell membrane (Figure 6.10A). Likewise, negative control that included EEA1 
antibody (green dye) was also subjected to the same condition and had the 
EGF along the cell membrane that did not co-localise with EEA1 (Figure 6.10B). 
The cells that had their slides subjected to incubation at 37°C (EGF ‘chased’) 
for 30 min after EGF binding were observed as having the EGF as large rough-
edged cluster of vesicle-like structures at close proximity to the nucleus (Figure 
6.10C). These images are a representation of the positive control where 
internalization has taken place after ligand stimulation. Figure 6.10D also 
represents the positive control with EEA1 antibody included. Co-localization 
between EGF and EEA1 was not observed even after ligand stimulation. 
PN502 perturbed EGF internalization (Figure 6.10E) but did not cause EGF and 
EEA1 co-localization (Figure 6.10F). Likewise, PN590 also perturbed EGF 
internalization with EGF forming tiny rounded vesicle-like structures that spread 
far away from the nucleus (Figure 6.10G). PN590 did lead to EGF and EEA1 
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co-localizing (Figure 6.10H). PN548 had an effect on the internalization of EGF 
but in this case the vesicle-like structures were not very visible (Figure 6.10I). 
With PN549, the EGF was clearly spread across the cytoplasm as tiny vesicles 
(Figure 6.10J). PN591 and PN592 also had the EGF spread across the 
cytoplasm as tiny vesicle-like structures that were not clustered in close 
proximity to the nucleus (Figures 6.10K and 6.10L respectively).
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Figure 6.11 (A – F) Effect of diaspirins with HEPES on EGF-100 ng/ml 
internalization and EGF co-localization with EEA1.
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Figure 6.11 Effect of diaspirins with HEPES on EGF-100 ng/ml internalization and 
EGF co-localization with EEA1.  
Confocal images of SW480 CRC cells treated with or without compounds, negative 
control [EGF receptor unstimulated] (A), negative control with EEA1 (B), positive 
control [EGF receptor stimulated] (C), positive control with EEA1 (D), PN517 
[fumaryldiaspirin] (E), PN517 showing EEA1 (F), PN508 [diaspirin] (G), PN508 showing 
EEA1 (H), PN524 [m-bromobenzoylsalicylate] (I), PN524 showing EEA1 (J). Cells were 
treated with 0.5 mM aspirin analogue (pH adjusted with HEPES, pH8) for 30 min. The 
EGF used is complexed to Alexa Fluor® 555 (100 ng/ml) for 1 h on ice after which it 
was ‘chased’ at 37°C for 30 min. The cells were then fixed for 5 min. For EEA1 co-
localization, the slides were then treated with EEA1 primary antibody and a 
corresponding secondary antibody. Images were acquired at 405 nm-DAPI (blue) for 
nucleus, 561 nm-Alexa Fluor (red) for EGF and 488 nm-FITC (green) for EEA1. 
Representative images are shown taken at 40X oil/1.30 oil immersion objective (n=3). 
Scale bar represents 10 μm.  
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The negative and positive controls in Figure 6.11 are the same as in Figure 
6.10 because they all belong to the same experimental conditions but 
separated into different figures for easy visualisation and comparison. PN517 is 
seen to disturb the internalization of EGF by causing it to spread across the 
cytoplasm as small rounded vesicle-like structures (Figure 6.11E) instead of 
clustering close to the cytoplasm as in the positive control (Figure 6.11C). Many 
EGF foci co-localized with EEA1 when the cells were treated with PN517. This 
can be observed qualitatively due to the yellow fluorescence seen in close 
proximity to almost all the nuclei (Figure 6.11F). PN508 and PN524 also caused 
the EGF to appear as tiny vesicles spread across the cytoplasm of each cell 
(Figure 6.11G and 6.11I respectively) but with only PN508 causing slight co-
localization between EGF and EEA1 seen as yellow fluorescence in about 10%  
of the sample area (Figure 6.11H).
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Figure 6.12 (A – F) Effect of salicylates with HEPES on EGF-100 ng/ml  
internalization and EGF co-localization with EEA1.
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Figure 6.12 Effect of salicylates with HEPES on EGF-100 ng/ml internalization 
and EGF co-localization with EEA1.  
Confocal images of SW480 CRC cells treated with or without compounds, negative 
control [EGF receptor unstimulated] (A), negative control with EEA1 (B), positive 
control [EGF receptor stimulated] (C), positive control with EEA1 (D) Salicylic acid (E), 
Salicylic acid showing EEA1 (F), Diflunisal (G), Diflunisal showing EEA1 (H). Cells 
were treated with 0.5 mM aspirin analogue (pH adjusted with HEPES, pH8) for 30 min. 
The EGF used is complexed to Alexa Fluor® 555 (100 ng/ml) for 1 h on ice after which 
it was ‘chased’ at 37°C for 30 min. The cells were then fixed for 5 min. For EEA1 co-
localization, the slides were then treated with EEA1 primary antibody and a 
corresponding secondary antibody. Images were acquired at 405 nm-DAPI (blue) for 
nucleus, 561 nm-Alexa Fluor (red) for EGF and 488 nm-FITC (green) for EEA1. 
Representative images are shown taken at 40X oil/1.30 oil immersion objective (n=3). 
Scale bar represents 10 μm.  
  
 
Negative and positive controls for EGF internalization and EGF co-localization 
with EEA1 in Figure 6.12 is the same as in Figures 6.10 and 6.11 because all 
experiments were carried out at the same time and under the same conditions. 
Salicylic acid, a precursor and metabolite of these aspirin analogues also 
disrupted EGF internalization (Figure 6.12E) with EGF as rounded structures 
spread across the cytoplasm. These tiny structures were accompanied by 
larger clusters of EGF, which are also seen in Figure 6.12 F. However, it did not 
cause EGF co-localization with EEA1. Interestingly, diflunisal did not only 
perturb but inhibited EGF internalization altogether (Figure 6.12D) as the EGF 
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can still be seen along the cell membrane similar to the negative control, thus, 
appearing to be unstimulated. Same as the negative control, there was no co-
localization between EGF and EEA1 when cells were treated with diflunisal 
(Figure 6.12H). 
 
Henriksen et al. (2013) had previously suggested that EGF used in a 
concentration greater than 20 ng/ml as a stimulant could lead to the receptor 
following different pathways. This apparently means that low doses of EGF as 
stimulant lead to the internalization of the receptor through the clathrin pathway, 
which ultimately results in the receptor being recycled back to the cell surface 
(Sigismund et al., 2008) but stimulating with high doses of EGF will lead to 
internalization through clathrin-independent pathways (Sigismund et al., 2005). 
Little is known of the clathrin-independent pathway and it could be made up of a 
single or multiple pathways all with similar features (Mayor and Pagano, 2007). 
To address these points it was decided to carry the same experiment only this 
time using a concentration of 20 ng/ml EGF instead of 100 ng/ml as used 
previously. 
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Figure 6.13 (A – F) Effect of aspirin analogues with HEPES on EGF-20 ng/ml 
internalization and EGF co-localization with EEA1.
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Figure 6.13 (G – L) Effect of aspirin analogues with HEPES on EGF-20 ng/ml 
internalization and EGF co-localization with EEA1.
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Figure 6.13 (M – R) Effect of aspirin analogues with HEPES on EGF-20 ng/ml 
internalization and EGF co-localization with EEA1.
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Figure 6.13 Effect of aspirin analogues with HEPES on EGF-20 ng/ml 
internalization and EGF co-localization with EEA1.  
Confocal images of SW480 CRC cells treated with or without compounds, negative 
control [EGF receptor unstimulated] (A), negative control with EEA1 (B), positive 
control [EGF receptor stimulated] (C), positive control with EEA1 (D) PN502 [ortho-
aspirin] (E), PN502 showing EEA1 (F), PN517 [fumaryldiaspirin] (G), PN517 showing 
EEA1 (H), Salicylic acid (I), Salicylic acid showing EEA1 (J), PN590 [ortho-thioaspirin] 
(K), Diflunisal (L), PN548 [meta-aspirin] (M), PN549 [para-aspirin] (N), PN591 [meta-
thioaspirin] (O), PN592 [para-thioaspirin] (P), PN508 [diaspirin] (Q), PN524 [m-
bromobenzoylsalicylate] (R). Cells were treated with 0.5 mM aspirin analogue (pH 
adjusted with HEPES, pH8) for 30 min. The EGF used is complexed to Alexa Fluor® 
555 (20 ng/ml) for 1 h on ice after which it was ‘chased’ at 37°C for 30 min. The cells 
were then fixed for 5 min. For EEA1 co-localization, the slides were then treated with 
EEA1 primary antibody and a corresponding secondary antibody. Images were 
acquired at 405 nm-DAPI (blue) for nucleus, 561 nm-Alexa Fluor (red) for EGF and 488 
nm-FITC (green) for EEA1. Representative images are shown taken at 40X oil/1.30 oil 
immersion objective (n=3). Scale bar represents 10 μm. 
 
Ligand stimulation with 20 ng/ml EGF at 37°C showed the EGF endocysed as 
large round vesicles at close proximity to the nuclei (Figure 6.13C) that did not 
show co-localization with EEA1 (Figure 6.13D). With the negative controls 
however, the EGF can be seen along the surface of the cell membrane (Figure 
6.13A) that also showed no co-localization with EEA1 (Figure 6.13B). Even at 
20ng/ml, the internalized EGF presented as tiny vesicles spread along the 
cytoplasm (Figure 6.13E) consistent with the results observed when the cells 
were stimulated with 100ng/ml EGF. The EGF however, did not co-localize with 
EEA1 (Figure 6.13F). PN517 also caused the EGF to appear as small vesicles 
spread across the cytoplasm (Figure 6.13G).  EGF and EEA1 co-localization 
was also seen, which has been consistent across all the different experimental 
conditions (Figure 6.13H). Salicylic acid also resulted in the EGF to co-localize 
with EEA1 (Figure 6.13J) that was accompanied with disruption of the 
internalization of the EGF (Figure 6.13I). As with the previous experimental 
conditions all the other analogues disturbed the normal appearance of 
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internalized EGF with diflunisal showing the most prominent effect, as the EGF 
still appeared to be along the surface of the cell membrane (Figure 6.13L). 
EGFR internalization pathways could differ between cell lines due to the 
expression of proteins involved in the mechanisms (Henriksen et al., 2013). 
This led to the application of the same experimental conditions on different cell 
lines that also have high EGFR expression. Cell lines found to exhibit this 
characteristic include OE33 and FLO1 oesophageal cancer cell lines (Song et 
al., 2015), which were chosen. 
The EGFR has been found to be overexpressed and responsible for the growth 
progression in a number of cancers including brain tumours, particularly in 
primary glioblastomas (Mendelsohn and Baselga, 2000) and a number of earlier 
studies have shown the EGFR to be an effective target for anti cancer therapy 
in gliomas found in humans (Kang et al., 2006). For this reason it was decided 
to include U251 MG cell line as a candidate for this assay. 
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Figure 6.14 (A – H) Effect of aspirin analogues with HEPES on EGF-20 ng/ml 
internalization in oesophageal cells.
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Figure 6.14 Effect of aspirin analogues with HEPES on EGF-20 ng/ml 
internalization in oesophageal cells.  
Confocal images of OE33 oesophageal cancer cells treated with or without compounds, 
negative control [EGF receptor unstimulated] (A), positive control [EGF receptor 
stimulated] (B), PN502 [ortho-aspirin] (C), PN548 [meta-aspirin] (D), PN549 [para-
aspirin] (E), PN590 [ortho-thioaspirin] (F), PN591 [meta-thioaspirin] (G), PN592 [para-
thioaspirin] (H), PN517 [fumaryldiaspirin] (I), PN508 [diaspirin] (J), PN524 [m-
bromobenzoylsalicylate] (K), Salicylic acid (L), Diflunisal (M). Cells were treated with 
0.5 mM aspirin analogue (pH adjusted with HEPES, pH8) for 30 min. The EGF used is 
complexed to Alexa Fluor® 555 (20 ng/ml) for 1 h on ice after which it was ‘chased’ at 
37°C for 30 min. The cells were then fixed for 5 min. Images were acquired at 405 nm-
DAPI (blue) for nucleus and 561 nm-Alexa Fluor (red) for EGF. Representative images 
are shown taken at 40X oil/1.30 oil immersion objective (n=3). Scale bar represents 
10μm.
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The distance between the cell membrane and the nucleus in OE33 
oesophageal cancer cells appeared to be much closer than in SW480 CRC 
cells and so distinguishing between complete internalization and perturbed 
internalization was more of the position of the EGF rather than the distance 
away from the nucleus. 
The negative control, which has the EGF not stimulated, is seen to have the 
EGF along the surface of the cell membrane (Figure 6.14A). However, when 
stimulated by subjecting the cells to 30 min of incubation time at 37°C, the EGF 
forms large vesicle-like structures that are in much closer proximity to the 
nucleus (Figure 6.14B). This is labelled as the positive control. After cell 
treatment with PN502, about 50% of the EGF had been internalized with the 
other half still along the surface of the cell membrane (Figure 6.14C), thus, 
internalization disturbed. PN548 treated cells showed the EGF as round vesicle 
at close proximity to the nuclei (Figure 6.14D). Very little EGF was along the 
surface of the cytoplasmic membrane after cells were treated with PN549 
(Figure 6.14E) with about 70% along the cell membrane in cells treated with 
PN590 (Figure 6.14F). PN591 and PN508-treated cells presented the EGF 
away from the cytoplasm and closer to the nucleus as small vesicle-like 
structures (Figure 6.14G and 6.14J) respectively. About 60% of the EGF 
remained along the cell membrane in cells treated with PN592 (Figure 6.14H) 
and a large amount also found along the cell surface in cells treated with PN517 
(Figure 6.14I). PN524 disrupted the internalization of some of the EGF (Figure 
6.14K) and for the cells treated with salicylic acid, none of the EGF could be 
seen along the cell membrane (Figure 6.14L) indicating that EGF internalization 
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was not perturbed. For cells treated with diflunisal, most of the EGF could still 
be seen along the surface of the cell membrane (Figure 6.14M). 
The images show that these aspirin analogues also perturb EGF internalization 
in OE33 cells, which means this could be applied to oesophageal cancer. 
A few of the compounds, namely PN502 and PN517 were chosen to see if they 
had the same effect in FLO1 oesophageal cancer and U251 malignant 
glioblastoma (MG) cell lines. These compounds were chosen because PN517 
had the most significant effect on the EGF internalization and PN502 was like a  
standard ‘yard stick’ for comparison.
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Figure 6.15 Effect of aspirin analogues on EGF-20 ng/ml internalization in 
oesophageal cells.  
Confocal images of FLO1 oesophageal cancer cells treated with or without compounds, 
negative control [EGF receptor unstimulated] (A), positive control [EGF receptor 
stimulated] (B), PN502 [ortho-aspirin] (C), PN517 [fumaryldiaspirin]  (D). Cells were 
treated at 0.5 mM (pH adjusted with HEPES, pH8) for 30 min. The EGF used is 
complexed to Alexa Fluor® 555 (20 ng/ml) for 1 h on ice after which it was ‘chased’ at 
37°C for 30 min. The cells were then fixed for 5 min. Images were acquired at 405 nm-
DAPI (blue) for nucleus and 561 nm-Alexa Fluor (red) for EGF. Representative images 
are shown taken at 40X oil/1.30 oil immersion objective (n=2). Scale bar represents 10 
μm.
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The negative control, which are the FLO1 cells with unstimulated EGF appear 
to have the EGF along the surface of the cell membrane (Figure 6.15A). 
However, when stimulated by subjecting to 37°C for 30 min, the EGF gets 
internalized toward the nucleus of each cell (Figure 6.15B). The cells treated 
with PN502 and PN517 in this cell line also appeared to have the EGF farther 
away from the nucleus when compared to the control (Figure 6.15C and 6.15D) 
respectively. But for this cell line the vesicle-like structures of the EGF in the 
treated cells appear to be the same size as the ones in the positive control (the  
EGF that have undergone internalization).
  
301 
 
 
Figure 6.16 Effect of aspirin analogues on EGF-20 ng/ml internalization in MG 
cells.  
Confocal images of U251 MG cells treated with or without compounds, negative control 
[EGF receptor unstimulated] (A), positive control [EGF receptor stimulated] (B), PN502 
[ortho-aspirin] (C), PN517 [fumaryldiaspirin]  (D). Cells were treated at 0.5 mM (pH 
adjusted with HEPES, pH8) for 30 min. The EGF used is complexed to Alexa Fluor® 
555 (20 ng/ml) for 1 h on ice after which it was ‘chased’ at 37°C for 30 min. The cells 
were then fixed for 5 min. Images were acquired at 405 nm-DAPI (blue) for nucleus 
and 561 nm-Alexa Fluor (red) for EGF. Representative images are shown taken at 40X  
oil/1.30 oil immersion objective (n=2). Scale bar represents 10 μm.
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The EGF is seen along the cell membrane in the cells that have not been 
stimulated (Figure 6.16A) and then internalized towards the nucleus in the cells 
that have been ligand stimulated (Figure 6.16B). 
In this particular cell line, however, the compounds appeared not to disturb the 
internalization of EGF.  Cells treated with PN502 appeared as vesicle-like 
structure in close proximity to the nucleus (Figure 6.16C). PN517 also failed to 
disturb the EGF internalization as the EGF is seen in a close distance to the 
nucleus (Figure 6.16D). 
PN502 and PN517 both affected EGF internalization in FLO1 oesophageal cell 
line. However, it did not or the effect was not clear in U251 MG. Perhaps, this 
can be clarified in the future by assessing if the aspirin analogues of interest 
affect any of the tyrosine kinase phosphorylation sites responsible for EGFR  
downstream signalling. 
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6.4.2 Effect of aspirin and its analogues on the Tyrosine phosphorylation 
sites of the EGF receptor 
The binding of EGF activates EGF receptor and this leads to a series of 
signalling pathways involved in multiple mechanisms. This signalling pathway is 
ultimately attenuated by the degradation of the receptor through binding to the 
Cbl site, internalization of Y1045 and sorting into lysosomes for degradation. 
Mutation of this binding site found in cancer cells leads to impaired 
ubiquitination of the receptor (Grovdal et al., 2004). 
A series of phosphorylation sites were examined; namely pEGFR: Y992, Y1045, 
Y1068, Y1101 and Y1173 to detect the ones sensitive to EGF stimulation in 
SW480 cell line and to also find out if the compounds in this study stimulated 
degradation of the EGF receptor. The characteristics and functions of these 
phosphorylation sites have been mentioned in the beginning of this chapter.  
Image J software was used to measure the level of EGFR expression and level 
of phosphorylation. EGFR expression was in relation to the EGFR expressed by 
untreated cells (Control). The level of phosphorylated tyrosine relative to EGF 
stimulation was normalized using the controls. The result gives a comparative 
measure of the phosphorylation level of tyrosine residues to that obtained after 
stimulation with 200 ng/ml of EGF. This particular dose for EGF was chosen 
because it gave the highest signal to the tyrosine kinase antibodies.  
A series of time and dose response/sensitivity tests to EGF was carried out to 
determine the optimal dose and stimulation time of EGF to the different tyrosine 
kinase phosphorylation sites used in this study. 
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The first question that needed to be answered was if these compounds affected 
the expression of EGFR. 
Cells were treated with some of the aspirin analogues buffered with PBS 
(pH7.4) for 24 h and it was discovered that there was a slight change in the  
level of EGFR expression.
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Figure 6.17 EGFR expression levels with aspirin analogues buffered with PBS in 
SW480 cells.  
Cells were treated with 0.5 mM of compounds for 24 h and resolved by SDS-PAGE 
and western blotting. β-Tubulin was used as a loading control (A). Quantitative analysis 
of the blots using Image J software. The average relative density of EGFR expression 
in relation to the control (n=3) (B). 
 
 
In comparison to EGFR expression level of control, the aspirin analogues 
PN502, PN548, PN549, PN590, PN591 and PN592 did not significantly affect 
the EGFR levels under the conditions tested (Figure 6.17A and 6.17B).  
  
306 
 
It was noted that compound addition alters the pH of the tissue culture media 
used (See Figure 6.9A). HEPES is one of the buffers recommended for 
biological studies (Good et al., 1966) and was thus also employed as a 
buffering agent. To this end, HEPES (pH8) was added to make a final 
concentration of 10 mM prior to addition of compounds to cells.
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Figure 6.18 EGFR expression levels with aspirin analogues buffered with HEPES 
(pH8) in SW480 cells.  
Cells were treated with 0.5 mM of compounds for 24 h and resolved by SDS-PAGE 
and western blotting. GAPDH was used as a loading control (A). Quantitative analysis 
of the blots using Image J software. The average relative density of EGFR expression 
is in relation to the control (n=3)  (B). 
 
 
 
The expression levels of EGFR was found to be reduced when SW480 CRC 
cells were treated with 0.5 mM diflunisal with slight changes observed when 
cells were treated with PN517, PN524 and PN529 for a period of 24 h (Figure 
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6.18A and B). This prompted the need to carry out a time-lapse observation of 
receptor expression levels after treatment. If perturbation of EGF internalization 
was visualized after approximately 2 h of treatment and effects of compounds 
on tyrosine kinase phosphorylation sites overnight, could this all be due to 
receptor binding and thus, less signalling travelling through the cell? 
The cells were therefore treated for a period between 1 h and overnight to see 
the effect of these aspirin analogues on EGFR expression levels.
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Figure 6.19 Time response to EGFR expression levels with aspirin analogues in 
SW480 cells.  
Cells were treated with 0.5 mM of compounds (PN502, PN517, PN524 and PN590) for 
0, 1, 3, 6 h and overnight. The protein extracts were resolved by SDS-PAGE and 
western blotting. GAPDH is used as a loading control (A). Densitometry of the blots 
using Image J software (n=3) for PN502 (B) PN517 (C) PN524 (D) and PN590 (E). The 
average relative density of EGFR expression is in relation to the control (0 h). 
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Levels of EGFR expression levels decreased significantly after cells were 
treated for 3 h with PN502 but then levels rose to similar levels to the control 
after 6 h (Figure 6.19B). However, when cells were treated with PN517, EGFR 
levels increased after an hour and then started to decrease when cells were 
treated overnight (Figure 6.19C). A slight increase of EGFR levels was 
observed after 1 h when treated with PN524, which normalised after 3 h (Figure 
6.19D). Expression levels with PN590 dipped after 3 h, shot up after 6 hours of 
treatment and normalised overnight. 
Over a time period of up to about 18 h (overnight), these compounds at 0.5mM 
did not significantly decrease EGFR expression levels which suggests that they 
do not competitively bind to the receptor thereby not causing a reduced signal 
altogether. 
If these compounds are perturbing the internalization of the EGFR, what 
happens to the tyrosine kinase phosphorylation process? Does selective 
phosphorylation of particular sites affect trafficking, or do aspirin analogues 
prevent phosphorylation of multiple sites. The tyrosine kinase phosphorylation 
site responsible for the EGF receptor ubiquitination and degradation is pEGFR 
Y1045. While pY1173, pY1068, pY992 and pY1101 are responsible for 
GRB2/MAPK activation, PLC/PKC activation and PI3K/AKT activation 
respectively. 
In order to find out the optimal dose and exposure time to enable receptor 
stimulation by EGF, the protein extract from SW480 cells exposed to different 
doses of EGF at different times was probed with pEGFR Y1068 antibody.
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Figure 6.20 EGF dose and exposure time optimization for pY1068 and pY1173 
antibodies.  
SW480 CRC cells were exposed to EGF for 5 min at 0.02 ng/ml, 0.2 ng/ml, 2 ng/ml 
and 200 ng/ml. Cells were also exposed to EGF at 200 ng/ml for 2 min, 5 min, 10 min, 
20 min and 30 min. The cells were then lysed in Laemmli buffer, resolved by SDS-
PAGE and western blotting. Bands were seen at about 180 kDa. 
 
 
The highest signal to pEGFR Y1068 was seen to be when exposed to EGF at 
200 ng/ml for 5 min (Figure 6.20). Thus, this exposure dose and time for EGF 
was used as a receptor stimulant when cells were being treated with aspirin and  
its analogues.
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Figure 6.21 EGF dose and exposure time optimization for EGFR stimulation 
against pY1045 antibody.  
SW480 CRC cells were exposed to EGF for 5 min at 0.02 ng/ml, 0.2 ng/ml, 2 ng/ml, 20 
ng/ml and 200 ng/ml. Cells were also exposed to EGF at 200 ng/ml for 1 min, 2 min, 5 
min, 10 min and 15 min. Cell lysates were separated through SDS-PAGE and then 
probed with pEGFR Y1045 antibody. Bands were seen at about 180 kDa. 
 
 
The signal for the phosphorylation of EGF was weak at 1 min and 2 min. 
However, the signal increased at 5 min and then weakened again after 10 min 
(Figure 6.21). Lower doses of EGF did not produce any signal, but this 
appeared at 20 ng/ml and 200 ng/ml. The highest signal for EGF was seen at 
200 ng/ml for 5 min. For this reason, the condition adapted for the cell ligand 
stimulation for extracts to be probed against pY1045 antibody was thus. 
Signals to EGF against pY1173 antibody were very weak at 0.02 ng/ml, 0.2 
ng/ml and 2 ng/ml with the strongest signal at 200 ng/ml (Figure 6.20). The 
exposure time course however showed a different pattern from pY1068 and 
pY1045, with the strongest signal to EGF phosphorylation at 10 min instead of 5 
min. 
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Figure 6.22 EGF dose and exposure time optimization for EGFR stimulation 
against pY992 and p1101 antibodies.  
SW480 CRC cells were exposed to EGF at different concentrations; 0.02 ng/ml, 0.2 
ng/ml, 2 ng/ml, 20 ng/ml and 200 ng/ml for 5 min and also exposed at 200 ng/ml for 
different times; 2 min, 5 min, 10 min, 20 min and 30 min. The cells were then lysed in 
Laemmli buffer, resolved by SDS-PAGE and then probed with pEGFR Y992 antibody 
and pEGFR Y1101 antibody. Signals for pY992 and pY1101 were absent over time 
and at different concentrations. 
 
 
EGF signals were not observed over time with different doses against pY992 
antibody (Figure 6.22). Due to the absence of any EGF signal, indicating that 
phosphorylation at that Y992 site was not turned on after ligand stimulation or 
the Abs not working, this site was not studied further with aspirin analogues. 
Signals for EGF indicating phosphorylation at Y1101 were also not seen at 
different concentrations and exposure times (Figure 6.22). Due to this, further 
studies with aspirin analogues in relation to their effect on pY1101 was halted.  
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SW480 CRC cells were treated with aspirin analogues and lysates probed with 
three antibodies to tyrosine phosphorylation sites, namely; pEGFR Y1068, 
pEGFR Y1045 and pEGFR Y1173 to see if these compounds had any effect on 
EGFR phosphorylation at these sites and ultimately the signalling pathway.  
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Figure 6.23 Effect of aspirin and its analogues on pEGFR tyrosine kinase 
phosphorylation sites.  
C- represents unstimulated and untreated cell while C+ represents untreated cells 
stimulated with 200 ng/ml of EGF for 5 min. GAPDH was used as loading control. 
SW480 CRC cells were treated with 0.5 mM of compounds for 24 h after which ligand 
was stimulated with EGF (200 ng/ml). Cell lysates were separated through SDS-PAGE 
and probed with pY1068, pY1045 and pY1173 antibodies. Image is a representation of 
n=3. Bands were seen at about 180 kDa. 
 
 
With the exception of the thioaspirins, PN590, PN591 and PN592, all the other 
compounds increased the expression of phosphorylation at Y1068 (Figure 6.23), 
which is the site responsible for binding to adaptor proteins GRB2 in order to 
activate the Ras and Mitogen-activated protein kinase (MAPK) pathway (Rojas 
et al., 1996). However, all compounds with the exception of PN502, PN548 and 
PN549 decreased expression of phosphorylation at the Y1045 and Y1173 sites 
(Figure 6.23). It was then decided to carry out a dose response analysis of 
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these compounds on the individual phosphorylation site affected to see if the 
effect is dose-dependent or not. Dose responses on pEGFR Y1045 were 
carried out with PN590, PN591, PN592, PN517, PN508 and PN524. 
Dose response blots were initially performed with doses arranged at a 
descending order. For presentation purposes, the images have been flipped 
horizontally so that the doses appear at an ascending order.
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Figure 6.24 Dose response effect of the thioaspirins on the pEGFR Y1045 and 
Y1173 tyrosine kinase phosphorylation sites.  
C- represents unstimulated and untreated cell while C+ represents untreated cells 
stimulated with 200 ng/ml of EGF for 5 min. β-Tubulin (55 kDa) and GAPDH (35 kDa) 
were used as loading control. SW480 CRC cells were treated with different doses of 
PN590 overnight (A) Cells treated with PN591 (B) Cells treated with PN592 (C). The 
cells were then lysed in Laemmli buffer, resolved by SDS-PAGE and western blotting 
using antibodies specific to pY1045 and pY1173. Images are a representation of n=3. 
pEGFR Tyr bands were detected around 180 kDa. 
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The signal that indicates phosphorylation at pY1045 started to get decreased by 
PN590 at 0.01 mM. But this increased at 0.03 mM and then started to decline at 
0.1 mM (Figure 6.24A). Complete disappearance in the signal for 
phosphorylation at pY1045 and pY1173 by PN590 at 0.3 mM and 0.5 mM 
concentrations was observed (Figure 6.24A). At pY1173, signal for 
phosphorylation increased at 0.01 mM, which then started to decrease steadily 
at 0.03 mM to a complete disappearance of any visible bands at 0.3 mM and 
0.5 mM (Figure 6.24A). PN591 appeared to abolish the signal for tyrosine 
kinase phosphorylation on both sites at 0.5 mM. However, the signal for 
phosphorylation appreciated at Y1045 from 0.01 mM, which started to decrease 
at 0.3 mM (Figure 6.24B). At the pY173 site, there was a slight decrease in 
phosphorylation at 0.01 mM, which then increased at 0.03 mM concentration 
and then steadily decreased again with an increase in the concentration of the 
thioaspirin. (Figure 6.24B). This could be due to the inhibition of a negative 
regulator selectively affected at lower concentrations, with another event taking 
place at higher concentrations. PN592 also caused a decrease in 
phosphorylation in a dose dependent manner at Y1045 and Y1173 tyrosine 
kinase sites (Figure 6.24C). These isomers of thioaspirin, PN591 and PN592 
have shown similarities in their effects on SW480 cell line in previous assays, 
which are different from the effect of the ortho-thioaspirin, PN590. This could be 
because of the position of the thiol group on the meta- and para- positions of 
the benzene ring being different from the ortho- position affects their  
pharmacological action.
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Figure 6.25 Dose response effect of ‘diaspirins’ on the pEGFR Y1045 and Y1173 
tyrosine kinase phosphorylation sites. 
C- represents unstimulated and untreated cell while C+ represents untreated cells 
stimulated with 200 ng/ml of EGF for 5 min. GAPDH (35 kDa) was used as a loading 
control. SW480 CRC cells were treated with different doses of PN508 overnight (A) 
Cells treated with PN517 (B) Cells treated with PN524 (C). The cells were then lysed in 
Laemmli buffer, resolved by SDS-PAGE and western blotting using antibodies specific 
to pY1045 and pY1173. Images are a representation of n=3. pEGFR Tyr bands were 
detected around 180 kDa. 
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For the ‘diaspirins’, there was a decrease in the signal for phosphorylation at 
the Y1045 site in relation to the control stimulated with 200 ng/ml EGF at 0.3 
mM and 0.5 mM PN508. There was an increase in phosphorylation at Y1045 
when cells were treated with 0.1 mM and 0.03 mM PN508 (Figure 6.25A). In 
relation to phosphorylation of tyrosine kinase Y1173, PN508 only caused a 
decrease in signal at 0.5 mM concentration. A decrease in phosphorylation at 
Y1045 site by PN517 was observed at 0.03 mM and more prominently at 0.5  
mM (Figure 6.25B). The reduction in signal for pY1173 was seen at 0.1 mM, 
which further decreased at 0.3 mM and 0.5 mM (Figure 6.25B). The effect of 
PN517 on phosphorylation at Y1173 appears to decrease in a dose-dependent 
fashion. PN524 appeared to have a dose relative inhibitory effect on the signal 
for pY1045 (Figure 6.25C). However, there was decrease in signal for Y1173 
phosphorylation site at 0.3 mM, which seemed to increase at 0.5 mM (Figure 
6.25C). Thus, the effect of PN524 on Y1173 tyrosine kinase site appears not to 
be dose-dependent. 
 
Qualitative EGF internalization assay using immunocytochemistry, showed 
internalization of EGF to be perturbed after cells were treated with these aspirin 
analogues for a period of 2 h. It was therefore decided to also treat SW480 cells 
with these compounds for the same time period in order to find out if there is 
any effect on pY1045 site, which is responsible for the ubiquitination of the 
receptor. This experimental condition is to mimic that of the qualitative EGF 
internalization confocal assay that was based on immunocytochemistry (Figure 
6.6 to 6.13). 
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Figure 6.26 Effect of aspirin and its analogues on pEGFR Y1045 site.  
C- represents unstimulated and untreated cell while C+ represents untreated cells 
stimulated with 200 ng/ml of EGF for 5 min. GAPDH was used as loading control. 
SW480 CRC cells were treated with 0.5 mM of compounds buffered with HEPES (pH8) 
for 2 h. Cell lysates were then separated through SDS-PAGE and probed with pY1045 
antibody (A). Quantitative analysis using Image J of signals to pY1045 (n=3) (B). 
Bands for pY1045 were observed at 185 kDa. 
 
 
PN517 and PN508, both ‘diaspirins’, decreased the signal for the pY1045 
antibody after treatment of SW480 CRC cells for 2 h (Figure 6.26B) with the 
salicylate-like compounds, salicylic acid and diflunisal increased the signal for 
the same phosphorylation site (Figure 6.26B). However, this change in 
phosphorylation was not significant. The thioaspirins, PN590 and PN591 
however significantly increased phosphorylation at Y1045 site after 2 h of 
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treatment. Surprisingly, after 2 h of treatment with the aspirins, PN502, PN548 
and PN549, there was a slight, non-significant decrease in signal for pY1045 in 
relation to the control stimulated with 200 ng/ml of EGF (Figure 6.26B). 
 
In order to study the possible effects of these aspirin analogues downstream of 
the EGFR signalling pathway, attempts were made to find out their effects on 
stat-3 and phosphorylation of stat-3 at Y705. 
 
 
Figure 6.27 Effect of aspirin analogues on stat-3. 
C+ represents control/untreated cells. All cells were stimulated with 200 ng/ml of EGF 
for 5 min. β-Tubulin (55 kDa) was used as loading control. First attempt as  ‘test-run’ 
without loading control of the treatment of SW480 CRC cells with 0.5 mM of aspirin 
analogues buffered with HEPES (pH8) overnight. Cell lysates were resolved using 
SDS-PAGE and probed with stat-3 primary antibody (A). Second attempt of treatment 
with analogues under the same conditions and probed with antibody specific to stat-3 
(B). Cells were treated with increasing doses of PN517 and then lysed with Laemmli 
buffer, resolved by SDS-PAGE and probed with stat-3 antibody. 
 
 
On the first attempt, although without a protein loading control, PN517 was 
found to inhibit the expression of stat-3 (Figure 6.27A). However, after two 
repeats accompanied by a loading control, it was found out that none of the 
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compounds had an effect on stat-3 expression; thus, result was not 
reproducible (Figure 6.27B). In the absence of a loading control in the first 
attempt, it is likely that the result seen was false and was due to difference in 
protein volume loaded into SDS-gel wells. To make sure that PN517 definitely 
did not have any effect on stat-3, a dose-dependent assay was carried out 
using doses that ranged from 0.01 mM to 0.5 mM (Figure 6.27C). It was 
observed that PN517 had an effect on stat-3 expression at 0.1 mM (Figure 
6.27C). Could this be because PN517 is affecting another target that indirectly 
affects stat-3? However, this was not investigated further due to time constraint. 
 
If none of the compounds affected the protein stat-3, could they affect the 
phosphorylation of stat-3? An effect on the phosphorylation of stat-3 indicates 
an effect on the STAT-signalling pathway as phosphorylation of stat-3 at Y705 
allows for stat dimerization and subsequent transcription activation (Schindler 
and Darnell, 1995). To answer this question SW480 CRC cells were treated 
with some aspirin analogues and lysates then probed with phospho-stat-3 
(Y705) antibody after resolution with SDS-PAGE. Stat-3 was used as a loading 
control since it appeared to be unaffected by the compounds at 0.5 mM. 
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Figure 6.28 Effect of aspirin analogues on stat-3 and Tyr705 phosphorylation.  
SW480 CRC cells were treated with 0.5 mM of compounds overnight and stimulated 
with 200 ng/ml of EGF for 5 min. Note the multiple bands around the expected region 
for Tyr705 band detection. 
 
 
The bands specific to Y705 was not clear as multiple bands around the region 
were seen (Figure 6.32). Since the band to stat-3 was observed at 100 kDa, the 
band to Y705 was expected around that region. This could be an issue of 
unspecificity of the antibody. In the absence of any clear bands and the period 
of this study coming to an end, investigation regarding stat-3 and Y705 had to 
be halted and saved for future studies. 
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6.5 Discussion 
The EGFR signalling pathway is complex (Figure 6.2) and internalization is a 
significant component of that pathway (Goh et al., 2010, Orth et al., 2006). 
Herein, it is suggested that aspirin and its analogues can rapidly perturb EGF 
receptor internalization in SW480 CRC cells (Figures 6.6 to 6.13) and in 
oesophageal cancer cell lines (Figure 6.14 and 6.15). Thus, causing a delay or 
halt in EGFR signalling.  
Ligand binding can be affected by low pH due to the EGF dissociating itself 
from the receptor (Roepstorff et al., 2009). Perturbation of internalization due to 
possible competitive binding between compounds with EGF and change in pH 
has been addressed by a control binding assay and buffering compounds with 
HEPES (Figures 6.5 and 6.9) respectively. In another assay, using western 
blotting, EGFR expression was not significantly different from the control when 
SW480 CRC cells were treated with aspirin and its analogues buffered with 
PBS for 24 h (Figure 6.17). When the same experiment was carried out with 
HEPES being the buffer of choice, diflunisal>PN524>PN517>PN529>salicylic 
acid decreased EGFR expression (Figure 6.18). PN517, PN524 and diflunisal 
are all diaspirins, which could explain why they exhibit similar effects to each 
other and their metabolite, salicylic acid. Salicylic acid, being acidic will cause 
the dissociation of any ligand present from the receptor (Roepstorff et al., 2009) 
and may provide a pocket for itself to bind onto the receptor instead. However, 
over a time period of up to about 18 h (overnight), these compounds at 0.5 mM 
did not significantly decrease EGFR expression levels (Figure 6.19). HEPES 
was the buffer of choice later adapted because it is considered as an effective 
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buffering agent for biological research (Good et al., 1966). EGF used in a 
concentration greater than 20 ng/ml as a stimulant could lead to the receptor 
following different pathways (Henriksen et al., 2013), which could either be 
clathrin dependent or independent (Sigismund et al., 2005) with little being 
known of the independent pathway (Mayor and Pagano, 2007). It was thus 
decided to use 20 ng/ml EGF to stimulate the receptor in order to find out if 
these aspirin analogues disrupt recycling of the EGFR (Sigismund et al., 2008). 
Aspirin and its analogues perturbed EGF internalization when the receptor was 
stimulated with 20 ng/ml of EGF (Figure 6.13), which suggests that these 
aspirin analogues may prevent or delay the EGFR from being recycled back to 
the cell surface for continuous stimulation of the signalling pathway because 
stimulating the EGFR with low doses of EGF results in the receptor being 
recycled back to the cell surface (Sigismund et al., 2008). Perturbation of 
receptor endocytosis by these aspirin analogues at 20 ng/ml in SW480 CRC 
cell line (Figure 6.13), OE33 oesophageal cell line (Figure 6.14) and FLO1 
oesophageal cell line (Figure 6.15) could lead to the prevention of receptor 
recycling and thus attenuation of repeated signalling and eventual ubiquitination 
of the receptor. 
 
Post internalization, the EGFR is translocated to the nucleus where it 
associates with genes responsible for cell proliferation and thus acting as a 
transcription factor (Lin et al., 2001). The EGFR also phosphorylates PCNA, 
while in the nucleus thereby disrupting interaction with MutSα and MutSβ, which 
are mismatch-recognition proteins. This consequently leads to interruption of 
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DNA MMR and the proliferation of cells that have damaged DNA, potentially 
causing genetic instability (Ortega et al., 2015). Time-lapse assay using 
Confocal Live imaging has further proven that aspirins do perturb internalization 
of the EGF (Figure 8.22). It has thus been discovered that aspirin and its 
analogues do prevent the translocation of EGF (and hence EGFR) from the 
surface of the cell membrane towards the nucleus, which implies that these 
compounds may have the ability to promote genetic stability in cancer as they 
will prevent inaccuracy in DNA replication and thus prevent tumour progression. 
This correlates with observed increase in the expression of hMLH1, hPMS2, 
hMSH2 and hMSH6 DNA MMR proteins in CRC cell lines (SW480, HCT116, 
HCT+chr3) after treatment with aspirin (Goel et al., 2003). 
 
Another cause for tumour progression is the sustained activation of Akt, which 
is dependent on EGFR internalization (Goh et al., 2010). This proposal concurs 
with Wheeler et al. (2010) and Chan et al. (1999) where it is mentioned that the 
activation of Akt/mTor pathway results in enhanced cell proliferation by 
phosphorylating caspase-9, an apoptosis pathway enzyme (Cardone et al., 
1998) and BAD, a BCL-2 family member (Datta et al., 1997). Thus, perturbation 
of receptor internalization will lead to the inactivation of the Akt/mTor pathway, 
which is favourable in cancer therapy.  
 
In a study carried out in OVCAR-3 ovarian cancer cell line, which 
overexpresses COX1 enzyme in vitro, 1 mM aspirin was found to inhibit EGFR 
associated Y1068 phosphorylation (Cho et al., 2013) as opposed to what was 
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observed with 0.5 mM of aspirin and its analogues with the exception of the 
thioaspirins (Figure 6.23). However, this could be a COX1 dependent effect for 
aspirins because of COX1 being overexpressed in OVCAR-3 ovarian cell line 
(Cho et al., 2013) and low levels detected in SW480 (Richter et al., 2001), 
which is the cell line used in this study.  
 
Furthermore, cyclin D1, an important protein responsible for cell cycle 
regulation at G1 to S phase transition (Malumbres and Barbacid, 2009) has 
been found to be inhibited by PN508 [referred in paper as DiA] and PN517 
[referred in paper as F-DiA] (Claudius et al., 2014) and of which is found to 
interact with nuclear EGFR to cause cell proliferation (Lin et al., 2001).  
Diflunisal, a salicylate-like compound with anti-cancer properties (Shirakawa et 
al., 2016) appeared to totally inhibit EGF internalization (Figure 6.12G, 6.13L), 
suggesting that it might inhibit signalling of the EGFR pathway. The effect of 
diflunisal on the EGFR could be an addition to its mechanism of action as 
potential oral therapy for patients with acute myelogenous leukaemia 
(Shirakawa et al., 2016). 
 
EGFR is stimulated when bound to EGF, which is then followed by 
internalization of the receptor and its delivery to early EEA1 endosomes (Zoncu 
et al., 2009), whereby the receptor is either recycled or delivered to the 
lysosomes for degradation (Beas et al., 2012, Platta and Stenmark, 2011, 
Sorkin and von Zastrow, 2009). EEA1 is an effector protein required at the early 
endosome, which is a compartment responsible for the sorting of ligand-
  
329 
 
receptor complexes into late endosomes and lysosomes for degradation or 
back to the cell surface for recycling (Mu et al., 1995, Shepherd, 1989). This 
compartmentalization is part of the signalling pathway of the EGFR and takes 
place after endocytosis of a receptor (Schlessinger, 2000). However, in SW480  
cells, it was observed that EGF did not co-localise with EEA1 even after 
stimulation (Figure 6.6D, 6.10D and 6.13D), which suggests that the receptor 
may not have been delivered into the endosomes. Previous studies have 
demonstrated that P53 is involved in the production and regulation of 
endosomes and exosomes responsible for sorting of receptors either for 
recycling or degradation (Sun et al., 2016, Yu et al., 2006, Yu et al., 2009) and 
SW480 cells harbour a mutated TP53 (Din et al., 2010), which could mean that 
there is a disruption in the regulation of these endosomes, thus, the absence of 
co-localization of EGF with EEA1. Nevertheless, PN517, a diaspirin (Figure 
6.8F, 6.11F and 6.13H) seems to have restored the regulation of the 
endosomes for it forced the co-localization of EGF and EEA1. PN590, a 
thioaspirin (Figure 6.7F and 6.10H) also slightly forced some EGF to co-localize 
with the EEA1. The possible regulation of endosomes by these aspirin 
analogues may be due partly to the parent drug and partly to the salicylate 
moiety because salicylic acid (Figure 6.12F and 6.13J) also forced EGF to co-
localise with EEA1. However, further research into this is needed to find out if 
these aspirin analogues also restore regulation of endosomes rich in Rab5 for 
early endosomes, Rab4 or Rab11 for endosomes responsible for receptor 
recycling and Rab7 for late endosomes responsible for the degradation of the 
EGFR (Flores-Rodriguez et al., 2015, Zerial and McBride, 2001). These late 
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endosomes, also known as lysosomes are armed with lysosomal proteins such 
as LAMPs and are as a result of matured EEA1 that acquire Rab7 (Huotari and 
Helenius, 2011). If lysosomes are the final destination for stimulated EGFR, the 
receptor is then guaranteed to undergo degradation. This is particularly 
important because signalling continues even when EGFR has been delivered 
into the endosomal system (Di Guglielmo et al., 1994).  
 
It is therefore proposed that the signal of the EGFR signalling pathway is 
attenuated or dulled by these compounds, which led to the question of what 
happens at the ubiquitination phase of this receptor? The action of these 
compounds on tyrosine phosphorylation means there might be an effect 
downstream. The maximal dose and time of exposure for EGF used to 
stimulate the phosphorylation of specific sites (Y1068, Y1045 and Y1173) was 
found to be 200 ng/ml for 5 min (Figure 6.20 and 6.21). However, no signal was 
observed against pY992 and pY1101 antibodies (Figure 6.22). Phosphorylation 
at Y1101 is Src-dependent and not ligand induced (Biscardi et al., 1999). Thus, 
phosphorylation is not likely to be activated by EGF stimulation. Another 
possibility could be that this particular cell line undergoes serine/threonine 
instead of tyrosine kinase phosphorylation, thus, having a kinase inactive 
mutant, which does not undergo autophosphorylation on those particular 
tyrosine residues. This happens if the receptor is missing a portion/portions of 
the carboxy-terminal tail (Zwang and Yarden, 2006). Frantz and O’Neill, (1995) 
believed that the effect of salicylates on tyrosine kinases were non-specific. 
However, contrary to this and in agreement with Kopp and Gosh, (1994), it has 
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been found that these salicylate compounds have specific effects on various 
phosphorylation sites. The thioaspirins decreased phosphorylation at Y1068, 
while the aspirins and ‘diaspirins’ increased phosphorylation on the same Tyr 
site (Figure 6.23). In addition, all the compounds with the exception of PN502, 
PN548 and PN549 decreased phosphorylation at Y1045 and Y1173 (Figure 
6.23). With the compounds perturbing EGF internalization, it was quite 
unexpected for them to also inhibit the phosphorylation of the receptor at the 
site responsible for ubiquitination. However, the process of EGFR 
internalization is independent of tyrosine phosphorylation (Wang et al., 2005). In 
relation to the effect of these compounds on the phosphorylation sites (Y1045 
and Y1173) studied (Figure 6.24 and 6.25), dose-dependent effects were 
observed with some of these compounds, which correlates well with results 
reported previously (Wang and Xie, 2007). Aspirin and its analogues with the 
exception of PN590 did not inhibit EGFR phosphorylation at Y1068 (Figure 
6.23), but perturbed EGF internalization (Figure 6.6 to 6.13). This is opposed to 
the notion that EGFR internalization is as a result of tyrosine phosphorylation 
(Schmidt et al., 2003, Sorkina et al., 2002) but correlates with the early notion 
that the two processes are independent of each other (Felder et al., 1992, 
Felder et al., 1990, Honegger et al., 1987). However, these differences in 
opinion could be due to different cell lines having different requirements for the 
degree of EGFR phosphorylation and its involvement in EGFR internalization  
(Jiang et al., 2003).
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Chapter 7. General Discussion and Future Studies 
7.1 General Discussion 
The compounds with single benzene rings, aspirin (PN502) and its isomers, 
PN548 and PN549 exhibited their effects in a similar manner. Likewise the 
thioaspirins, PN590, PN591 and PN592 had similar effects different from the 
‘diaspirins’, PN517, PN508 and PN524, which are made up of two benzene 
rings. Similarities in the effects (Table 7.1) exhibited by these compounds on 
SW480 cells may thus be attributed to their chemical structures (Table 3.3).  
In this study, 5-FU decreased the expression of p21 (Figure 5.2 and 5.3), 
however when used in combination with 3-bromopyruvic acid, an inhibitor of 
energy metabolism, p21 expression was increased in SW480 cells (Chong et al., 
2017). Lung cancer cells, Calu-6 and colon cancer cells, HCT 116 treated with 
100 μM of 5-FU for a period of 24 h also down-regulated p21 expression 
(Esposito et al., 2014). This study has the same dosing and duration of 
treatment with 5-FU as ours and also agrees with the findings in this study. 
Along with 5-FU, aspirin and the thioaspirins also decreased the expression of 
p21 (Figure 5.3). On the other hand, the isomers of aspirin, PN548 and PN549 
appear to induce apoptosis in SW480 cells through the BCL2/BAX pathway 
(Figure 5.4) of which was achieved by combining 5-FU and dimethoxycurcumin 
in SW480 CRC cells (Zhao et al., 2017). The effect of aspirin and the 
thioaspirins via p21 appear to inhibit the oncogenic activity of the protein 
(Karimian et al., 2016) and thus hopefully lead to better disease free survival in 
patients with colorectal cancer (Esposito et al., 2014, Noske et al., 2009, Rau et 
al., 2003). The apoptotic effect of these compounds is reflected in the ICC 
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studies using YO-PRO-1® and PI fluorescence dyes as positive stains for 
apoptosis and necrosis respectively (Figure 5.6 to 5.11). Flow analysis also 
show apoptosis (Figure 5.6 to 5.12) accompanied by a large percentage of late 
apoptotic/necrotic cells, which could be attributed to harvesting of adherent cells 
even though this percentage is significantly lower than the percentage of 
necrotic cells caused by treatment with H2O2, which was used as the positive 
control for necrosis (Figure 5.13). One of the shortcomings of this analysis is 
the inability to distinguish between late apoptotic and necrotic/dead cells, which 
is a disadvantage as cells could still be undergoing apoptosis but are then 
stained with PI and clustered in the UR (Figure 2.2) quadrant thereby being 
forced to be labelled as necrotic or dead cells. 
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Compounds Cell 
proliferation 
(MTT 
assay) 
% 
Apoptosis 
(16 h) 
% 
Apoptosis 
(40 h) 
Apoptosis 
(ICC) 
p21 BCL2 BAX Synergy 
at ED50 
pY1068 pY1045 pY1173 EGF 
internalization 
EGF co-
localization 
with EEA1 
5-FU      
 
 
 
 
 
 
      
Staurosporine  41.6 21.4 +  x x       
PN502 
(aspirin) 
 0.8 11.0 +  x x CP, OX  x x − x 
PN548  1.5 8.7 +    CP, OX  x x − x 
PN549  1.5 12.8 +    CP, OX  x x − x 
PN590  6.2 5.9 +  x x −    −− + 
PN591  0.2 1.9 +  x x −    − x 
PN592  2.5 3.6 +  x x −    − x 
PN517        CP, OX, 
CB 
   −− +++ 
PN508        CP, OX    −  
PN524        CP, OX    − x 
Salicylic acid            −− + 
Diflunisal            −−− x 
Table 7.1 Summary of the effect of aspirin analogues on SW480 CRC cells.
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EGFR expression was not significantly different from the control when SW480 
cells were treated with aspirin and its analogues buffered with PBS for 24 h 
(Figure 6.17). When the same experiment was carried out with HEPES being 
the buffer of choice, diflunisal>PN524>PN517>PN529>salicylic acid decreased 
EGFR expression. In chapter three, it was found out that PN517 metabolises 
into salicylate at a faster rate than PN502 (Figure 3.14). Furthermore, PN517, 
PN524 and diflunisal are all diaspirins, which could explain why they exhibit 
similar effects to each other and their metabolite, salicylic acid. Salicylic acid, 
being acidic will cause the dissociation of any ligand present from the receptor 
(Roepstorff et al., 2009) and may provide a pocket for itself to bind onto the 
receptor instead. However, over a time period of up to about 18 h (overnight), 
these compounds at 0.5 mM did not significantly decrease EGFR expression 
levels during the experimental study.  
 
These compounds perturbed EGF internalization in SW480 cells when the 
receptor was stimulated with both 100 ng/ml (Figure 6.6 to 6.12) and 20 ng/ml 
of EGF (Figure 6.13) and under PBS and HEPES buffering systems. 
Perturbation of EGF internalization by these compounds was also observed in 
oesophageal cancer cell lines, OE33 (Figure 6.14) and FLO1 (Figure 6.15). 
This effect will eventually lead to a decrease in proliferation of cancer cells via 
preventing translocation of the EGFR into the nucleus where it acts as a 
transcription factor (Lin et al., 2001). The EGFR also phosphorylates PCNA, 
while in the nucleus thereby disrupting interaction with MutSα and MutSβ, which 
are mismatch-recognition proteins. This consequently leads to interruption of 
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DNA MMR and the proliferation of cells that have damaged DNA, potentially 
causing genetic instability (Ortega et al., 2015). The perturbation of EGF by the 
aspirins was also observed when a time-lapse assay over a 60 min period using 
confocal live imaging was adopted (Screen shots in Figure 8.22 and Movies 
on DVD). It has thus been discovered that aspirin and its analogues do prevent 
the translocation of EGF from the surface of the cell membrane towards the 
nucleus, which implies that these compounds may have the ability to promote 
genetic stability in cancer as they will prevent inaccuracy in DNA replication and 
thus prevent tumour progression. This correlates with observed increase in the 
expression of hMLH1, hPMS2, hMSH2 and hMSH6 DNA MMR proteins in CRC 
cell lines (SW480, HCT116, HCT+chr3) after treatment with aspirin (Goel et al., 
2003). 
 
Furthermore, the results show that the aspirin analogues do affect 
phosphorylation at Tyr1068, in that the thioaspirins, PN590, PN591 and PN592 
decrease phosphorylation at Y1068 while the aspirins and ‘diaspirins’ caused 
an increase in phosphorylation at Y1068 (Figure 6.23), which might suggest 
that binding of GRB2 to the docking site is regulated, thus could lead to the 
regulation of EGF-induced Ras/MAPK activation and the signalling pathway 
altogether. This agrees with published data which shows that in CRC cell lines 
with high basal EGFR phosphorylation at the Y1068 site correlated with 
synergistic effects when oxaliplatin and gefitinib were used in combination in 
that particular cell line and low basal pY1068 was related to antagonistic effects 
between these compounds (Van Schaeybroeck et al., 2005). It has also been 
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found that the thioaspirins did not exhibit synergistic effect in SW480 CRC cells 
at ED50 with oxaliplatin (Table 4.6). Thus, an increase in phosphorylation at 
Y1068 by the aspirins and ‘diaspirins’ encouraged synergistic effects when 
combined with oxaliplatin. Nevertheless, further studies will be needed to see 
the particular effects these compounds have on what particular protein in the 
EGFR downstream signalling pathway.  
The phosphorylated Y1045 is able to bind to Cbl, which eventually leads to 
endocytosis of the receptor (Levkowitz et al., 1998). These aspirin analogues 
with the exception of PN502, PN548 and PN549 decreased phosphorylation at 
this docking site, thus assumed to lead to the perturbation of EGF 
internalization seen in the qualitative ICC assay. This will eventually affect 
repetition of signalling (Figures 6.6 to 6.13). 
It was observed that EGF did not co-localise with EEA1 even after stimulation in 
SW480 cells (Figure 6.6D, 6.10D and 6.13D), which suggests that the receptor 
may have not been delivered into the endosomes. Previous studies have 
demonstrated that P53 is involved in the production and regulation of 
endosomes and exosomes responsible for sorting of receptors either for 
recycling or degradation (Sun et al., 2016, Yu et al., 2006, Yu et al., 2009) and 
SW480 CRC cells harbour a mutated TP53 (Din et al., 2010), which could mean 
that there is a disruption in the regulation of these endosomes, thus, the 
absence of co-localization of EGF with EEA1. Nevertheless, PN517, a diaspirin 
(Figure 6.8F, 6.11F and 6.13H) seems to have restored the regulation of the 
endosomes for it forced the co-localization of EGF and EEA1. PN590, a 
thioaspirin (Figure 6.7F and 6.10H) also slightly forced some EGF to co-
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localize with the EEA1. The possible regulation of endosomes by these aspirin 
analogues may be due partly to the parent drug and partly to the salicylate 
moiety because salicylic acid (Figure 6.12F and 6.13J) also forced EGF to co-
localise with EEA1. In addition, it has been found out that these aspirin 
analogues rather quickly breakdown into their precursor salicylate (Figure 3.13). 
 
A previous study has found PN508 (diaspin) and PN517 (fumaryldiaspirin) 
referred to as DiA and F-DiA respectively to inhibit the stimulation of NFκB in a 
number of CRC cell lines (Claudius et al., 2014) and in this study it was found 
out that these aspirin analogues also perturbed internalization of the EGFR and 
some decreased phosphorylation at Y1045 and Y1173 (Figure 6.23). 
Endogenous EGF as a ligand to the EGFR has been reported to be involved in 
wound healing process (Schultz et al., 1991, Werner and Grose, 2003) and its 
inhibition by aspirin via disruption of the hydrophobic surface in mucosal cell 
membrane (Barrett et al., 2012), thus leading to unhindered spreading of gastric 
acid and eventually GI toxicity (Lichtenberger et al., 2006, Lichtenberger et al., 
2012, Pereira-Leite et al., 2013), which in cancer cell membranes could also 
cause perturbation of the lipid membrane layer (Alsop et al., 2015) leading to 
disruption of EGF internalization. This disruption in the lipid bilayer arrangement 
of EGFR membrane, will surely also disrupt the cascade of signalling pathways. 
EGFR activates NFκB in a number of cancers (Jorissen et al., 2003, Shostak 
and Chariot, 2015) such as in A431 cells when stimulated by EGF (Sun and 
Carpenter, 1998) via phosphorylation of IκBα and degradation thus rendering it 
incapable of masking NFκB nuclear signals, which ultimately results in nuclear 
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translocation of NFκB followed by a series of proliferative signals (Beg et al., 
1992, Cautain et al., 2015, Habib et al., 2001). This interplay between EGFR 
and NFκB is as a result of the hyperactivation of NFκB in cells that overexpress 
EGFR (Lehman et al., 2017), which is found in most CRC cell lines (Spano et 
al., 2005). EGFR has also been found to activate NFκB in cultured rat aortic 
smooth muscle cells (Obata et al., 1996), in a number of oestrogen receptor-
negative breast cancer cell lines (Biswas et al., 2000) and also results in the 
promotion of lung carcinogenesis (Saxon et al., 2016). The effect of these 
aspirin analogues on the EGFR is thus beneficial in cancer therapy. With this in 
mind, the mechanism of action for these aspirin analogues cannot be concluded 
until further studies are carried out on the effects to the downstream EGFR 
signalling pathway. Although PN590 has been found to have cytotoxic and 
synergy effects with platinum compounds in SW480 cell line, the potential of 
this compound as an anti cancer compound is let down by its ability to cause 
nuclear co-localization of β-catenin when dissolved in DMSO (Figure 5.14B), 
however, this effect is not seen when dissolved in acetone (Figure 5.14D). 
Thus, dissolution of PN590 in DMSO should be avoided.  
Clearly, there are limitations to some of the experimental designs in this study. 
There is therefore an awareness that further work need to be carried out in 
order for a conclusion to be drawn. Having said this, more light has been shed 
on how aspirin and its analogues act in SW480, OE33 and FLO1 cancer cell 
lines and it is believed that there is hope for these aspirin analogues to be 
adapted as a more affordable, less toxic therapy for the prevention, treatment  
and management of cancer. 
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7.2 Future Studies 
Radioligand binding of the EGFR with EGF could act as an assay that will show 
clearly whether these aspirins act as antagonists by measuring the amount of 
EGF still bound to the receptor after treatment with aspirin analogues as 
compared to the amount of bound EGF without treatment with the aspirin 
analogues. 
In this study, it has been shown that aspirin analogues perturb EGF 
internalization. Could these aspirin analogues then be blocking the clarithrin-
dependent pathway in order to mediate degradation of the EGFR by delivering 
the receptor to the lysosomes? In addition, do PN517, PN590 and salicylic acid 
promote delivery of EGFR into late endosomes (Rab7 and Lamp2) for 
degradation or with Rab4 and Rab11, recycling endosome markers, remains 
open (Flores-Rodriguez et al., 2015, Zerial and McBride, 2001). In other words, 
do these compounds drive co-localization of EGF with Rab7, Lamp2, Rab4 or 
Rab11? 
These aspirin analogues have been found out to perturb EGF internalization in 
SW480 cancer cell lines. Could this effect extend to colonocytes from healthy 
colon tissues? 
The phosphorylation of PCNA by EGFR interferes with its interaction with 
mismatch-recognition proteins MutSα and MutSβ, which leads to the 
deactivation of DNA mismatch repair (MMR) process (Ortega et al., 2015). Can 
aspirin and its analogues promote genome stability in cancer by inhibiting the 
phosphorylation of PCNA when the internalization of EGFR is perturbed? 
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Do aspirin analogues deregulate NFκB by inhibiting the phosphorylation of IκB 
alpha at serine 32 and 36 (Habib et al., 2001) in order to prevent its nuclear 
localization and stop transcription?  
Western blot analysis can be used to find out if these compounds interfere with 
Akt expression and also interfere with phosho-Akt? Data from this analysis 
could conclude if these compounds have a downstream effect on the EGFR 
signalling pathway. Another indication of these compounds having a 
downstream effect on the EGFR signalling pathway is if they have an effect on 
Stat-3 and phosphor-Stat-3; Stat-5 and phosphor-Stat-5 (Schindler and Darnell, 
1995). 
For the EGFR phosphorylation experiments using western blot analysis, the 
receptor was stimulated using 200 ng/ml of EGF. This dose of EGF is now 
understood to be too high and should be substituted with 20 ng/ml in future 
experiments. 
Is there any link between phosphorylation of EGFR at Y1045, Y1173 and 
clarithrin? This could be pursued by comparing the levels of phosphorylation of 
the EGFR at Y1045, Y1173 with levels of clarithrin when treated with these 
aspirin analogues. 
TNF (tumour necrosis factor) regulates proliferation of the intestinal cell line in 
mice, which is due to downregulation of EGF-dependent EGFR activation 
(Kaiser and Polk, 1997). Is there a relationship between these aspirin 
analogues and TNF? 
Elevated Akt and STATs signalling are found in cell lines with mutated EGFR 
(Sordella et al., 2004). An increase in the expression of Akt is also associated 
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with increase in p21 expression (Karimian et al., 2016). Thus the study of the 
expression of Akt and STATs in SW480 CRC cell line together with the effect 
aspirin analogues will have on the expression of Akt and STAT could be 
beneficial because it shows that this particular cell line may not be responsive 
to standard therapy. This information could be added to the findings in this 
study of aspirin (PN502), PN590, PN591 and PN592 decreasing p21 
expression (Figure 5.3). Furthermore, cytoplasmic p21 promotes survival by 
inhibiting apoptosis (Dehennaut et al., 2013). For example, cytoplasmic 
localization of p21 in testicular cancer cells has been found to safeguard cells 
from apoptosis caused by cisplatin (Karimian et al., 2016). 
Immunocytochemistry (ICC) can be used to find out if increases in p21 
expression via western blot correlates with p21 expression in the cytoplasmic 
region of the cells and whether treatment with these compounds cause any 
changes. 
To further study the effects of these aspirin analogues on p21 expression and 
its effect on apoptosis, the effect of these aspirin analogues on the expression 
of p53 as a tumour suppressor alongside p21 on SW480 CRC cell line and 
other cancer cell lines without TP53 mutations should be investigated. The 
results could be compared against normal/healthy cell lines. A non-adherent 
cell line or alternative methods to harvest adherent cells should also be 
included. For example, the use of RNase A, which enables the removal of 
cytoplasmic RNA and thus eliminates any false necrotic values due to PI 
staining (Rieger et al., 2011) could be added to the protocol.    
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Chapter 8. Appendix 
8.1 13C NMR Spectra for aspirin and its analogues 
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Figure 8.1 13C NMR spectrum for aspirin (PN502). 
 
   
 
 
345 
 
 
Figure 8.2 13C NMR spectrum for PN508. 
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Figure 8.3 13C NMR spectrum for PN517. 
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Figure 8.4 13C NMR spectrum for PN548 
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Figure 8.5 13C NMR spectrum for PN549. 
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Figure 8.6 13C NMR spectrum for PN590. 
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Figure 8.7 13C NMR spectrum for PN591. 
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Figure 8.8 13C NMR spectrum for PN592. 
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8.2 IR Spectra for aspirin and its analogues 
 
Figure 8.9 IR Spectrum of PN502. 
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Figure 8.10 IR Spectrum of PN517. 
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Figure 8.11 IR Spectrum of PN548. 
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Figure 8.12 IR Spectrum of PN549. 
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Figure 8.13 IR Spectrum of PN590. 
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Figure 8.14 IR Spectrum of PN591. 
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Figure 8.15 IR Spectrum of PN592. 
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Figure 8.16 IR Spectrum of Salicylic acid. 
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Figure 8.17 IR Spectrum of Thiosalicylic acid. 
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Figure 8.18 IR Spectrum of 3-hydroxybenzoic acid. 
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Figure 8.19 IR Spectrum of 4-hydroxybenzoic acid. 
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Figure 8.20 IR Spectrum of 3-mercaptobenzoic acid. 
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Figure 8.21 IR Spectrum of 4-mercaptobenzoic acid. 
 
   
 
 
365 
 
8.3 Supplementary: Screen shots and Legend for Live Imaging 
Movies (on DVD) of EGF in cells incubated with aspirin and 
aspirin analogue. 
 
 
Figure 8.22 Screen shots of Movies showing SW480 CRC cells untreated 
(control), treated with aspirin and PN517 at 0 min and 30 min after stimulation. 
EGF was internalized in the untreated cells while internalization was perturbed 
when cells were treated with 0.5 mM of aspirin and PN517 (Movies are on attached 
DVD). 
 
 
 
 
 
 
Movie 1: Binding and internalisation of EGF control (untreated) in SW480 CRC 
cell line imaged confocal microscopy uninterruptedly for 60 min. SW40 CRC 
cells (37°C, 5% CO2) were exposed to Alexa Fluor® 555 EGF (red). Time 
series after addition of ligand is 120 cycles at 0.5 min intervals. 
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Movie 2: Binding and internalisation of EGF after treatment with 0.5 mM aspirin 
(buffered with HEPES, pH8) for 30 min in SW480 CRC cell line and imaged 
using confocal microscopy uninterruptedly for 60 min. SW40 CRC cells (37°C, 
5% CO2) were exposed to Alexa Fluor® 555 EGF (red). Time series after 
addition of ligand is 120 cycles at 0.5 min intervals. 
Movie 3: Binding and internalisation of EGF after treatment with 0.5 mM PN517 
(buffered with HEPES, pH8) for 30 min in SW480 CRC cell line and imaged 
using confocal microscopy uninterruptedly for 60 min. SW40 CRC cells (37°C, 
5% CO2) were exposed to Alexa Fluor® 555 EGF (red). Time series after 
addition of ligand is 120 cycles at 0.5 min intervals. 
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